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Abstract 
 
Background 
Burns is a complex condition requiring assessment and addressing of both the wound and the 
patient in a holistic way. In spite of tremendous improvements in burn care, infection continues 
to remain an important cause of morbidity and mortality. Human Β Defensins (HBD) are a 
group of recently discovered antimicrobial peptides. The main subtypes include HBD1, 2 and 3 
and are individually known to have other functions apart from being anti-microbial. Some of 
these are inherently expressed while others are induced in response to microbial challenge.  
 
Aims 
The aim of the current PhD was to understand the pattern of expression of HBDs in acute 
burns, their source of expression, and factors influencing the expression, with a view to use 
these peptides as therapeutic agents in future. 
 
Methods 
The expression of HBD1, 2 & 3 was determined at mRNA and protein levels in acute burn 
wounds of different burn durations, using real time rt-PCR and immunohistochemistry, 
respectively. The influence of type and quantity of bacteria, contribution from blood cells and 
the influence of stress on HBD expression was determined in separate clinical situations 
similar to those seen in major burns. 
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Results 
The results show that HBD1, 2 and 3 mRNA is highly expressed in both early and late burns, 
but a parallel increase is not reciprocated at protein levels. The bacteria isolated from the burn 
wounds showed a trend changing from colonising organisms to more resistant forms in time, 
however no significant correlation with HBD was established. 
Peripheral blood cells produced HBD in response to inflammatory mediator’s in-vivo, thus 
suggesting to a possible contribution of HBD 1, 2 and 3 from blood cells in granulating burn 
wounds. 
There was no down regulation of HBD1, 2 and 3 in the presence of increased cortisol levels – 
a reflection of heightened stress as seen in burns. HBD1 and 3 mRNA expressions showed an 
early up-regulation, followed by elevation in HBD2 mRNA levels. There was no HBD2 mRNA 
and protein expression in keloid tissue specimens from various parts of the body. The absence 
of HBD2 – a unique intrinsic peptide with an ability to trigger the anti-fibrotic cytokines 
suggests to the possibility that HBD’s are implicated in the pathogenesis of keloids, which are 
usually associated with burn scars. 
 
Conclusion 
The studies suggest a possible role of HBD in the pathogenesis of burn wounds and the 
potential to use these as therapeutic peptides to prevent infections and scarring associated 
with burns. 
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Chapter 1 
 
General Introduction 
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1.1 Skin  
Figure 1.1 Diagrammatic representation of skin 
Adapted from www.nlm.nih.gov/.../ency/imagepages/8912.htm and 
www.histol.chuvashia.com/.../epithelia-en.htm. Part A of the figure shows the 
diagrammatic representation of the different layers of skin. Part B shows the epidermis 
stained with Haematoxylin and Eosin stain, showing the different layers of epidermis. 1-
stratum basale, 2-stratum spinosum,3-granular layer, 4-lucidal layer,5-cornified layer.  
 
Skin is considered to be the heaviest organ in the body accounting for nearly 16% of the total 
body weight and extending over to an area of 1.2-2.3 m2.It consists of 2 main layers, the 
epidermis and dermis (figure1.1). The layer beneath the dermis, namely the hypodermis is not 
considered a part of the skin. 
Epidermis (cuticle or scarf skin) 
The epidermis is an avascular layer composed of stratified cells predominantly squamous in 
nature and comprises mainly of keratinocytes (85%). The other cell types consist of 
Epidermis 
Dermis 
Hypodermis 
A B 
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Langerhans cells, melanocytes and Merkel cells. The cells in the basal layer proliferate to 
generate the cells, which are constantly lost from above. This movement from the basal layer 
to the environment takes about 47-48 days (Iizuka, 1994) and is called the “epidermal turnover 
time”. The cells differentiate from the basal layers as they reach the top layer to mature cells. 
Skin consists of five layers from deep to superficial; the stratum basale, stratum spinosum, 
stratum granulosum, stratum lucidum and the stratum corneum. The stratum basale is the 
deepest of the 5 layers and is composed of single layer of proliferating cuboidal (or columnar) 
cells over the basement membrane. Connective tissue elements called hemidesmosomes and 
desomosomes attach it to the basement membrane, and to each other respectively. 
Specialised cells such as melanocytes and Merkel cells are scattered within this layer. Both 
these cell types are of neural crest origin but have varied functions. The melanocytes produce 
a pigment melanin which serves to absorb the UV rays and protect the skin while the Merkel 
cells aid in the sensory perception of light touch. Langerhans cells are derived from bone 
marrow and serve as antigen presenting cells and are distributed in the basal, spinous and 
granular layers of epidermis (Don R Revis Jr, 2006). 
The next layer after the basal layer is the stratum spinosum that is composed of multiple layers 
of proliferating cuboidal or polygonal cells with a central euchromatic nucleus. The cytoplasm 
is composed of dense connective tissue elements called tonofilaments which project as spines 
into desmosomes, hence this layer is called the stratum spinosum. Interspersed in this layer 
are giant cells called Langerhans cells. Sometimes the term stratum germinativum is used for 
the above 2 layers. 
The stratum granulosum consists of 3-5 layers of flattened polygonal cells. Nuclei are present 
but there is no active cell proliferation. They are characterised by an abundance of 
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keratohyaline granules composed of phosphorylated proteins, hence the term stratum 
granulosum. The cells also contain lamellar granules rich in protein and lipids. The contents of 
these granules are secreted over the surface making it waterproof. The stratum lucidum is a 
thin layer composed of translucent eosinophilic cells. 
The outermost layer of skin, the stratum corneum consists of dead cells arranged in 4-5 layers 
and these are shed as new cells are added from below. It serves as a barrier regulating the 
entry and exit of substances into and out of the skin.  
 
Nutrition of the Epidermis  
Since the epidermis is avascular, nutrition is obtained by diffusion from the underlying vascular 
dermis. The cells of epidermis progressively die as they migrate upwards from the basal layer 
hence the epidermis, except in the stratum basale and stratum spinosum is composed of dead 
cells. 
 
Dermis 
This can be further divided into the papillary layer and the reticular layer. The papillary layer 
consists of the rich network of blood vessels and also houses the free nerve endings in the 
form of eminences called papillae. The rich vasculature aids in thermoregulation and in 
delivering the nutrients to the avascular epidermis while the nerve endings help in tactile 
sensation either directly or by forming specialised touch receptors called Meissners 
corpuscles. The reticular layer is composed of predominantly white fibrous tissue and some 
fibres of yellow elastic tissue with other connective tissues. 
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Functions of skin  
Some of the important functions of skin are listed in Table 1.1.  
 
Table 1.1 The functions of skin 
1 Mechanical and biological protection  
2 Maintenance of internal homeostasis by preventing 
loss of water, electrolytes  and macro-
macromolecules 
3 Sensory  organ  
4 Vitamin D and hormonal synthesis 
5 Thermoregulation  
6 Lubrication and waterproofing  
 
1.2 Burn wounds 
Classifications of burns 
Burns result in destruction of skin and subcutaneous tissues and can result from a variety of 
causes. The burn wounds can be classified either in relation to the depth of the injury or the 
cause of the injury(Sheridan et al., 1995a, Sheridan et al., 1995b). A brief and simplified 
classification and summary of the management and outcome is outline below(Johnson and 
Richard, 2003). 
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Superficial  
The two major causes are ultraviolet radiation from sun or transient contact with hot objects. 
The patient presents with pain, erythema, absence of blistering and oedema.  The burn injury 
is confined to epidermis and localised vasodilation of the vascular plexus at the dermo-
epidermal junction results in erythema. Apart from analgesia, specific management includes 
application of topical Aloe vera gel and usually within 5 days, complete healing is seen without 
scarring. 
 
Partial thickness burns 
These can be divided into two types, superficial and deep. 
Superficial partial thickness 
The aetiology is varied and may result from thermal contact, electrical, chemical, radiation or 
friction injuries. The patient presents with pain, erythema, hypersensitivity, blistering and 
oedema. In this case, the burn injury extends beyond the epidermis into the papillary dermis. 
Localised vasodilation of the vascular plexus at the dermo-epidermal junction results in 
erythema. The patient is given analgesia and specific management includes dressings aimed 
to keep the wound moist. Complete healing is noted without scarring within 5-7days. 
 
Deep partial thickness 
The aetiology is varied and the burn may result from thermal contact, electrical or friction 
injuries. The patients present with altered sensation, poor or absent capillary refill, mixed red or 
white lesions, oedema and an absence of blisters. The burn injury extends to the level of 
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reticular dermis or areolar tissue deep to dermis. The patient is given analgesia and topical 
antiseptics and antibiotics are used. Surgical debridement and grafting are commonly required.  
 
Full thickness and Sub dermal burns 
The aetiology is varied and burns may result from thermal contact, electric burns or friction 
injuries.  The burnt area is insensitive to touch but sensitive to pressure, capillary refill is 
absent. The burn is white or black in appearance with an absence of blisters, the patient has 
thrombosed vessels, poor distal circulation and the area is dry, rigid and leathery. In this case, 
the burn injury extends beyond dermis. The patient is given fluid replacement and the burn is 
treated with antibiotics and dressings. Skin grafting may be necessary and the burns have a 
high potential for scarring. 
 
Subdermal burns 
The aetiology is varied and is the result of a severe insult. The skin is charred and the 
underlying tissue exposed. The patient has little sensation in the area. In this case, all layers of 
the skin and hypodermis are burnt with subcutaneous and underlying tissues exposed. All the 
nerve endings and sensory cutaneous receptors are destroyed. 
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Classification based on the aetiology of burn wound.  
Table 1.2 Categories of burns based on aetiology 
1 Thermal burns  
2 Chemical burns  
3 Electrical burns  
4 Friction burns  
5 Ultraviolet radiation induced burns  
 
Physiological effects of Burn injury 
Burn injury results in both local and systemic responses. These responses can be variable 
depending on the nature and the extent of the burn injury. 
 
Figure 1.2 The local response to burn injury and the Jacksonian zones surrounding the 
burn injury site. Adapted from (Hettiaratchy and Dziewulski, 2004b) 
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The local responses are summarised in the figure 1.2 and result in tissue damage which can 
be of variable degree depending on the distance from the area of insult. Jackson in 1947 
classified the area of damage into three zones, the zone of coagulation, the zone of stasis and 
the zone of hyperaemia. However burn results in damage to some or all the layers of skin and 
thus variable loss of function. The systemic changes involve a number of organ systems as 
summarised in the figure 3 below. The responses are more pronounced with the increase in 
the percentage of the total burn surface area (TBSA) and are seen when the TBSA 
approaches 30%(Hettiaratchy and Dziewulski, 2004b). These effects are mediated by the 
release of cytokines and inflammatory mediators IL-1,TNF-α, IL-6 etc which are elevated in the 
post burn scenario(Drost et al., 1993). 
 
 
 
 
 
 
 
 
 
Figure 1.3 –The multiple systemic affects following a burn injury.(Adapted from 
(Hettiaratchy and Dziewulski, 2004b) 
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Cardiovascular changes and Respiratory Changes 
 
The changes are reflected in the form of increased capillary permeability, resulting in the loss 
of intravascular proteins and fluids to the interstitium. This is associated with compensated 
splanchnic and peripheral vasoconstriction. There is also decreased cardiac contractility 
secondary to release of cytokines like Tumour necrosis alpha (TNF-α). Loss of fluid from the 
burn wound, from intravascular compartment and decreased contractility result in systemic 
hypotension and organ hypo-perfusion resulting in end organ failure. 
The respiratory effects are in the form of broncho-constriction and in severe cases result in 
adult respiratory distress syndrome. 
 
Metabolic changes  
Burns result in a hypermetabolic state with the basal metabolic rate (BMR) increasing to twice 
the normal in burns of 40% TBSA. This increased metabolic rate with ongoing tissue 
regeneration and loss of intravascular proteins increases the metabolic demand and need for 
nutritional supplementation. 
 
Immunological changes 
It is reported that there is a non –specific down- regulation of both adaptive and innate 
immunity following a major burn injury. There are alterations in the arachidonic acid pathway 
and the cytokine cascade. There have also been reports of neuro-endocrine axis dysregulation 
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and changes affecting all the cells of the immune system. Changes in the humoral immunity 
have also been reported(Munster, 1994). 
 
Management of burn wounds 
The management of major burns needs to be aggressive to achieve the best outcome. The 
systemic management of the patient should be according to the ATLS (acute trauma and life 
support) and EMSB (Emergency Management of Severe burns) guidelines. The patient should 
be adequately resuscitated and subsequently special attention should be given to the nutrition 
of the patient as burn is a hypermetabolic state.  
Local management of a burn wound depends on the depth of the burn. It can be either 
conservative using a variety of dressings aimed at providing a sterile cover and an 
environment to promote healing; this mode of management however relies on the presence of 
adnexal structures in the burnt area from where re-epithealisation begins. 
 
 
Unmeshed graft    Meshed graft 
 Figure 1.4 An illustration of unmeshed and meshed skin grafts 
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Surgical-Debridement and grafting  
This is generally undertaken for deep dermal and full thickness burn injuries and is aimed at 
removing the dead tissues and at providing epithelial cover over the burn area. The epithelial 
cover can be provided in the form of partial thickness skin graft either meshed or unmeshed 
(figure 1.4) Systemic management comprises of adequate fluid resuscitation and supportive 
care in the form of nutritional and psychological support. 
 
Complications associated with burn injuries 
There can be a number of complications associated with burn injuries; the important ones are 
listed in Table 1.3. Some of these are directly related to the burn, others are related to the 
physiological changes associated with these types of injuries. The most common complication 
associated with burns is infection in the early stages and scarring in the delayed state.  
 
Table 1.3- Complications of burn injuries. 
Immediate /early  Delayed 
Infection: local and /or systemic Scarring and disfigurement 
Contractures/keloids/hypertrophic scars  
Dehydration  
Hypothermia  
Shock:hypovolaemic and/or septic  
Multi-organ failure  
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The current study addresses some of these complications in relation to anti-microbial peptides 
specifically β defensins. 
 
1.3 Skin antimicrobial peptides 
There have been tremendous advances in the management of burns in the last decade. 
However infection continues to be one of the most important causes of morbidity and mortality 
in burn patients. A variety of dressings have been developed aimed at providing the best 
mechanical cover over the burn wound. Controlled temperature, humidity and laminar air flow 
in burn wards and theatres provide an environment which helps prevent infection, and provide 
conditions aimed at compensating for the loss of mechanical cover provided by the skin. 
Replacing the skin by grafting is the most effective way of managing burn wounds; however 
this option is not suitable if the areas involved are large and it also requires availability of 
specialist skills.  
Since loss of skin is common to all burns wounds, it is envisaged that the loss of mechanical 
and biological protection provided by the skin is partly responsible for this high incidence of 
infections. Although a variety of dressings have been developed which to some extent provide 
a good mechanical cover, the biological properties of the skin need to be addressed. The 
biological properties of the remnant epithelial cells in the burn wound vicinity, especially those 
in the zone of statsis, is unclear. In the current study we endeavoured to study the 
antimicrobial peptide expression in the burn wounds. 
Antimicrobial peptides (AMP) constitute a group of polypeptides, each less than 100 amino 
acids (10-50 amino acids) in length, found in the body which have antimicrobial properties 
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under physiological conditions in the tissues of their origin(Ganz, 2003). Since the antimicrobial 
effects of these peptides are mediated directly and indirectly in vivo they are referred to also as 
host defence peptides (HDP)(Sahl et al., 2005). About a hundred antimicrobial peptides have 
been described to date, however cathelidins and defensins are the two most important 
members of this group.  
 
1.3.1 Defensins  
Defensins are a unique family of structured peptides found in vertebrates. They are 
characterised by their high cationic charge, β-sheet fold and cysteine rich residues interlinked 
by six disulphide bridges(Selsted et al., 1985). They are all synthesised as pre-propeptides 
and undergo further processing depending on the site of expression and the type of 
defensin(Selsted and Ouellette, 2005). The molecular weights of defensins are in the range of 
3-5 kDa. Similar peptides containing 6-8 interlinked cysteine residues found in non-vertebrates 
and plants, and are also known as defensins. The family is divided into subclasses α (alpha) 
and β (β), based on differences in structure, the lengths of the peptide segments between the 
cysteine residues and the pairing of the residues(Hoover et al., 2000). 
Recently a third group of θ- defensins has been described in primates, which are cyclical 
peptides, probably derived by fusion of α-defensin-like precursor peptides. These peptides are 
not found in humans as their synthesis is disrupted by the formation of premature stop 
codons(Trabi et al., 2001). 
Functionally the defensins have a broad spectrum of antimicrobial activity against gram 
positive and  gram-negative bacteria, fungi and some viruses(Huttner and Bevins, 1999). They 
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mediate the killing of the microbes by forming pores in their membranes(Raj and Dentino, 
2002). Six different α and about 28 different β defensins (BD) have been described in humans 
so far, however only four β-defensins have been characterised. 
1.3.2  α –Defensins 
Skeleton Structure 
 
Figure 1.5. A representative skeleton structure of α –defensins;S-S represent the 
disulphide linkages to the carbons in the skeleton structure. 
 
Characteristics 
These are cationic peptides 29 –35 amino acids in length and differ from β defensins in terms 
of the position of the cysteine residues and the disulphide motifs(Raj and Dentino, 2002). The 
six cysteines residues are linked at positions 1-6, 2-4, 3-5. They have been further divided into 
subtypes HNP1-4, HD5 and HD6. 
 
 
 
C1-------- C2-------- C3-------- C4-------- C5-------- C6-- 
-s-s- 
-s-s- -s-s- 
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Genes and synthesis 
The gene for α-defensin synthesis is located along with the BD gene cluster at chromosome 
8p23. This gene cluster is associated with polymorphisms with the number of copies of 
defensin genes varying between individuals(Mars et al., 1995). They are synthesised in 
promyelocytes in the bone marrow as tripartite pre-pro-peptides containing an amino terminal 
signal sequence, an anionic pro-piece, and mature defensins at the carboxy terminal 
end(Daher et al., 1988, Valore and Ganz, 1992). Mature neutrophils contain large amounts of 
defensins but do not actually synthesise the peptide, the actual peptide is synthesised in the 
bone marrow when the neutrophils are in the state of pro-myelocytes(Ganz, 2003). 
 
Distribution 
α-Defensins have been found in the neutrophils of most mammalian species,  in the intestinal 
paneth cells of humans and rodents(Risso, 2000) and the female genital tract of 
humans(Quayle et al., 1998). The concentrations of defensins in granules of leukocytes and 
the crypts of small intestine have been found to be >10mg/ml(Ganz et al., 1985, Selsted et al., 
1983, Ayabe et al., 2000). 
 
Spectrum of activity and mechanism of action  
Alpha defensins have a wide spectrum of anti microbial activity in vitro against bacteria, fungi 
and enveloped viruses(Selsted et al., 1983, Ganz et al., 1985, Lehrer et al., 1985). Their 
mechanism of antimicrobial activity is considered to be electro- statically mediated and specific 
against prokaryotic cells(Weinberg et al., 1998, Ganz, 2003). 
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1.3.3 β-Defensins (BD)/Human Β Defensins (HBD’s) 
1.3.4 Structures 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
Figure 1.6 Three dimensional structures of β defensins- in approximately similar 
orientation, with three β sheet and three disulphide bonds (shown in yellow) (Adapted 
from(Hoover et al., 2002, Hoover et al., 2000, Schibli et al., 2002). 
Skeleton structure 
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Figure1.7  Structure of human β-Defensins (HBD; S-S represent the disulphide linkages 
to the carbons in the skeleton structure. 
Characteristics 
 Human Β defensins (HBD) are characterised by the presence of cysteine residues linked in 1-
5, 2-4 and 3-6 positions as seen in the figures 1.6 and 1.7 above. Despite the difference in the 
linkages of the cysteine residues between α and β-defensins, they a have common three-
dimensional structure with the three disulphide bonds stabilising the three anti-parallel β 
strands. Though initially they were given different names, they were finally classified as β 
defensins based on their common properties. 
 
Immunological properties, genes and synthesis 
HBD has also been shown to stimulate the adaptive immune response and thus may be a link 
between the primitive innate immunity and the advanced adaptive immunity(Yang et al., 1999). 
HBD genes are located on 8p23.  Further studies showed that the encoded peptides differed 
from each other in features such as sequence similarity, size of introns, site of expression and 
elements of genetic regulation, and hence were further subdivided. Four different varieties of 
BD, human β defensin 1 (HBD1), human β defensin 2 (HBD2), human β defensin 3 (HBD3) 
C1-------- C2-------- C3-------- C4-------- C5-------- C6 
-s-s- 
-s-s- -s-s- 
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and human β defensin 4 (HBD4), have been isolated and extensively studied, although a total 
28 different types of β-defensins have been described. 
 
Distribution  
β- Defensins have been isolated from a variety of organisms ranging from plants to 
invertebrates, vertebrates and mammals, including man. In man they are expressed, by the 
epithelial cells of the respiratory tract, skin and the urogenital tract, in response to inflammatory 
mediators and the microbes. This response has been shown in vitro and in vivo. 
 
Human β defensin 1 (HBD1) 
The genito-urinary tract is the principal site of production of HBD1. However it has been 
reported to be produced by epithelial cells at a number of sites including skin, kidney, gut, oral 
cavity,lung(Zhao et al., 1996, Ali et al., 2001) and macrophages(Alp et al., 2005). The 
production of HBD1 is not influenced by inflammatory activity and the challenge with microbes 
although there are consensus sites for nuclear factor (NF) interleukin (IL)-6 and γ-interferon at 
the 5` flanking region of HBD1, suggesting that inflammation may mediate its 
expression(Valore et al., 1998). HBD1 shows antimicrobial activity more markedly against 
gram negative bacteria as compared to gram positive bacteria. 
 
 
 
 40
Human β defensin 2 (HBD2) 
Human β defensin 2 was the first reported inducible antimicrobial peptide. It was first isolated 
from psoriatic scales(Harder et al., 1997). It was shown to be induced both in vitro and in vivo 
by a number of inflammatory mediators and bacteria(Liu et al., 2002a). HBD2 is active against 
gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa and yeasts such 
as Candida albicans . It is also shown to be bacteriostatic at higher concentrations against S. 
aureus(Schroder and Harder, 1999). 
 
Human β defensin 3 (HBD 3) 
HBD 3 is another important inducible 45 amino acid long antimicrobial peptide first isolated 
from psoriatic scales. It is produced at various sites in the body(Jia et al., 2001) in response to 
bacterial challenge and TNF -alpha. HBD3 has shown a wide spectrum of antimicrobial activity 
against multi-drug resistant S .aureus and vancomycin resistant Enterococcus faecium. and 
also has chemo attractant properties(Harder et al., 2001). 
 
Human β defensin 4 (HBD 4) 
Recently HBD4 has also been identified and it has been found to be tissue specific. There are 
reports that it has been isolated from testis, uterus, thyroid gland, lung and kidney during 
infection(Garcia et al., 2001b). It is thought to influence monocyte migration. They have been 
shown to demonstrate the antimicrobial activity in genetically modified keratinocytes(Smiley et 
al., 2007). 
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1.4 Overview of the PhD 
The current study was carried out to investigate the various aspects related to HBD expression 
in relation to conditions found in burn wounds. Five clinical studies were conducted in either 
burns patients or in non –burn patients with trauma similar to that found in burn patients.  
 
Studies1 and 2- Chapter 3 
Title: Human β-Defensin expression in burn wounds and correlation to bacteria and 
duration of burn wound. 
The primary study was to analyse the expression of HBD 1, 2 & 3 in debrided burn wounds at 
different time points. Estimation of bacteria present, both qualitatively and quantitatively was 
also performed in these wounds and this was correlated to the HBD1, 2 & 3 expression at 
mRNA and protein levels 
 
Study 3-Chapter 4 
Title: Expression analysis of Β –Defensins (HBD1, 2&3) in peripheral blood cells: 
comparison of profiles between septic (microbiologically positive and negative) and 
healthy individuals. 
The aims of the study were to understand, the contribution of blood cells in vivo to HBD 
expression in a bacteria-challenged environment and the role of HBD in states of systemic 
sepsis 
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Study 4-Chapter 5 
Title: Buccal HBD 1, 2and 3 expression profile in peri-operative states: correlation to 
cortisol levels 
The aim of this part of the work was to understand the effect of stress on the expression of 
HBD in an in vivo environment similar to that experienced by a severely burnt patient.  
 
Study 5 –Chapter 6 
Title: The role of human β Defensins in the pathogenesis of keloids 
In this study, the expression of HBD in keloids was analysed to determine whether HBD play a 
role in the pathogenesis of keloids. 
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Chapter 2 
General Methodology 
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2.1 Collection of clinical samples 
 
Collection of samples is the most important and the most difficult part of a clinical research 
project. It is technically demanding as it involves co-ordinating between the surgeons, theatres, 
patients and the laboratory. It is also important to ensure that the samples are collected in the 
optimised way for the kind of experiment being planned as collecting samples in an un-
optimised manner can result in un-interpretable and void results; resulting in wastage of 
resources and time. 
The samples for the current projects were collected after obtaining Ethics Committee approval 
and consent from individual patients (refer to Appendix).The details of the methods and the 
problems encountered during collections for individual experiments will be discussed in 
chapters related to specific experiments. 
 
2.2 Immunohistochemistry 
 
This is the technique of localisation of antigens in a tissue specimen using specific antibodies 
which are in turn visualised using different reporter technologies such as enzymatic reactions, 
fluorescent dyes and radioactive elements. The technique is based on the underlying principle 
that antibodies bind to specific antigens. 
 
Antibodies 
Antibodies can be polyclonal or monoclonal, the type being based on the clone of cells from 
which they are produced. As the name suggests, polyclonal antibodies are produced by 
multiple clones of cells and hence they are immunologically dissimilar and recognise different 
epitopes on the same antigen (figure 2.1A). Monoclonal antibodies on the other hand are 
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produced by a single clone of cells, are therefore immunologically similar and thus bind to the 
same epitope (figure 2.1B). 
 
Figure 2.1 The principle of immunohistochemistry with polyclonal (part A) and 
monoclonal (part B) antibodies. 
Availability of a specific pre-tested antibody is an important prerequisite for successful 
completion of immunohistochemical techniques in a short time. All the antibodies used were 
obtained commercially. Specific antibody search engines such as Abcam 
(http://www.abcam.com/) and Linscotts Directory of Immunological and Biological Reagents 
(http://www.abcam.com/, http://www.linscottsdirectory.com/) were used to locate the required 
antibodies. The searches revealed that there was no existing commercially available antibody 
specific to human β defensin 3. There were polyclonal antibodies available which detected 
human β defensin 1, 2 and 3 but since our study was looking at the differential expression of 
each of these peptides it was decided that using such non-specific antibodies would be futile. 
Further searches revealed that there were specific rabbit polyclonal antibodies to human β 
defensin 1and 2 but not to defensin 3. Professor Navsaria (Centre for cutaneous research) 
Monoclonal  
Antibodies 
Epitopes
Polyclonal antibodies
A B
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generously agreed to provide these two antibodies. Since there was no antibody targeted to 
human β defensin 3, the closest possible commercially available alternative, the rabbit 
antibody to mouse β defensin 3 was purchased from Autogen Bioclear. Though there is more 
than 50% homology between mouse and human β defensin 3(Bourcier et al., 2004) there was 
no information available as to whether the anti mouse antibody could be used on human 
material. This antibody had not been previously tested in immunohistochemical techniques. So 
this antibody was used on human tissues using immunohistochemistry techniques as the first 
part of the project. Our results showed that the anti mouse β defensin 3 antibody showed 
specific binding to human tissues (figure 2.2). 
 
Figure 2.2 Representative skin sections stained MBD3 and visualised using FITC.  
Part A of the figure shows the background staining and part B shows the fluorescence in the 
basement membrane and the lining of the glands. 
 
However subsequently commercial antibodies were also marketed for Human β defensin 3 
(HBD3) which were used for the later immunohistochemistry studies. 
 
 
-ve MBD3 stained 
A B
+ ve
Basement 
membrane 
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Tissue processing for embedding in paraffin blocks 
Fixation and dehydration 
Fixation is the process by which the cell contents are prevented from being lost as a result of 
storage or further chemical treatment. The mechanism of fixation varies, depending on the 
fixative used. A number of chemical fixatives can be used such as alcohol, acetone, 
glutaraldehyde, formalin as well as combined fixatives such as B5. The most common fixative, 
formalin, can be used in various concentrations 
(http://www.ihcworld.com/_books/Dako_Handbook.pdf). Formalin treatment results in fixation 
by covalently cross-linking proteins between α and ε amino groups. This results invariably in 
the alteration of the antigenicity which is especially significant when the tissue is being used for 
the detection of proteins. The degree of antigenic variation induced depends on the 
composition of the fixative, duration of fixation, concentration of the fixative and the size of the 
tissue specimen. In order to compensate for the change in the antigenic structure various 
antigen retrieval techniques are used which restore at least partially the antigenicity of the 
proteins. Some of the common antigen retrieval techniques are digestion with enzymes like 
pepsin or trypsin or incubation with citrate buffer in a microwave oven. 
Graded dehydration, the taking of the tissue through various concentrations of alcohols and 
other organic solvents such as xylene or chloroform, allows the sample to be dehydrated. 
 
Embedding 
Embedding was carried on weekly basis using batches of tissue samples. 10% formal- PBS 
was used for fixation. Though ideally the tissues are better not left in formalin for more than 24 
hours they were usually processed after fixation for periods ranging from 48-72 hours. An 
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account of time duration of fixation was made for each of the sample. During antibody staining, 
assessment was made to determine the effect of time on staining pattern.  Each batch 
consisted of about 4 to 10 specimens, the number being dependent on the availability of 
patient tissues. The embedding process was done manually following a 3-day standard 
protocol as described in Carleton’s Histological Techniques.  
 
Tissue processing for frozen material 
Cooling of the tissue usually results in some degree of fixation although chemical fixatives like 
methanol, ethanol or acetone can be used to supplement this. No other special measures are 
required apart from storage of the tissue at temperatures below –70ο C for long-term storage. 
 
Cutting of tissue sections 
Paraffin blocks  
Sections of 5-micron thickness were cut from paraffin blocks using a standard microtome 
(Medcon microtome, USA). The technique of taking the section from the stage of the 
microtome to the time the section is set on the slide varies between laboratories. The 
techniques followed in our laboratory along with practical considerations are summarised. 
Before starting the procedure it was ensured that a water bath set at 52ο C (a little below the 
melting point of wax) was available. It was found that the sections were easier to cut if they 
were left in a freezer for a short time before being cut; hence they were left at - 20ο C for half an 
hour before use. The tissue sections stuck to each other forming long chains. Chains of 4-6 
sections were the best to handle and they were separated using pointed forceps after being 
floated on a large slide of alcohol. Separating sections directly in the water bath was more 
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successful if a small nick was made in the edge of the block, from where the separation can be 
initiated.  
All the sections were orientated in the same direction while transferring them onto the slide; 
this was useful when visualising the slide under the microscope since changing the field for 
each slide was not required. Once the section was mounted on the slide it was left overnight in 
an incubator maintained at 37οC .The slides were then ready for use. 
Cutting cryo-sections 
Sections of 5-micron thickness were cut using a standard cryostat (Bright Instrument Co Ltd, 
England). While mounting the tissues on the cryostat, the long axis of the tissue was orientated 
perpendicular to the blade. This made it easier to take the tissue on the slide. The 
temperatures of the cryostat were maintained between –20 to –30οC during the entire process 
and the tissue samples were taken out in turns from the –70 οC freezer. The slides were then 
appropriately labelled and stored in plastic bags at -70 ο C until required. 
 
Immunostaining 1 
Two step indirect immunofluorescence was chosen owing to its 10 fold higher sensitivity as 
compared to the direct immunoflourescence techniques. Since the anti mouse β defensin 3 
had not been previously tested in immunohistochemistry, it was tested on mouse sections and 
human tissues. Since there was no information available from the manufacturer regarding the 
dilution to be used and the duration of staining, a protocol was devised.  The use of the 
antibody on paraffin embedded tissues required pre-treatment to facilitate the retrieval of the 
epitopes, which might have been altered during the processing of the tissue. This gives scope 
for variation in the results depending on incomplete antigen retrieval or the antibody not being 
 50
effective on human tissue. Since there was no need for any pre-treatment in case of frozen 
tissue, the antibody was first tested on frozen tissue.  
 
Immunostaining-2 
Antibodies for HBD3 became commercially available and it was therefore decided to use these 
antibodies along with those to HBD1 and HBD2 for estimation of protein expression of BD. To 
avoid the problems posed by the immunofluorescence such as loss of fluorescence and the 
costs involved, colorimetric detection of the bound antibodies was used. The steps involved in 
the immunohistochemical analysis with antibodies(Taylor CR, 1994) are described below. A 
two step indirect method was used (figure 2.3). Dewaxing involved removing wax from the 
section and rehydrating the tissues for further staining. The slides were taken through a series 
of solutions as shown (table 2.1). 
 
Figure 2.3 principle of Indirect immunoflourescence. 
 The primary antibody binds to the epitope and the secondary antibody, which is linked to the 
fluorescent or enzyme linked substrate, binds to the primary antibody. The presence of specific 
epitopes causes binding of the primary and secondary antibodies, resulting in activation of the 
substrate or fluorescent tag, leading to detection.  
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Table 2.1 Summary of the steps of the rehydration of paraffin sections 
 
 
 
 
 
 
 
 
 
 
Antigen retrieval  
No antigen retrieval was required for immunohistochemistry using β defensin antibodies since 
it was demonstrated in previous experiments that similar results were obtained with or without 
antigen retrieval (data not shown). 
 
Blocking endogenous peroxidase activity  
The presence of endogenous peroxidase activity in cells or tissues to be stained using horse 
radish peroxidase labelled antibodies (either primary or secondary) can result in non-specific 
background staining. To counteract this endogenous peroxidase activity, the slides were pre-
treated with saturating amounts of hydrogen peroxide. This resulted in irreversible inactivation 
of endogenous peroxidase; and thereby reduction of the degree of background staining.  
 
Purpose Solution  Duration  No of 
cycles 
De-paraffinising Xylene 5 minutes 2 
Graded rehydration Absolute alcohol 3 minutes 2 
Graded rehydration 90% alcohol 3 minutes  1 
Graded rehydration 70% alcohol 3 minutes 1 
Rehydration  Distilled water Until further use 1 
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The slides were immersed in a solution of freshly prepared 3% (v/v) ice cold hydrogen 
peroxide in methanol for 10 minutes. The slides were then immersed in PBS and kept in PBS 
until further use. The sections were treated (blocked) with normal serum derived from the host 
species from which the secondary antibody was derived; the serum contains antibodies, which 
bind to undesirable antigens to which the secondary antibody can potentially bind and give a 
non-specific result. For mouse and rabbit antibodies blocking was done using horse serum and 
rabbit serum was used for goat antibodies. Freshly thawed serum was added over the smear, 
keeping the slides in a moist chamber to cover the smear. This was left to stand for 30 minutes 
before the serum was removed from the slide. No washing was done after this step as the 
serum may have been washed off. 
 
Primary antibody binding 
Primary antibody specific to the antigen (protein) under question, i.e. HBD1, HBD2, HBD3 was 
added respectively to each of the slides being stained for each of the antigens detected. The 
optimum dilution was found using a trial run with different dilutions. The optimum dilutions for 
each of the antibody were as follows (table 2.2); 
 
Table 2.2 –The optimised dilutions of the three HBD antibodies. 
Antibody type  Dilution  
HBD1 1:800 
HBD2 1:500 
HBD3 1:300 
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Circles were made with a wax pen around the tissue sections to prevent the flowing of the 
antibody into neighbouring sections. The slides were then left in a cooling chamber at 4ºC 
overnight for incubation with the primary antibody for 18 hours. 
 
Secondary antibody stain 
The following day the secondary antibody was added. For HBD1 and HBD2 anti goat antibody 
(Vector laboratories Ltd, UK) was used and for HBD3 Universal vectastatin ABC kit (Vector 
laboratories Ltd, UK) was used. The slides were stained with secondary antibody after two 
PBS washes each lasting 10 minutes. Secondary antibody was incubated for 30 minutes at 
room temperature. 
 
Tertiary antibody and colour development with DAB (Diamino benzidine dye complex) 
Two washes of PBS each lasting for 10 minutes were undertaken before adding the tertiary 
antibody. Tertiary antibody was prepared as per the manufacturers instructions and 30μl were 
added for each section. The slides were incubated for 30 minutes at room temperature. DAB 
complex was freshly prepared as per manufacturers instructions and added to the slides. 
Slides were visualised under the microscope and once optimum colour development was 
observed they were washed with PBS. The duration of colour development allowed for each of 
the antibodies at the concentrations above was as follows for the staining of tissue sections: 
HBD1-1 minute 30 seconds 
HBD2 –4 minute 15 seconds 
HBD3- 1 minute 30 seconds 
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Counterstaining with haematoxylin  
The slides were immersed in eosin for a brief period of about 30 seconds, followed by 
immersion in haematoxylin for 1 minute.  
 
Dehydrating and mounting 
The slides were taken through a series of graded alcohols and xylene to dehydrate the 
sections, mounted using petroleum based jelly and cover slips and, after allowing them to dry, 
visualised under the microscope.  
 
Grading-stoichiometric analysis 
A colleague in the laboratory not associated with current experiment blindly scored slides on a 
scale of 0-4 (least to most staining). 
 
 
Immunocytochemistry  
 
This involves the same principle as immunohistochemistry; however the term is applied to the 
technique used on cells rather than tissues and was thus aimed at in situ localisation of 
proteins within cells. Details of the method of collection of different types of cells will be given 
in relevant chapters. 
 
Fixation of cells 
The cells were fixed using 4% para formaldehyde or 10% acetone-alcohol depending on the 
availability of fixative and nature of the cells. 
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Preparation of slides 
Slides were prepared using a cytospin centrifuge (Shandon, UK). Each cell suspension was 
concentrated by spinning in a centrifuge at 1000 rpm for 10 minutes. The cell pellet was re-
suspended in 1ml of fixative. Seventy μl of this concentrated suspension was used in the 
preparation of each slide. Between 10 and 12 slides were prepared from each patient sample. 
The slides were then air dried and stored in racks until required for further staining.  
 
Staining of slides 
Haematoxylin and Eosin staining was carried out for each of the slides to understand the 
morphology before proceeding to immunohistochemical staining with antibodies. 
 
Analysis of stained slides 
 
The slides were analysed under the microscope at different magnifications and staining and 
comparison drawn between different samples and controls. 
 
2.3 Extraction of RNA  
 
This was done using the choloroform-isopropanol method, RNAzol B or SVtotal RNA isolation 
kit (Promega corp. UK). 
 
Choloroform-Isopropanol method 
Each frozen tissue specimen was cut into 5µ sections using a cryotome and then the tissue 
was transferred to a glass homogeniser (Jencons England, UK) and 1ml of RNAzol 
(Cinna/Biotex lab Inc, UK) was added to it. The tissue was carefully homogenised until no 
intact tissue was visible. The contents of the homogeniser were then transferred to a sterile, 
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freshly autoclaved eppendorf tube. To this 80μl of chloroform was added and the contents 
were mixed. The tube was centrifuged at 5000rpm for 10 minutes. The upper layer was then 
collected in a fresh autoclaved eppendorf tube containing 1 ml of isopropanol .The contents 
were mixed well and left at –20 ο C for 1 hour. The contents were subsequently spun at 
10,000rpm for 10 minutes, keeping the tubes in a known orientation. 
The supernatant was discarded and the pellet dried. The pellet was then redissolved in 20μl of 
nuclease free water. 10μl of this was added to 2μl of loading dye, which was run on a 1% 
agarose gel in 1x TBE for 1 hour, stained with ethidium bromide (0.05μg/ml) (Sigma, UK) and 
visualised under UV light to determine the integrity of the RNA. 
 
RNAzol TM B Method: 
The RNAzol method was used to extract total RNA from isolated cells-leukocytes using 
RNAzol B reagent (Biogene,UK) which is a monophase solution containing phenol and 
guanidinium thiocyanate(Chomczynski and Sacchi, 1987).However the same method can be 
used for isolation of RNA from other cell types with small modifications. The following 
description is for the isolation of RNA from leukocytes. The suspended leukocytes in the 
eppendorf tubes were spun in a micro-centrifuge for 10 minutes at 1000 rpm. Supernatants 
were discarded and the pellets, which contained leukocytes, were used for total RNA isolation. 
 
For each sample of 1 X 106 cells/ml, 1ml of RNAzol reagent was added. After leukocytes were 
counted, approximately 1ml of RNAzol was added to each leukocyte pellet resulting from 700μl 
of leukocyte suspension. Suspended leukocytes in RNAzol were stored at – 70° C and were 
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processed further in small batches. Since two pellets were obtained in two different eppendorf 
tubes from each blood sample for RNA isolation, one of them was re-suspended and stored 
with RNAzol at –70° C to be used as a back-up in case of error occurring during RNA 
extraction procedures. The other pellet was used for RNA isolation. 
After RNAzol had been added, 80μl of chloroform was added per 1ml of RNAzol reagent and 
the mixture was mixed vigorously by vortexing for 1 – 2 minutes.  The mixture was stored at   –
70° C for 10 minutes to facilitate the lysis of leukocytes in order to release the RNA from them.  
Centrifugation of the chloroform RNAzol mixture was performed at 10,000 rpm for 20 minutes.  
As a result of the centrifugation, the sample formed the lower blue phenol-chloroform phase, 
the interface which contained DNA and proteins, and the upper colourless aqueous phase 
which exclusively contained total leukocyte RNA. The upper aqueous phase was transferred to 
a fresh autoclaved eppendorf tube and 1ml of iso-propanol was added in order to precipitate 
the RNA from the aqueous phase.   
The sample was stored at –70° C for 10 minutes to facilitate the precipitation followed by 
centrifugation of the sample at 10,000 rpm for 10 minutes.  The RNA precipitate formed a 
white pellet at the bottom of the eppendorf tube.  The supernatant was removed and the pellet 
was dried for 30 minutes and re-suspended in 20 μl of diethyl pyrocarbonate (DECP) treated 
water (RNase free water) and stored at –70° C to minimise RNA degradation until the 
subsequent steps. The above steps are summarised in the figure 2.4. 
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Figure 2.4: Schematic representation of the total RNA isolation from peripheral blood 
leukocytes by RNAzol B method. 
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The purity and integrity of the RNA is critical to the success of any RNA based analysis.  In this 
study, the quantity and the quality of the extracted RNA from each sample were determined by 
means of spectrophotometry and gel electrophoresis. 
 
Extraction of RNA by SV Total RNA Isolation system TM (Promega; Z3100,UK) 
 
All standard precautions were taken to ensure the environment was free of RNAses and that 
all instruments and the work bench were pretreated with RNAZap (Promega;UK ). The frozen 
tissue was put in a sterile porcelain bowl and was ground to fine powder with liquid nitrogen 
added to the bowl. The powdered tissue material, after allowing the liquid nitrogen to 
evaporate, was then transferred to a pre-weighed eppendorf tube according to the 
manufacturer’s protocol(http://www.promega.com/tbs/tm048/tm048.pdf).  Lysis buffer was 
added, 175μl per 30mg tissue. The contents of the eppendorf tube were homogenised using 
glass homogenisers. 175μl of lysate was retained for further purification and any excess was 
frozen at –70 °C. Subsequent steps were as per manufacturers protocol, and are summarised 
in figure 2.5. 
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Figure 2.5: Diagramatic illustration of the steps involved in the isolation of RNA using 
the SV total RNA isolation system. 
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To 175μl of lysate, 350μl of dilution buffer was added and the contents mixed by inversion. 
This was then placed for 3 minutes in a heat block maintained at 70°C; the tubes were then 
centrifuged for 10 minutes at 13,000 rpm. Lysate was then transferred to the spin column 
assembly (supplied by the manufacturer) without disturbing the pellet. To the column, 200μl of 
95% ethanol was added; after mixing gently for 3-4 times, the contents were spun at 13,000 
rpm for 1 minute. To the column 600μl of SV RNA wash solution was added after discarding 
the liquid in the collection tube. This was again centrifuged at 130,000rpm for 1 minute. After 
emptying the collection tube, 50μl of freshly prepared DNase incubation mix was added to spin 
column assembly. DNase incubation mix was prepared according to the manufacturer’s 
protocol by mixing 40μl of core buffer, 5μl of 0.09M MnCl2 and 5μl of DNase 1 enzyme mix. 
After adding the incubation mix, the contents of the spin column assembly were incubated for 
15 minutes at 25°C; following this 200μl of SV DNase stop solution was added and the spin 
column assembly spun at 13,000 rpm for 1 minute. Subsequently, 600μl of SV RNA wash 
solution was added and a further spin of 13,000 rpm given for 1minute. After emptying the 
collection tube and adding 250μl of SV RNA wash solution, the assembly was spun at 
13,000rpm for 2 minutes. The spin basket was transferred from the collection tube to elution 
tube and the new assembly spun at 13,000rpm for 1 min after adding 100μl of water. The 
RNA, which was collected in the elution tube, was assessed by spectrophotometric analysis for 
purity and stored at –70°C until further processing.  
 
Quantifying RNA  
Measuring the optical density (OD) at 260nm and 280nm wavelengths in a spectrophotometer 
determined purity and concentration of the extracted RNA in the sample. 1OD unit measured 
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at 260nm (A260) corresponds to 40μg of RNA per 1ml whereas the value of OD measured at 
280nm (A280) corresponds to the amount of the protein in the sample.  The ratio of A260 / A280 is 
indicative of the purity of the sample which in the case of RNA should be between 1.6-1.9. The 
procedure was achieved by taking 2μl of the resuspended RNA in DEPC treated water and 
diluting with 98μl of sterile distilled water. The amount of RNA per 1μl sample was calculated 
as follows: 
[RNA]μg/ml  = A260 X 40μg/ml X Dilution Factor 50 (1:50 = 2μl RNA to 98μl sterilised distilled 
water) 
For example one of the samples has A260 = 2.4230, the amount of the RNA in 1μl of this 
sample is:  
[RNA]μg/ml =  2.4230 X 40μg / ml X 50 = 4847.0μg/ml = 4.8470μg/μl. 
For extractions where it was anticipated that the RNA quantity was expected to be low, the 
dilution factor was decreased to 1 in 20 or at times neat RNA was also used. 
 
RNA Quality 
Quantifying RNA by spectrophotometry does not indicate the degree of RNA degradation in 
the sample, so that the assessment of RNA quality is an important step to be determined prior 
the conversion of RNA into cDNA. 
The quality of RNA was analysed by using gel electrophoresis (3-4 % agarose gel in 1x TBE) 
and ethidium bromide staining. Two sharp bands should appear on the gel which represents 
28S and 18S ribosomal RNA bands with a streak of mRNA from 200-2000 bp that in turn 
reflects the quality of the extracted RNA. To be visualised using ethidium bromide, at least 
200ng of RNA must be loaded onto gel. However other more sensitive nucleic acid stains such 
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as SYBR® gold or SYBR® green (Invitrogen; Molecular probes, UK) may be used which enable 
detection of 1-2ng of RNA. For the current set of experiments only ethidium bromide was used 
owing to limited resources. In some instances where the quantity of RNA was expected to be 
low, although the ribosomal RNA bands were not obtained, the conversion of RNA into cDNA 
was continued and PCR products were visualised and analysed. 
 
2.4 cDNA conversion 
 
Reverse transcription was performed using ImProm II Reverse Transcriptase (RT) kit 
(Promega corp UK). The method was based on the manufacturer’s two-step RT protocol. After 
checking the optical density, the initial template was taken such that 1μg of RNA was present 
in each 20μl reaction. Experiments were carried out using both oligo dT and random hexamer 
primers. The best results were obtained using a combination of both primers. After confirming 
that the experiments were working, 40μl reactions were carried out to ensure enough cDNA 
was available for further PCR reactions from the same conversion. This was done to avoid 
variations due to inter-experimental error. 
Steps: 
Template-   1-4μl (based on the optical density) 
Oligo dT primers  0.5μl(1 μM final concentration) 
Random hexamers  0.5μl (1 μM final concentration) 
Nuclease free H20  0-3μl 
Total volume   5μl 
The reaction tubes were transferred to a pre-heated heat block at 70 ºC for 5 min and were 
then kept on ice ice 5 min. The tubes were then centrifuged at 13 000 rpm  for 10 sec and then 
transferred to ice, until the reaction mix was added. 
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Reaction Mix (Per 5μl reaction) 
5× Reaction mix 4μl 
25(mM) MgCl2 4μl 
dNTP mix(0.5mM) 1μl 
Reverse Transcriptase  1μl 
Nuclease free H20  5μl 
Total volume  15μl 
 
The mixture was incubated at 25 ºC for 5 min, then 42 º C for 1 hour, and finally at 70 ºC for 15 
minutes. The cDNA thus obtained was stored at –70 ºC until required for further use. 
 
2.5 Polymerase chain reaction (PCR) 
Reverse transcriptase polymerase chain reaction (RT–PCR) is one of the commonly used 
techniques for the quantification of transcription. There are other methods such as in situ 
hybridisation, Northern blotting and RNAse protection assays which can be used for mRNA 
quantification. However, PCR is the most sensitive of the available assays. 
 
PCR optimisation 
PCR was carried out initially on a Perkin Elmer thermal cycler to optimise the conditions of 
PCR for the burn samples. A range of combinations of annealing temperatures, denaturing 
temperature, duration and number of cycles were trialled. The best results were obtained at 
the following conditions: 
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Initial Denaturation   94 ºC  2 min  
Denaturation   94 ºC  30 sec 
Annealing   60 ºC  1 min  --- 40 Cycles 
Extension    68 ºC  2 min 
 
Final Extension   68 ºC  7 min 
Soak    4 ºC  to end 
All the experiments included a negative and positive control. The negative control was water 
as template and a negative control for cDNA conversion was also included. The amplicons 
were run on a 3% agarose gel in 1xTBE and the size of the bands estimated by comparison 
with 1 Kb standard marker. 
 
Real time PCR 
Having confirmed that a single product was obtained and conditions for PCR had been 
optimised, the expression of the defensin genes was assessed quantitatively in real time using 
SYBR green on an Opticon QT-PCR machine (GRI systems, UK). Real time or quantitative 
PCR has the advantage of allowing quantitation as the amount of product is calculated by the 
system after each cycle. The conditions of PCR had to be re-optimised for real time analysis 
but best results were obtained at annealing temperatures of 60ºC and 40-cycle reaction, as 
above. Quantitative PCR was carried out using Dynamo SYBR green qt PCR kit (Finnzymes 
F-400L, UK). The reactions were undertaken following the manufacturers protocol. 
For experiments in which the quantity of RNA was low, a further modification of PCR, Duplex 
PCR, was performed.  
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Duplex PCR 
This involves amplifying two genes simultaneously in one reaction and helps in conserving the 
limited resources. This was done using Qiagen Multiplex PCR no ROX kit (Qiagen; UK). Each 
duplex reaction was composed of the housekeeping gene β actin and the gene of interest i.e. 
HBD1, HBD2 or HBD3. 
 
Primer design 
The primer design is one of the key factors influencing the specificity and sensitivity of the 
duplex PCR. The primers require to have similar amplification efficiencies and should not form 
primer dimmers. This can be achieved by designing primers with similar annealing 
temperatures, GC content between 35-60% and by choosing primers which lack homology 
within themselves or with one another. These factors were considered and the primers were 
designed using the software on the Qiagen Website 
(https://customassays.qiagen.com/design/inputsequences.asp). Preliminary experiments to 
optimise the duplex assay were performed, which included comparison of primer efficiencies 
and optimisation of the annealing temperatures. Subsequently the individual experiments were 
carried out in triplicate and the mean of the Ct values (the point at which the amplification 
curve crosses a threshold of amplification) was taken to analyse the results. 
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2.6 Microbial estimation 
Microbial estimation was done on a day-to-day basis. The sample was transported as 
described above taking all necessary aseptic precautions. 1μl and 10μl of the sample that had 
been transported in PBS were plated on day 1 on blood agar, Neomycin blood agar and Mac 
Conkey plates, and incubated at 37 ο C under aerobic and anaerobic conditions. The plates 
incubated under aerobic conditions were observed after 24 hours and those incubated under 
anaerobic conditions were observed after 48 hours. On day 2 a further 1μl or 10μl were plated 
depending on whether or not there was growth or no growth on plates from day 1. These 
plates were used to further analyse the growth in terms of counts and types of bacteria and 
also to obtain distinct colonies so that further tests could be done.  
 
The aliquots of the tissue transported in Robertson’s cooked meat medium (RCM) was also 
plated in a similar way. Robertson’s cooked meat medium served for enrichment of organisms 
present in small numbers, as transport medium for the anaerobes, and also to dilute the effects 
of any antibiotics that might have been used. The containers used were weighed before and 
after tissue addition to ascertain the weight of the tissue within. The colonies were counted 
manually if they were distinct, otherwise they were approximated as shown in the diagram, 
after being plated by streak method of serial dilution (figure 2.6). 
(http://www.microbiologyprocedure.com/microbiological-methods/streak-plate-method.htm) 
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Figure 2.6. An illustration showing the approximation of bacterial counts on an agar plate 
 
The bacterial count of each of the plates was recorded. The counts from day 1 PBS plates 
were regarded as most significant unless the counts on day 1 from 1 μl RCM plates were 
drastically different, when the average of the two counts was taken. Gram staining was 
performed on all colonies taking care that a distinct colony was picked up.  
 
Preparation of a bacterial smear on the slide 
A new slide was taken, cleaned with alcohol and labelled to identify from which plate the 
colony was taken. 1μl of sterile PBS was taken with a sterile loop and transferred to the slide. 
Taking a sterile loop, a small aliquot of a distinct colony was transferred to the PBS on the 
slide. The colony was mixed gently to form an even smear and then the slide was transferred 
to a hot plate to allow the smear to dry. Once the smear was adequately dry it was removed 
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from the hotplate and stored for future use. The slide could be stored normally in any rack and 
no special conditions were required. 
 
Gram Staining 
Bacteria can be classified as gram positive or gram negative based on the properties of the 
cell wall that affects whether the bacteria retain the primary stain, or lose it and take up the 
secondary stain. In gram negative bacteria, due to the permeability of the cell wall, alcohol 
washes off the primary stain whereas in gram positive bacteria the stain is retained. 
 
Crystal violet was used as the primary stain, which was left on the slide for a minute. The slide 
was then washed with distilled water and the mordant Lugols iodine (QCM Laboratories, UK) 
was applied for a minute. This was followed by a wash with distilled water. Decolourising was 
achieved using 3% acid alcohol (QCM Laboratories, UK) and lasted no more than 30 seconds. 
Safranin (QCM Laboratories,UK) was used as counter stain and the step lasted for a minute 
(http://www.ganfyd.org/index.php?title=Gram_stain). After this the slides were washed with 
distilled water to remove the excess stain and after being dried the slides were visualised 
under oil immersion. The physical characteristics of the colonies such as shape, colour, 
haemolysis, mucuoid nature, spreading pattern and any characteristic smell were noted. After 
this the bacteria were characterised using confirmatory tests such as catalase, coagulase and 
oxidase activity as needed (http://www.ganfyd.org/index.php?title=Gram_stain, 
http://www.splammo.net/JLbactsite.html). 
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2.7 Cell Culture 
 
mRNA and protein extracted from cultured cells were used to optimise the conditions for real 
time rt-PCR and immunohistochemistry. This was done to ensure that invaluable patient 
material is not lost in optimising the techniques. Psoriatic cell lines provided the positive control 
and the specificities of the commercially available antibodies was determined using western 
blot, on the protein extracted from these cell lines. 
Keratinocytes are the principal cellular components of the epidermis while fibroblasts constitute 
the principal cellular type in the dermis. Experiments were carried out on the primary 
fibroblasts derived from normal skin, keratinocyte and psoriatic cell lines. 
Keratinocyte cell lines rTS31b, which are immortalized squamous cell carcinoma cells lines 
and nTERT, which are keratinocytes immortalised by fusion with telomerase positive cells 
were provided by Professor Navsaria (Centre for cutaneous research). Psoriatic cell lines –
PSA 1 and PSA 2, were originally developed at the Institute of Cell and Molecular Science 
(ICMS) by Professor Navsaria’s group. These cell lines were produced from the lesional 
psoriatic scale cells after fusion with telomerase positive cells. 
Cells were cultured for at least two passages and enough stocks were produced before 
starting the experiments to ensure availability of similar passage stock cells for all the 
experiments. 
 
The keratinocyte cell lines were grown in E4+ F12 medium with 10% foetal calf serum; E4 + 
F12 is a mixture of 3 parts DMEM (Dulbeco’s modified Eagles medium) and 1 part Hams 
medium and supplied pre-made by the Cancer Research UK at the ICMS. 
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The E4+F12 medium was supplied in 400ml bottles and the final medium was prepared 
according to the following protocol. 
 
Protocol for preparation of the medium 
To 400ml of E4 +T12 (usually stored at 4ºC in cold room) 4 ml of glutamine (1% final 
concentration of the 100x stock) and 40 ml of freshly thawed foetal calf serum (FCS) were 
added and the solution was mixed well. The solution was sterilised using a sterile vacuum filter 
and then stored at 4ºC. For primary fibroblasts and keratinocyte culture an additional 
supplement 4 ml of RM+ (Appendix) was added to the media. 
 
Protocols for plating the cryopreserved cells 
All the work was carried out in sterile environment inside a Class II tissue culture cabinet, using 
sterile disposable pipettes. The cabinet was cleaned each time with either 95% alcohol or 
other cleaning solutions depending on the protocol of the laboratory.  
The media was prepared and warmed to 37 °C in a water bath.  About 20 ml of warm medium 
was transferred into a 50ml falcon tube. The vial containing frozen cells was quickly thawed in 
a water bath at 37°C as rapid thawing was considered to give better yields of cells than 
gradual thawing, as cells spend less time in DMSO environment. Better results were obtained 
by gently shaking the tube than by pipetting, which can kill the cells. The cells were centrifuged 
at 1000rpm for 5 minutes; the supernatant pipetted out, ensuring the pellet was not disturbed, 
leaving about 0.5ml of medium along with cell pellet. 
The cells could have been washed once again with the medium as described above; however 
it was advisable to seed the cells at this stage as more cells were lost in re-suspending and 
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spinning the pellet. The pellet was resuspended in 2 ml of warm medium and transferred into a 
75ml flask. The flask was labelled with the name of the cells, passage number, user name and 
date seeded. 20ml of warm medium was added before transferring the cells to the flask. The 
cells were checked under the microscope at low power (5 x magnifications) to ensure 
presence of cells, which at this stage would still be floating. The flask was placed in an 
incubator at 37 °C with 10% CO2 and cells were checked the following day to ensure the cells 
had attached and there was no bacterial contamination. 
The medium was initially changed once every 5 days and once the cells were about 50% 
confluent, the media was changed every 2nd or 3rd. If cells were dying, or there was suspicion 
of contamination then the medium was changed earlier. The cells were split at about 70-80% 
confluence. It has been observed that when cells are allowed to grow in more abundance they 
undergo phenotypic changes and may also undergo mutations. Such changes can give rise to 
varied results especially when different experiments are planned from this cell stock. 
 
Tissue culture -protocol for sub-culturing (splitting) the keratinocytes 
The normal splitting ratio was 1:5 but this was varied as required. The media was aspirated 
and 5ml of versene (an aqueous solution of EDTA a chelating agent; GIBCO-Versene, 
Invitrogen UK) was added to each 75ml flask and incubated at 37°C for 10 minutes. The 
versene was aspirated and the cells were washed twice with 10ml of warm PBSA each time. 
10ml of PBSA was then added and flasks were incubated at 37°C for 20min. The PBSA was 
aspirated and 10ml of a 1:1 Trypsin/Versene (at 37°C) solution was added and flasks were 
incubated for 8-10 minutes. After this time, the cells were viewed under the microscope and 
tapped on the sides to facilitate cells into suspension.  When cells appeared to round up, the 
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solution was neutralised with an equal volume of culture media, the contents of the flask 
pipetted up and down and then transferred to a Falcon tube. 
If some cells were still adherent, the trypsin step was repeated to facilitate complete removal. 
The cell suspension was vortexed at low speed to produce a homogeneous suspension and 
the cells counted. 
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Performing cell count 
A Neubaeurs counting chamber and the thick cover slip were cleaned with alcohol and the 
cover slip was placed over the H of the counting chamber. About 10µl of homogeneous cell 
suspension was inserted into the space to cover the mirrored surface. 
The 4 corner squares and the central square in each counting chamber were counted in 40X 
magnification (4 x objective). The total count was divided by the umber of squares counted and 
as the depth of the counting chamber was 0.1 mm, the count was divided by 0.1 which gave 
the number of cells /mm3, and multiplied by 1000 to yield the number of cells per ml. 
A million cells were added per flask, together with fresh media, and the flasks were placed in 
an incubator with 10% CO2 at 37°C. Cells were observed as described previously for viability 
and infection. The cultured cells were further processed for extraction of RNA or protein. 
 
Protein extraction from cultured cells  
For protein extraction, cells were grown on a 100mm plate. When the cells were about 70-80% 
confluent protein was extracted. This is preferred as at this stage the majority of the cells are 
the same stage of development and hence the extraction would be most representative. The 
plates were placed flat on ice during the extraction. To wash each plate ice cold PBS (5-10 ml 
per plate) was added and mixed by swirling the plate around so that all areas were covered, 
the liquid was then discarded and the wash was repeated twice. 
 
Preparation of the RIPA buffer and proteinase inhibitor mix 
For each plate of 100mm size 300µl of RIPA buffer (Prepared as described in the Appendix) 
containing commercial proteinase inhibitor was added following the manufacturers instructions. 
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The buffer was swirled around until it covered all the areas on the plate. The plate was then 
incubated at 4°C for 20 minutes (on ice). Having removed all the PBS, the cells were 
harvested using a cell scraper and the recovered cells were transferred to an eppendorf tube 
using a pipette. The contents of the eppendorf tube (low speed) were sonicated. The sonicator 
probe was washed twice with distilled water before, after and in-between each sonication. 
The extracted proteins were then analysed using Western blotting.  
 
2.8 Protein analysis 
 
Bradford Assay; protein quantitation 
 
One ml of Bradford concentrate (BIORAD, UK) was added to 4ml of distilled water. Bovine 
serum albumin (BSA) (Cambio, UK) was prepared at a concentration of 1ug/ul. One ml of 
Bradford reagent was added to 2µl of RIPA buffer and the appropriate concentration of BSA. 
The tubes were mixed and the absorbance read at 595nm.  
Different concentrations of BSA (0, 1, 2, 4, 8, 12, 16 and 20µg) were used to construct a 
standard curve. 1ml of diluted Bradford reagent was added to 2µl sample and the absorbance 
was assessed at 595nm. The samples were diluted if required in RIPA buffer and protein 
concentration was read from the standard curve.  
 
SDS-PAGE Western blotting  
20µg of protein in a total volume of 16µl was added to 4µl of loading buffer. (For preparation 
refer Appendix). The samples were incubated for 5 minutes at 90°C. The ladder (Invitrogen, 
UK) was prepared according to the manufacturers instructions. 
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Preparation of SDS PAG 
The 16% gel was prepared as per the protocol(Sambrook and Russell, 2001) 
Once the separating and stacking gels had set, the samples and ladder were loaded. 
Electrophoresis was carried out at a voltage of 100V until the protein bands began to move 
and subsequently the voltage was increased to 140 V for 45 minutes. 
 
Western blot 
The blot was set up according to the manufacturer’s instruction and a. PVDF membrane (VWR 
international, UK) was used to capture the blotted proteins. Blotting was carried out at 400mA 
(constant current) for 2 hours for 2 gels of full size.  
The membrane was removed and the transfer of the markers was assessed by visualisation of 
the coloured bands in the standard marker. The membrane was washed on a rotator in 1x 
TBS–T (T= tween 20) three times, each wash lasting for 5 minutes. The membrane was then 
blocked with 10% milk (10% milk in TBS–T) for 30 minutes. 
 
Table 2.3- The concentrations of the primary antibodies used for western blotting 
Concentration  Primary Antibody 
1:3000 GAPDH 
1:3000 HBD1 
1:2000 HBD2 
1:5000 HBD3 
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Incubation with the primary antibody (details of dilution as shown in table 2.3) was done 
overnight in 5% milk buffer. Antibodies for GAPDH gave good results when incubated for 30 
minutes at room temperature. Two washes of 10 min each were performed with 10% milk in 
TBS-T. Incubation with the suitable secondary was done for 30 min at room temperature in 5% 
milk in buffer, followed by 2 washes as above. ECL plus reagent (GE-Healthcare, UK) was 
used for development of the bands. This was performed in a dark room according to the 
manufacturer’s protocol using an X-ray film. 
 
RNA was extracted from the cultured cells according to the following protocol 
For RNA extraction the cultured plates were washed with PBS as described earlier. 300µl of 
SV total RNA lysis buffer (Promega, UK) was added to each plate which was then scraped 
with a cell scraper. The contents of the plate, which were a mixture of cell lysate and lysis 
buffer, were then transferred to an eppendorf tube and stored at -80°C.Subsequent extraction 
of RNA was as described in the section on RNA extraction and PCR. 
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Chapter 3 
Human β-Defensin expression in 
burn wounds and correlation to 
bacteria and duration of burn 
wound. 
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3.1 Introduction 
 
Wound infections account for high morbidity and mortality in patients with burns(Pruitt et al., 
1998, Polavarapu et al., 2008). The loss of skin is considered a major factor in such infections. 
The skin was thought to protect the body by mainly providing a mechanical cover but more 
recently other specialised functions of this organ have been described. Recent studies have 
shown that epithelial cells in various parts of the body can produce a number of antimicrobial 
chemicals. Many such chemicals have been described and have diverse properties. 
Defensins, one such family of chemicals, are of interest as they show a promise in defence 
against infections. 
 
Burn wounds  
Effective wound care is paramount for the success of any surgical procedure and in patients 
who have sustained burn wounds. In these patients wound infection is associated with high 
mortality and morbidity(Aufwerber et al., 1991, Polavarapu et al., 2008). Burn wounds are 
prone to colonisation by microbes, which may cause tissue invasion and lead to infection. 
Burn wounds are assessed based on the surface area involved and depth of the wound as 
these are of critical importance in deciding the management plan and predicting the prognosis 
of a burn injury. Burn wounds are initially colonised in the first 48 hours and subsequently the 
invasion of the viable tissues occurs resulting in invasive infections. If viable tissues are 
invaded, disseminated systemic infection can occur. The colonising organisms are usually 
derived from the skin flora, usually gram positive cocci resident in the depths of the sweat 
glands and hair follicles, and thus escaping the initial injury(Luterman et al., 1986, Mooney and 
Gamelli, 1989). However the nature and type of the infective organisms are variable and 
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depend on a number of host and institutional factors(Vindenes and Bjerknes, 1995, Erol et al., 
2004). The type of organisms also vary depending on the duration since burn, the type of 
colonisation at non-burn areas in the host and the nature of the antimicrobial therapy 
administered(Erol et al., 2004).   
The importance of prevention of infection in burn wound care is a well recognised concept and 
is considered to be one of the most important factors predicting the outcome of the burn injury. 
Interestingly by investigating  the organisms that cause infection in these patients it has been 
ascertained that these patients have altered immune function, since the majority of the 
organisms causing infections are of an opportunistic nature(Pruitt and McManus, 1992, Taylor 
et al., 1992). Also the fact that serious infections in these patients involve sites other than the 
burn site further confirms this concept of immune dysregulation(Engelich et al., 2001) that 
influences both innate and adaptive components of the immune system.  
The aim of the current study was to investigate whether the high incidence of infections in 
burns patients was associated with alterations in β-defensin expression and if the type and 
pattern of HBD correlated with bacterial flora in burn wounds. The expression of HBD 1, 2 and 
3 was studied in full thickness burns in relation to microbial flora and the duration of the burn 
wound. 
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3.2 Materials and methods 
 
The materials were collected from Burns Theatre at Chelsea and Westminster Hospital; after 
obtaining ethical committee approval for the study-RREC 2992. 
 
Patient recruitment 
The patients admitted to the Burns Unit who were in relatively stable and conversable 
condition were approached. Children, pregnant women, comatose patients and mentally 
incapacitated patients were not approached either directly or indirectly because of ethical and 
practical reasons. Consent was taken after giving enough time for the patient to go through the 
information sheet and clarifying any doubts that had arisen in due course. This process would 
have become all the more difficult but for the co-operation from the doctors involved in the 
treatment of patients. The plan was to recruit patients who were undergoing debridement 
within 24 hours of trauma. These patients usually have large burns and would have been ideal 
for the study. However, they could not be recruited since they were in a very stressful situation 
and the relatives were either not approachable or refused consent. 
 
Collection of material for microbial estimation 
Material for microbial estimation was collected in 1.5ml eppendorf tubes containing 1ml of 
sterile PBS (phosphate buffered saline pH7.4).  PBS was chosen as it is considered an inert 
transport medium which does not favour the proliferation of the microbes. These tubes were 
weighed before and after the specimens were collected to calculate the mass of the tissue. 
Since the thickness of the tissues was nearly uniform the mass was taken proportional to the 
length. A punch biopsy could not be taken to maintain uniformity as regards the amount of 
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material owing to financial and practical constraints. A small piece of the tissue was 
transported in Robertson’s cooked meat medium (RCM), which served for enrichment of 
bacteria and dilution of any antibiotics which may have been used. The tissue was placed in 
the media as rapidly as possible post-collection and the media were streaked onto the 
respective bacterial nutrient plates at the earliest opportunity, taking all the necessary aseptic 
precautions. The average time lapse between collection and plating was about 3 hours. 
 
Collection of material for formalin fixation  
The material was collected at the earliest opportunity (time lapse not more than 15 minutes) 
and transferred to a container containing 10% formalin. At the time of collection the burnt 
tissue was distinguished from the relatively normal tissue present at the edges. The skin taken 
from the edges was classified as peri-burn. Either the difference in colour or the presence or 
absence of hair was considered as the criteria for differentiating between the two. Burnt tissue 
was collected in a different container from that of relatively normal tissue. 
 
Collection of material for snap freezing 
Liquid nitrogen was obtained for the process from the hospital Pathology Department after 
obtaining permission from the appropriate authorities. Different techniques were evaluated 
before selecting the best technique. Initially the tissue was placed into small cryotubes and the 
tubes were dropped in liquid nitrogen. It was realised that it was not possible to get the tissue 
out from such tubes without completely thawing the material as the small drops of fluid were 
freezing and attaching to the sides of the tube. It was considered better if the tubes and the 
tissues were frozen separately first and then the tissue transferred to the tubes. Though this 
 83
was probably the best method, it was not practical in our case since it required large quantities 
of liquid nitrogen and long forceps for taking the tissues and tubes from liquid nitrogen flask. It 
was therefore decided to put the tissues into wider mouthed tubes. Thin walled plastic tubes 
were selected for use since there was a risk of glass or thick walled tubes would break during 
freezing.  
 
The tissue has to be thawed before it is mounted on a cork in the proper orientation to be cut 
on a cryotome. Since it was not considered to be good to repeatedly thaw and freeze the 
tissue, it was decided to mount the tissue directly on cork before putting it into liquid nitrogen. 
This was done using the tissue adhesive OCT (Raymond A Lamb Laboratory Supplies; UK), 
which was applied on the cork before the tissue was laid on it. Since the skin material was thin 
it would not stand in the correct orientation, it was decided to cut through the cork and hence 
the skin was laid flat on the cork for adhesion. However, owing to the practical difficulties 
involved in cutting through the cork it was decided to orient the tissue by stiffening it by partial 
freezing using an instant freezing spray (iso-pentane) and then putting it on the cork to which 
OCT was applied. Additional pieces of skin were stored frozen by laying them on cork without 
application of any OCT. Pre-treatment  such as graded cooling using isopentane or hexane are 
considered better than direct freezing in liquid nitrogen since sudden chilling is likely to make 
the tissue brittle which in turn poses difficulties while making sections. Also washes with PBS 
can be given to rid the material of blood. Since it was not practically possible to transport 
frozen material on a day-to-day basis from the hospital to the university laboratory the samples 
were batched up and transported either in liquid nitrogen or on solid CO2. 
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Thus the final protocol was as follows: tissue material for RNA work was collected in wide 
mouthed plastic containers, the material for cryo-sections was first hardened using iso-pentane 
spray and then applied to OCT coated cork.  
 
Labelling of materials 
All the materials were adequately labelled using a unique coding system so as not to reveal 
the patient identity. Uniformity of labelling was maintained with regards to the tissues being 
stored and processed by different methods. 
 
Immunohistochemistry 
The tissue sections were processed by immuno-fluorescence techniques as described earlier 
and were analysed by stoichiometric methods. 
 
Microbial estimation 
A qualitative and quantitative microbiological analysis was performed as described in the 
methods chapter. 
 
RNA extraction and expression analysis 
Since the debrided skin was from areas which was exudative and burnt, RNA extraction was 
not predicted to be easy. Exudates are considered to be rich in RNAses and the burning 
process destroys the cells and the RNA. A variety of different methods of RNA extraction were 
trialled and the best extraction was achieved using SVtotal RNA (Promega, UK; Z3100) 
isolation system. 
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RNA was extracted from frozen burn skin material using the following steps. Tissue material 
was ground into fine powder using a ceramic homogeniser in an atmosphere of liquid nitrogen. 
All standard precautions were taken to ensure the environment was free of RNAses and that 
all instruments and the work bench were pre-treated with RNAZap (Promega, UK). The 
powdered tissue material was then transferred to a pre-weighed eppendorf tube containing 1ml 
of lysis buffer according to the manufacturer’s protocol (SV total RNA extraction kit; Promega, 
UK) after allowing the liquid nitrogen to evaporate. The eppendorf tube was weighed to 
estimate the weight of the tissue, which was 30mg per 175μl of lysis buffer. The contents of the 
eppendorf tube were homogenised using glass homogenisers. Additional lysate beyond 175μl 
was frozen at –70 °C. To 175μl of lysate 350μl of dilution buffer was added and the contents 
mixed by inversion. Subsequent extraction steps were as described earlier in the methods 
chapter. The RNA, which was collected in the elution tube, was assessed by 
spectrophotometric analysis for purity and stored at –70° C until further processing.  
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Table 3.1 NCBI accession numbers of the genes analysed, and the sequence of the 
specific forward and reverse primers 
Gene 
 
Accession number Sequence;5’-3’ 
HBD1 U73945 Forward-
AATCCTGAGTGTTGCCTG 
Reverse-
GCGTCATTTCTTCTGGTC 
 
HBD2 Z71389 Forward-
CAGCCATCAGCCATGAGGGT 
Reverse-
GGAGCCCTTTCTGAATCCGCA 
 
HBD3 AJ237673 Forward-
GCCTAGCAGCTATGAGGATC 
Reverse-
CTTCGGCAGCATTTTGCGCCA 
 
Β Actin NM_001101 Forward-
CCAACAGAGAGAAGATGAC 
Reverse-
AGGAAGGAAGCCTGCAAC 
 
 
cDNA conversion 
mRNA was converted to cDNA  using ImProm II Reverse Transcriptase (RT) kit 
(Promega;UK). Conversion was based following the manufacturers protocol as described 
earlier. The samples were run on the gel and the size of the bands estimated by comparison 
with 1Kb standard marker. 
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Real time PCR 
Real time (quantitative) PCR analysis was carried after optimization as described earlier using 
Opticon II quantitative thermal cycler (GRI Biosystems; UK). The set of primers as shown in 
Table 3.1, used for RT-PCR were used for quantitative PCR. 
 
3.3 Data Analysis and Results 
The patients were subdivided into two groups; B and C. Group B included patients with burn 
wounds of less than 2 weeks duration at the time of debridement and group C comprised of 
patients with burn wounds of more than 2 weeks duration. The details of the patients are 
shown in table 2.1. The mean age was 48.44 years with a range-24-88 years, the sex 
distribution was 8:10; male: female. The mean percentage burn was 7.05%. This varied 
between the groups, the mean percentage burn for B group was 3.73 (min-1%, max-15%) for 
group C was 8.88%, (min-1%, max-30%). The range of burns was 1-30%. The distribution of 
burns in our study population was very varied as seen in table 3.2 and figure 3.1. The most 
common site was arm followed by the forearm. 
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Table 3.2 Patient details 
Patient 
code Sex 
Age 
(Years) 
Percentage 
of burn 
Duration of 
burn in days Site of burn 
1B M 29 1 7 Leg 
2B F 70 8 3 Arm 
3B F 67 2 5 Abdomen 
4B F 24 1 7 Arm 
5B M 30 1 10 Hand 
6B F 41 2 2 Fore arm 
7B M 42 4 3 Groin 
8B M 47 5 7 Back 
9B F 50 1 2 Finger 
10B F 47 15 3 Fore arm 
11B M 67 1 6 Fore arm 
1C M Not noted 4 14 Not noted 
2C F 36 6 14 Chest 
3C F 38 2 16 Arm 
4C M 64 6 14 Axilla 
5C M 88 1 60 Sole 
6C F 27 20 30 Back 
7C M 58 30 21 Arm 
8C F 47 2 14 Forearm 
 
 
 89
5.26%
5.26%
5.26%
5.26%
5.26%
10.53%
5.26% 26.32%
21.05%
10.53%
axilla
abdomen
sole
leg
groin
back
chest
arm
fore arm
hand
SiteSite Distribution of the samples
 
 
Figure 3.1 Summary of the burn sites in the patients.  
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L1-empty, L2 –psoriatic sample, L3-Normal Skin, L4-empty, L5-16 patient samples 
Figure 3.2 shows the analysis of RNA extracted from skin and separated on a 1% agarose 
gel.  Two bands (arrows), 23s (upper band) and 18s (lower band) rRNA were noted in the 
patient samples and the psoriatic and normal skin specimens. The quality of the total RNA 
extracted varied between the patient samples with some samples (6 and 11) showing good 
quality RNA (distinct 23S and 18s bands) whereas others (15 and 16) giving a hazy smear. 
23S
18S
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Real time PCR data  
 
The experiments with each sample were done in triplicate and Table 3 shows the final values, 
which were taken for further calculation of the relative expression. The samples that did not 
show clear peaks on melting curves for the products were not considered and the experiment 
repeated. Those showing slight alteration in the melting temperature of the product away from 
the control were considered as significant if they showed clear single peak in melting curve. 
Some samples were run on the gel to confirm the presence of the product. 
Table 3.3 Quantitative PCR data for HBD1 and housekeeping gene-β- Actin (Ba) 
Patient code 
Mean 
C(T)-B1 Mean Tm 
Mean 
C(T) Ba  Mean Tm
7B/burn B1 20.5 80.1 29.0 86.6
7B/periburn B1 19.6 80.8 23.4 86.3 
8B/burn B1 22.0 81.2 17.9 86.2 
8B/periburn B1 16.1 81.6 16.9 86.5 
9B/burn B1 16.2 80.8 21.2 82.5 
9B/periburn B1 20.9 83.5 28.6 86.4 
10B/burn B1 9.71 82.9 11.7 85.8 
10B/periburn B1 18.2 78.4 17.9 85.4 
11B/burn B1 20.6 81.8 26.8 78.0 
11B/periburn B1 17.4 83.4 19.3 86.2 
1C/periburn B1 20.1 86.1 24.8 85.7 
2C/burn B1 17.7 84.3 17.2 86.3 
2C/periburn B1 17.7 82.7 15.4 85.9 
4C/burn B1 24.5 83 28.5 86.8 
4C/periburn B1 20.8 82.4 29.5 86.7 
5C/burn B1 23.5 81.5 21.2 86.0 
5C/periburn B1 20.9 82.2 21.0 85.9 
6C/burn B1 23.9 80.2 26.4 78.0 
6C/periburnB1 23.6 84.4 24.3 78.4 
7C/burn B1 20.3 81.8 22.2 85.7 
7C/periburn B1 21.3 83.4 23.5 86.8 
8C/burnB1 21.1 82.7 27.5 85.9 
8C/periburn B1 19.8 82.2 26.8 86.5 
Psoriatic Skin 16.8 84.8 14.8 87.8 
Normal Skin B1 28.2 83.6 13.0 78.8 
Mean SD 3.4 1.7 5.2 3.0 
Mean  82.3  84.8 
 92
 
Table 3.4-Real time PCR data for HBD 2 gene and housekeeping gene-β- Actin (Ba). 
Label 
Mean 
C(T) B 2 Mean Tm Mean Ba 
Mean Tm 
Ba 
7B/burn B2 21.7 82.2 29.0 86.6 
7B/periburn B2 20.7 82.3 23.4 86.6 
8B/burn B2 21.0 81.9 18.0 86.4 
8B/periburn B2 16.0 82.0 16.9 87.0 
9B/burn B2 18.8 80.1 21.2 86.6 
9B/periburn B2 21.8 81.9 28.6 86.6 
10B/burn B2 10.4 82.1 11.7 86.0 
10B/periburn B2 21.4 79.8 17.9 86.0 
11B/burn B2 23.6 81.3 26.8 78.0 
11B/periburn B2 17.5 81.0 19.3 86.2 
1C/burn B2 24.1 82.1 28.2 86.6 
1C/periburn B2 23.6 82.5 20.2 86.4 
2C/burn B2 17.2 82.3 17.2 86.8 
2C/periburn B2 16.5 81.5 15.5 86.0 
4C/burn B2 20.5 82.0 28.5 86.0 
4C/periburn B2 20.2 82.2 29.5 86.0 
5C/burn B2 14.0 81.2 21.2 86.0 
5C/periburn B2 13.3 80.3 21.1 86.6 
6C/burn B2 28.6 78.4 26.4 78.0 
6C/periburnB2 25.9 83.6 24.3 78.4 
7C/burn B2 17.4 80.8 20.8 86.2 
7C/periburn B2 21.6 86.2 23.5 86.8 
8C/burn B2 16.4 83.0 27.5 86.6 
8C/ periburn B2 21.8 81.5 26.8 86.4 
Psoriatic skin 15.3 83.2 14.8 87.8 
Normal skin 23.2 78.4 13.1 78.8 
Mean SD 3.4 2.4 5.4 2.9 
Mean   81.5   85.0 
 
 93
Table 3.5-Real time PCR data for HBD3 gene and housekeeping gene- Β Actin (Ba). 
Label 
Mean 
C(T) B3 Mean Tm Mean Ba Mean Tm
7B/burn B3 24.4 78.2 29.0 86.6 
7B/periburn B3 22.7 79.1 23.4 86.3 
8B/burn B3 20.0 81.5 18.0 86.2 
8B/periburn B3 21.0 82.6 16.9 86.5 
9B/burn B3 19.2 84.8 25.0 86.6 
9B/periburn B3 24.1 84.8 28.6 86.4 
10b/burn B3 14.2 85.0 11.7 85.8 
10b/periburn B3 21.8 78.4 22.0 86.0 
11B/burn B3 25.0 81.8 20.1 78.4 
11B/periburn B3 20.4 84.6 19.3 86.2 
1C/burn B3 26.7 78.5 28.2 83.3 
1C/periburn B3 23.2 83.1 24.8 85.7 
2C/burn B3 18.1 81.4 17.2 86.2 
2C/periburn B3 18.4 81.4 15.5 85.9 
4C/burn B3 23.8 78.9 28.5 86.8 
4C/periburn B3 24.2 82.0 29.5 86.7 
5C/burn B3 19.2 84.6 20.8 86.1 
5C/periburn B3 18.7 84.3 21.1 85.9 
6C/burn B3 23.4 80.4 26.4 78.0 
6c/peri-burn B3 24.1 80.2 24.3 78.4 
7C/periburn B3 20.8 79.6 20.8 86.2 
7C/graft B3 20.1 84.6 23.5 86.8 
8c/periburn B3 16.2 82.7 27.5 85.9 
8c/graft B3 25.7 78.9 26.8 86.5 
Psoriatic Skin 16.6 78.4 14.8 87.8 
Normal skin 25.6 79.2 13.1 79.0 
Mean SD 3.4 2.4 5.4 2.9 
Mean    81.5   85.0 
 
Tables 3.3, 3.4 and 3.5 show the mean threshold cycle [C(T)] and mean melting temperature 
of the product (Tm) for each of the samples for the HBD(B1,B2 &B3) and Β Actin(Ba) genes. 
The patient codes indicate the patient serial number followed by B or C which indicates 
whether the patient belonged to the <2 weeks group or >2 weeks group respectively. Only 
those pairs have been listed from whose RNA successful amplification was possible. B1-
denotes HBD1, B2-denotes HBD2, B3-HBD3 and Ba-Β Actin. 
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Variability of Tm was seen in some samples. The mean Tm wereas follows: for HBD1-82.3ºC 
(SD-1.6ºC), HBD2-81.5ºC (SD- 2.4ºC), HBD3-81.5ºC (SD- 2.4ºC), Β Actin-85ºC (SD-3ºC). 
 
The individual patient samples showed slight variation in melting temperatures as indicated by 
the standard deviations. The melting temperature for the products was lower in the burns 
patient’s samples than in the normal skin sample; this is probably related to the difference in 
salt concentrations required for normal and burn skin samples. 
The Tm for HBD3 varied between 78/ and 79ºC or 82ºC and 83ºC, this could be related to the 
presence of a yet undescribed polymorphisms in the HBD3 gene. It is intended to sequence 
the product of the amplification to confirm this finding. 
 
RNA and Protein expression  
 
RNA and protein expression for individual patient samples is listed in Table 4. RNA expression 
is expressed in the form of 2-DdCt. Dct is calculated as difference between Ct (cycle number 
when the product appeared) of the defensin gene and the actin gene. Taking a reference 
sample among the samples (in this experiment psoriatic sample) and subtracting the Dct of 
sample from Dct of psoriatic tissue gives Ddct. This is then expressed as 2-DdCt. This gives the 
expression of RNA of the concerning gene relative to the reference gene normalised to the 
housekeeping gene. Psoriatic tissue was chosen as the reference sample for this study and 
the reference gene was β–actin. Protein expression, detected by immunohistochemistry was 
graded blindly (stoichiometric analysis) on a scale of 0-4 with 0 being the lowest expression 
corresponding to no expression and 4 being the maximal expression (table 3.6). 
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Table 3.6 mRNA and protein expression. 
Number 
B1-RNA 
Expression 
2 -DdctB1 
B2-RNA 
Expression 
2 -Ddct B2 
B3-RNA 
Expression 
2 -Ddct B3 
Protein 
Expression 
B1 
Protein 
Expression 
B2 
Protein 
Expression 
B3 
1B/burn No RNA No RNA No RNA 2 2 3 
1B/periburn No RNA No RNA No RNA 1 1 3 
2B/burn No RNA No RNA No RNA 2 0 2 
2B/periburn No RNA No RNA No RNA 3 1 2 
3B/burn No RNA No RNA No RNA 2 0 1 
3B/periburn No RNA No RNA No RNA 3 0 2 
4B/burn No RNA No RNA No RNA 1 0 2 
4B/periburn No RNA No RNA No RNA 2 4 3 
5B/burn No RNA No RNA No RNA 1 0 3 
5B/periburn No RNA No RNA No RNA 2 1 1 
6B/burn No RNA No RNA No RNA 3 1 2 
6B/periburn No RNA No RNA No RNA 1 0 1 
7B/burn 212 26 29 2 0 3
7B/periburn 29 24 26 2 3 2 
8B/burn 23 22 27 1 0 3 
8B/periburn 23 27 27 2 3 4 
9B/burn 210 26 28 2 2 2 
9B/periburn 29 27 25 4 1 4 
10B/burn 29 25 26 2 4 3 
10B/periburn 24 22 27 2 4 1 
11B/burn 24 27 24 1 1 2 
11B/periburn 24 21 21 2 5 3 
       
1C/burn 212 28 26 0 0 3 
1C/periburn 20 20 1/21 2 0 2 
2C/burn 26 25 23 0 0 1 
2C/periburn 21 21 21 1 0 2 
3C/burn No RNA No RNA No RNA 0 0 1 
3C/periburn No RNA No RNA No RNA 1 1 2 
4C/burn 1/21 27 23 1 0 2 
4C/periburn 23 25 21 3 0 3 
5C/burn 1/22 210 26 1 0 2 
5C/periburn 24 27 24 1 0 1 
6C/burn 25 1/22 25 4 2 2 
6C/periburn 23 1/21 22 2 4 3 
7C/burn 24 25 24 1 0 1 
7C/periburn 22 24 22 1 1 2 
8C/burn 28 25 25 2 1 1 
8C/periburn 26 29 211 2 2 2 
7C/graft 26 22 24 3 3 3 
8C/graft 26 23 24 4 2 4 
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AmplifiableRNA could not be extracted from 7patient samples. These include 6 samples from 
the subset “B” and 1 from subset “C”. Protein expression could be visualised in all the patient 
samples in both B and C groups. B subgroup indicates samples<2 week’s duration while C 
subgroup indicates samples > 2 week’s duration. 
 
 
Figure 3.3 Summary of RNA and protein extraction from patient samples 
The Y –axis denotes the number of patients while the X axis denotes the protein or RNA 
extraction. All samples from group B and C patients expressed protein which could be 
visualised, whereas only in about 40% of those with burns less than 14 days and 75% of those 
with burns more than 14 days was RNA extractable (tables 3.6 and figure 3.3). 
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Figure 3.4 Boxplot of the protein expression in psoratic and burns tissues 
The median protein expression in psoriatic samples was higher than the median protein 
expression of the HBD1,2 and 3 in the burn patient samples(both burn and peri-burn).(B1,2&3 
refer to the β defensin expression).The scale on the Y-axis represents an arbitrary grading 
scale. 
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Figure 3.5 Boxplot of the mRNA expression in psoratic and burns tissues 
The boxplot comparing the expression demonstrates that the median HBD1,2 & 3 RNA 
expression (shown by the black line inside the box) in the burn patient samples (both burn and 
periburn) was higher as compared to the expression in psoriatic tissue. This difference was 
statistically significant as shown by the independent sample t-test (Table 7). The small circles 
at the bottom of the figure denote the outlying values where the expression was less than that 
of psoriatic sample. 
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Table 3.7: Independent samples t-test-comparing HBD1,2& 3 RNA and protein expression 
between psoriatic and burn samples(All burn samples included both burn and periburn) 
  
Levene's Test 
for Equality 
of Variances t-test for Equality of Means 
  F Sig. T Df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
                Lower Upper 
B1RNA Equal 
variances 
assumed 4.2 0.1 -1.9 22.0 0.1 -5.4 2.8 -11.1 0.4
  Equal 
variances 
not assumed    -6.6 21.0 0.0 -5.4 0.8 -7.1 -3.7
B2RNA Equal 
variances 
assumed 3.1 0.1 -2.1 22.0 0.0 -4.6 2.2 -9.2 -0.1
  Equal 
variances 
not assumed 
   -7.1 21.0 0.0 -4.6 0.7 -6.0 -3.3
B3RNA Equal 
variances 
assumed 3.0 0.1 -2.2 22.0 0.0 -4.3 1.9 -8.3 -0.3
  Equal 
variances 
not assumed    -7.5 21.0 0.0 -4.3 0.6 -5.5 -3.1
B1protein Equal 
variances 
assumed 3.1 0.1 3.3 38.0 0.0 2.3 0.7 0.9 3.6
  Equal 
variances 
not assumed    14.7 37.0 0.0 2.3 0.2 2.0 2.6
B2protein Equal 
variances 
assumed 4.4 0.0 2.7 38.0 0.0 2.8 1.0 0.7 4.9
  Equal 
variances 
not assumed    12.0 37.0 0.0 2.8 0.2 2.3 3.3
B3protein Equal 
variances 
assumed 3.0 0.1 3.1 38.0 0.0 1.8 0.6 0.6 3.0
  Equal 
variances 
not assumed    13.8 37.0 0.0 1.8 0.1 1.6 2.1
 
As shown (highlighted column) in Table 3.7 the difference between protein and RNA 
expression in the psoriatic and burn tissue was statistically significant for all the three HBDs. 
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Figure 3.6 Individual protein expression in both the B(< 2weeks) and the C(>2 weeks) groups. 
The expression in both the burn and the peri- burn area is shown in each sample with the mean 
expression of all the samples in the group shown with a thick orange line. 
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As seen in the figure 3.6 the periburn HBD1, 2 & 3 protein expression in the B group (ie < 
2weeks) was higher as compared to the defensin expression of the burns in most of the 
samples (e.g. 9 of 11). Samples 6 and 11 showed expression contrary to the general pattern 
for all the three defensins. The expression of HBD 1, 2 & 3 proteins in the C group (>14 days 
group) was predominantly higher or equal in peri-burn area to that in the burn group except in 
samples 3,7 for HBD1, 8 for HBD2 & 1,5 for HBD3. In these samples the expression was 
higher in the burn area compared to the peri-burn areas.  
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Figure 3.7 Individual expression of HBD1, 2 & 3 RNA in both the B and the C groups.  
The individual expressions in both the burn and the peri-burn areas are shown with the mean 
expression in the group depicted by the thicker line. 
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As seen in the figure 3.7, the RNA expression of all three HBDs in B group (< 2 weeks) the 
expression was predominantly higher in the burn group as compared to the peri-burn group 
except in the sample 9b which showed expression opposite to the general norm for all the 
three β defensins. 
The HBD1, 2& 3 RNA expression in the patients of C group (> 2 weeks) was predominantly 
higher in the burn area as compared to the peri-burn area. There were however individual 
variations to this trend in that the expression was higher in the peri-burn areas in samples 4c, 
5c for HBD1 RNA, 6c, 8c for HBD2 RNA and 8c for HBD3. The RNA expression among 
individual samples was elevated as compared to psoriatic tissue expression except in samples 
1c, 4c, 5c, and 6c. In sample 1c the periburn area showed a decreased expression of HBD3 
RNA. In samples 4c and 5c the HBD1 expression in burn area was less than the psoriatic 
tissue expression. In sample 6c both the burn and periburn area showed a decreased 
expression of HBD2 RNA. 
 
Thus to summarise, as seen in figures 3.8 and 3.10, the mean expression of HBD1,2& 3 
mRNA was higher in the burn areas compared to peri-burn areas in burn wounds of both less 
than 2 weeks and more than 2 weeks duration. However the protein expression was higher in 
the peri-burn areas in burns of both less than and greater than 2 weeks as seen in summary 
figure 3.10.  
Figure 3.9 shows representative sections stained with HBD1, 2, and 3 antibodies. 
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Figure 3.8 Mean HBD1,2 &3 RNA expression in the Burn and the Peri-burn area.  
The upper panel shows the expression in the early (<2 weeks or B group), while the lower 
panel shows the expression in the late (>2 weeks or C group). The bars represent the standard 
error. 
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Figure 3.9 Immunostaining of the burn skin sections stained with the HBD antibodies 
and the developed with DAB.  
The arrows show the immunolocalisation of the individual HBD. Panel A shows the no primary 
antibody –ve control; Panel B, C, D show the HBD1, 2 and 3 localisation respectively graded 
by stoichiometric methods. 
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Figure 3.10 The mean HBD1,2 &3 protein expression in the Burn and the Peri-burn area 
The upper panel shows the expression in the early (<2 weeks or B group), while the lower 
panel shows the expression in the late (>2 weeks or  C group). The bars represent the 
standard error. 
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Table 3.8: Paired samples test-comparing the RNA and protein expression between the 
burn and peri-burn samples in both the early and late burn groups 
 
 Paired Differences t Df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference       
        Lower Upper       
Pair 1 burnB1RNA - 
periburnB1RNA 
1.3 4.3 1.3 -1.6 4.2 1.0 10.0 0.4 
Pair 2 BurnB2RNA - 
PeriburnB2RNA 
0.9 3.3 1.0 -1.3 3.1 0.9 10.0 0.4 
Pair 3 BurnB3RNA - 
PeriburnB3RNA 
1.5 2.9 0.9 -0.5 3.4 1.7 10.0 0.1 
Pair 4 BurnproteinB1 - 
PeriburnproteinB1 -0.4 1.2 0.3 -1.0 0.2 -1.5 18.0 0.1 
Pair 5 burnproteinB2 - 
periburnproetinB2 
-0.7 1.6 0.4 -1.5 0.0 -2.1 18.0 0.1 
Pair 6 burnproteinB3 – 
periburnpreoteinB3 
-0.1 1.2 0.3 -0.7 0.5 -0.4 18.0 0.7 
 
 
 
Table 3.9: Paired samples test; comparing the RNA and protein expression of HBD1,2& 
3 between burn and the peri-burn samples in the early (< 2 weeks) samples 
 
 Paired Differences t df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference       
        Lower Upper       
Pair 1 burnB1RNA - 
periburnB1RNA 
2.6 4.5 2.0 -3.0 8.2 1.3 4.0 0.3
Pair 2 BurnB2RNA - 
PeriburnB2RNA 
1.0 4.1 1.8 -4.0 6.0 0.6 4.0 0.6
Pair 3 BurnB3RNA - 
PeriburnB3RNA 2.2 2.4 1.1 -0.8 5.2 2.1 4.0 0.1
Pair 4 BurnproteinB1 - 
PeriburnproteinB1 -0.5 1.1 0.3 -1.2 0.3 -1.3 10.0 0.2
Pair 5 burnproteinB2 - 
periburnproetinB2 -1.1 1.9 0.6 -2.3 0.2 -1.9 10.0 0.1
Pair 6 burnproteinB3 - 
periburnpreoteinB3 
0.1 1.4 0.4 -0.8 1.0 0.2 10.0 0.8
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Table 3.10 :Paired samples test-comparing the burn and peri-burn RNA and protein 
expression between late burn samples 
 
 Paired Differences t df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference       
        Lower Upper       
Pair 1 burnB1RNA - 
periburnB1RNA 0.2 4.2 1.7 -4.3 4.6 0.1 5.0 0.9
Pair 2 BurnB2RNA - 
PeriburnB2RNA 0.8 2.9 1.2 -2.2 3.9 0.7 5.0 0.5
Pair 3 BurnB3RNA - 
PeriburnB3RNA 0.8 3.4 1.4 -2.7 4.4 0.6 5.0 0.6
Pair 4 BurnproteinB1 - 
PeriburnproteinB1 -0.4 1.4 0.5 -1.6 0.8 -0.8 7.0 0.5
Pair 5 burnproteinB2 - 
periburnproetinB2 -0.3 0.9 0.3 -1.0 0.5 -0.8 7.0 0.5
Pair 6 burnproteinB3 - 
periburnpreoteinB3 -0.4 0.9 0.3 -1.1 0.4 -1.2 7.0 0.3
 
 
The tables 3.8, 3.9 & 3.10 show the results of paired sample t-tests comparing the β defensin 
1, 2 & 3 protein and RNA expression between burn and periburn samples, early and late 
burns. The difference between the groups was not statistically significant. 
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Table 3.11. Microbiological analysis 
 
Patient 
code 
Age % Burn Duration
Of Burn 
Variety of 
organisms Organism 1 Organism 2 CFU/gram 
1B 
 
29 
 
1 
 
7 2 
Coagulase negative 
Staphylococci 
Klebsiella.sp. 
107 
       2B 
70 8 3 
1 
S. aureus 
  102 
3B 67 2 5 0 None    
4B 24 1 7 0 None    
5B 30 1 10 0 None    
6B 
 
41 
 
2 
 
2 3 
Coagulase negative 
Staphylococci   103 
7B 
 
42 
 
4 
 
3 2 E.coli 
Coagulase negative 
Staphylococci 105 
8B 
 
47 
 
5 
 
7 2 
S. aureus Coagulase negative 
Staphylococci 107 
9B 50 1 2 2 Coryneform bacteria   105 
10B 
 
47 
 
15 
 
3 2 
S. aureus Coagulase negative 
Staphylococci 106 
11B 
 
67 
 
1 
 
6 2 
Coagulase negative 
Staphylococci 
E.coli 
106 
2C 
 
36 
 
6 
 
14 1 
Coagulase negative 
Staphylococci   103 
3C 
38 2 16 
1 
MRSA 
  106 
4C 
 
64 
 
6 
 
14 1 
Coagulase negative 
Staphylococci   106 
5C 
 
88 
 
1 
 
60 4 
Coagulase negative 
Staphylococci Proteus. sp. 105 
6C 27 20 30 1 Pseudomonas.sp.   105 
7C 
 
58 
 
30 
 
21 2 
Coagulase negative 
Staphylococci E.coli 107 
8C 47 2 14 1 Bacillus sps.   106 
 
The results presented in table 3.11 show that 3 patients had no detectable micro organisms 
and 7 had 2 types of organism present. The table also shows the duration of the burn and the 
organisms are presented as the number of colony forming units per gram of tissue. 
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Table 3.12. Correlation between microbes and % burn  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage of 
burn 
Duration of Burn(days) 
Organism 1 Organsim 2 
1 
7 
Coagulase-ve Staphylococci Klebsiella.sp 
1 10 Coagulase-ve Staphylococci E.coli 
1 7     
1 10     
1 60 Coagulase-ve Staphylococci Others-Proteus 
1 2 Others-coryneform bacteria   
2 5     
2 16 Methicillin resistant S.aureus   
2 14 Others-Bacillus sps   
4 
3 
E.coli 
Coagulase-ve 
Staphylococci 
5 
7 
S. aureus 
Coagulase-ve 
Staphylococci 
6 14 Coagulase-ve Staphylococci   
6 14 Coagulase-ve Staphylococci   
8 3 S. aureus   
15 
3 
S. aureus 
Coagulase-ve 
Staphylococci 
20 30 Pseudomonas.sp   
30 21 Coagulase-ve Staphylococci E.coli 
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Figure 3.11 Summary of the samples from which bacteria were isolated and in what 
numbers. 
As can be seen from the figure 3.11, bacteria were isolated from all the late burn patients 
whereas only 72.7% of the early group patients showed the presence of bacteria. 
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6b 3 coagulase-ve staph 3
6c 1 Pseudomonas.sp 5
7b 2 E.coli coagulase-ve staph 5
7c 2 coagulase-ve staph E.coli 7
8b 2 S. aureas coagulase-ve staph 7
8c 1 Others-bacillus sps
9b 2 bacteria
Pseudomonas Staphylococcus . aureusCoagulase negat
Group B 0 3 6
Group C 1 0 4
Pseudomonas Staphylococcus . aureusCoagulase negat
11 Group B = 11 0 27.2 54.5
7 Group C = 7 14.2 0 57.7
0
1
2
3
4
5
6
No of patients, 
total n=18
Group B Group C
Duration of burn
Microorganisms in relati n to duaration of burn wound
Pseudomonas
Staphylococcus. aureus
Coagulase negative
Staphylococci
MRSA
Others
No organsims
 
Figure 3.12- The change in the type of flora with the duration of the burn wound. 
As seen in figure 3.12 the predominant organisms change from skin commensals (e.g 
Coagulase negative Staphylococci) into more resistant forms (e.g, Methicillin resistant 
Staphylococcus aureus (MRSA)) with increase in duration of the burn wound. 
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Figure 3.13 The average HBD mRNA expression in relation to micro-organisms present.  
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All three β defensins were expressed in samples from which organisms were isolated as 
shown in figure 3.13. It was seen that the HBD1 was relatively highly expressed in samples 
from which Bacillus sp.and E.coli were isolated. HBD2 expression was markedly decreased in 
samples from which Pseudomonas was isolated and was highly expressed in samples from 
which coagulase negative Staphylococci were isolated. HBD3 RNA was highly expressed in all 
samples irrespective of the type of organism present. The expression was relatively higher in 
samples with Bacillus, E.coli, Pseudomonas and lower in samples with Staphylococci. 
 Organisms isolated and average protein expression(Burn area)
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Figure 3.14 The average HBD protein expression and organisms isolated from the 
patient burns.  
It can be seen from figure 3.14, that with the exception of samples in which MRSA was 
isolated, all the three HBD proteins were expressed in all the patient samples from which 
organisms were isolated. There was no peptide expression of HBD1 and 2 in this sample in 
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the sample colonised with MRSA. The samples in which no organisms were isolated showed 
no expression of HBD2 protein and HBD1 was expressed in relatively lower amounts. 
 
3.4 Discussion 
Infection is one of the important causes of mortality and morbidity in burns patients. This is 
related to loss of skin, which serves as a mechanical and biological barrier. Alteration in the 
expression of HBDs, which form a part of the biological cover, may play a role in burn wound 
infections. It has been shown previously that the expression of HBD2 is reduced at mRNA and 
protein level in burn skin(Milner and Ortega, 1999, Bick et al., 2004). The expression of HBD3 
which is specifically active against Staphylococci has never been studied in burn wounds.  
The common organisms implicated in burn wound infections are resident skin flora in early 
infections followed by resistant organisms such as Pseudomonas sp and MRSA with increase 
in the duration of the burn wound. Burn wounds are characterised by systemic and local 
responses. Local responses vary within the extent of the burn. Three zones namely zone of 
coagulation, zone of stasis and zone of hyperaemia have been described in a burn by Jackson 
in 1947 (figure.3.15). 
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Figure 3.15. Diagrammatic representation of the 3 zones of of a burn 
The central zone is characterised by coagulation of the proteins and is the actual part which 
has been in contact with the hot surface. The zone of stasis has decreased perfusion but the 
tissues themselves are salvageable and no irreversible damage has occured in this zone. How 
the tissues in this area recover depends on the management and presence of complications 
like infection. The tissues may completely recover or progress to a state of irreversible 
damage. The zone of hyperaemia is characterised by increased perfusion and intense 
inflammatory activity, but the tissues themselves recover with time unless secondary tissue 
loss following infection occurs(Hettiaratchy and Dziewulski, 2004b). The burn area in our study 
would include zone of coagulation and variable amounts of zone of stasis, which would be 
specific to the nature of the insult causing burn and the patient. The periburn area would 
comprise zone of stasis to a variable extent and the zone of hyperaemia; thus being 
characterised by vasodilatation and influx of inflammatory mediators. 
 stasis 
BURN 
Coagulation 
hyperaemia
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This is the first study looking at the expression of HBD 1, 2, 3 at protein and mRNA levels 
simultaneously with quantitative analysis of the flora in the burn wounds of different durations. 
Our study demonstrates that all the three defensins are expressed in burn wounds at mRNA 
level in all patient samples in which RNA was extractable. This suggests that living cells in the 
burn and periburn areas have increased expression of HBD mRNA. Burn injury is followed by 
release of inflammatory mediators such as IL1 and TNF-α . These mediators, in vitro, are 
known to enhance the expression of HBDs(Bick et al., 2004). The expression of HBD was 
studied in relation to psoriatic tissue expression normalised to the housekeeping gene β-Actin. 
The expression of mRNA in most of the samples was elevated and much higher than the 
expression in psoriatic tissue. It is known from previous studies that psoriatic tissue has 
elevated level of HBD 1, 2 and 3 expression(Harder et al., 2001). There was variation in the 
level of expression between the patient samples; this was expected as the expression of HBDs 
is influenced by a number of factors such as the degree of immunosuppression, percentage of 
burn, age of the patient and the site of burn. Although it would have been ideal to have a 
number of psoriatic samples for comparison purposes it was practical to get only one and this 
was provided by the Dermatology Department at Chelsea and Westminster Hospital. The ideal 
controls for this type of study would have been burn wound specimen and tissue from the 
corresponding non-burn area from the same person, as HBD expression is known to vary 
between individuals, and between different sites in the same person(Ali et al., 2001). Since this 
is unethical it was decided to take samples from the burn area and the peri burn area; the 
closest available analogue of the near normal skin. We considered using graft skin as a 
specimen of normal skin; but they were usually taken from the thigh which, being close to 
groin, may have a greater degree of colonisation by micro-organisms. Also the process of 
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taking a split skin thickness graft is traumatising to the tissue and may serve as a triggering 
factor for the stimulation of inflammatory mediators and cytokines, enhancing the expression of 
HBD. We analysed two graft tissue samples taken from thigh of the patients and the 
expression of the three HBD was found to be elevated and higher than the expression in 
psoriatic tissue. 
 
The distinction between burn and periburn is relative, being observer dependant. To avoid 
such bias all the samples were collected by a single observer and the patients included in the 
study were under the care of one of the two consultant surgeons working in the unit. The other 
possibility for controls would have skin samples from patients from different sites; this was also 
not practically possible although we obtained a normal abdominal skin sample from one patient 
to use as a control. Since the expression of HBD is inducible and hence may vary for normal 
skin depending on the nature of the flora inhabiting the area, we decided to discuss the 
expression of our experimental samples in relation to the psoriatic sample.  
 
RNA was not isolated from some of the patient samples either from the burn or periburn area. 
Thus, unless the samples had paired burn and peri-burn RNA they were not considered for 
expression analysis at RNA level. It is probable that in the burn area there were no living cells 
or any living cells in the remnant hair follicles. Since the description of burn and periburn area 
is relative it is possible that the periburn area was also affected by the burn injury and the RNA 
was destroyed. Also the necrotic slough and the exudates present in the wound are rich in 
RNAses, which might have resulted in the destruction of RNA thus affecting the RNA 
extraction. The number of living cells in the tissue is lower compared to the healthy normal 
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tissues and the extraction of RNA depended on meticulous extraction technique and stringent 
methods of avoiding RNAses. The tissues were stored at optimum temperatures for storage of 
material for RNA extraction. However any slight lapses in the transport and storage of the 
tissue might have impacted on the final RNA extraction.  
 
The quality of the extracted RNA was variable with clear bands seen for some samples 
demonstrating good quality RNA while others had only a smear. All the samples showing some 
RNA were processed further for cDNA conversion and amplification of the specific genes. 
Some of the samples, which had low quality RNA, and hence did not show clear peaks for the 
products of the HBD genes or the housekeeping genes, were taken as samples from which 
RNA could not be isolated. 
The melting temperature of the products within the same experiment varied within 2°C for most 
of the samples, however some samples showed a single peak for the product, but a melting 
temperature about four degree lower than the expected melting temperatures. This could be 
either due to the presence of chelating salts or presence of polymorphisms in the sample 
showing alteration of Tm. The other possibility of contamination was also considered but the 
Tm altered between one of the two melting temperatures and a single peak was 
observed(Ririe et al., 1997). 
 
The expression of HBD3 in the samples was characterised by one of the two melting 
temperatures either 79-80ºC or 84ºC. Since this alteration of Tm was consistent it is possible 
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that HBD3 is characterised by a common polymorphism, which can account for this alteration 
of Tm.  
 
The expression of HBD1, 2, 3 mRNA for most of the samples was seen to be markedly 
elevated as compared to the expression in the psoriatic tissue. The protein expression of 
HBD1, 2 and 3 however was relatively lower than the psoriatic tissue expression. The reason 
for the difference in the relative expression at mRNA and protein levels is unclear. This may be 
related either to failure of the conversion of the RNA message to protein due to failure or 
underdeveloped post transcriptional machinery, or to the coagulation of the proteins following 
the burn injury. The inability of the RNA message to be translated into the protein message 
may result in low expression of the HBD. This effect is more pronounced as not all the cells are 
viable and among the viable cells the expression is altered. Thus both these factors can 
account for higher incidence of infections in burn patients. 
Our study confirms the findings of previous researchers that there is a drift towards more 
resistant organisms with increase in duration of burn wounds. The study also demonstrates the 
expression of HBD1, 2, 3 at mRNA level is increased in relation to the presence of different 
organisms. The expression of HBD2 RNA was decreased relatively in samples from which 
pseudomonas is isolated. Although the expression of HBD2 was present at protein level the 
low mRNA may indicate failure of the cell machinery to enhance the expression further and 
thus may be related to high incidence of pseudomonas infections in burn patients. The cause 
of this decreased expression is unclear. The expression of HBD2 protein was absent in burn 
samples where either no organisms were isolated or MRSA was isolated. In the sample with 
MRSA there was no expression of HBD 1. This is perplexing, as HBD 1 is known to be 
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constitutively expressed. This expression could not be confirmed at mRNA level as no RNA 
could be extracted from this sample. Either the expression of the protein may have been low or 
coagulation of the proteins may account for the failure of detection. The low expression of 
HBD1 and the presence of MRSA can be correlated to failure of cell differentiation resulting in 
decreased expression of antimicrobial peptides leading to susceptibility to infection by resistant 
organisms as HBD1 is known to play a role in cell differentiation(Frye et al., 2001). 
Conclusion  
Thus we conclude that among surviving cells in the burn and in the periburn area the mRNA 
expression of HBD 1, 2 and 3 is increased to levels comparable or higher than psoriatic tissue 
levels. The expression at mRNA level is relatively higher in the burn area relative to the 
periburn area. The protein level expression does not relate with RNA expression levels; the 
overall expression being lower and relatively expression being higher in the periburn area as 
compared to the burn area. This low level of protein expression need to be confirmed on larger 
in vitro studies with prospects of preventing the burn wound infections by supplementing the 
HBD protein in burn wounds. 
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Chapter 4 
 
Expression analysis of HBDs 
(HBD1, 2 & 3) in peripheral blood 
cells; comparison of profiles 
between septic (microbiologically 
positive and negative) and healthy 
individuals. 
 
 
 
 122
4.1 Introduction  
 
The increasing development of bacterial resistance to traditional antibiotics has required the 
development of new antimicrobial agents. Defensins, which are natural antimicrobial peptides, 
have been shown to be key elements in the innate and adaptive immune system of many 
organisms representing the first line of defence against invading microbes.  These natural 
antibiotics possess novel mechanisms of action and different cellular targets compared with 
existing antibiotics. 
 
The basic role of mammalian defensins is  direct antimicrobial activity which occurs mainly in 
the phagocytic vacuoles of macrophages and on the surface of the skin and mucosa through 
the formation of multimeric pores within the bacterial cell membrane causing lysis(Hoover et 
al., 2000). These antimicrobial activities present new opportunities of using defensins as 
effective antibiotics or for construction of their more effective derivatives. 
 
Human β defensins 
The first HBD was isolated from hemofiltrate in 1995.  Subsequently, four other HBDs were 
identified as human epithelial defensins that have been suggested to play a pivotal role in the 
innate and adaptive immune responses in epithelial tissues.  
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Functions of human β defensin: 
The main function of HBD is as a regulator of innate antimicrobial immunity seems to be either 
the killing of bacteria and fungi on the epithelial surface of higher organisms or of 
phagocytosed microorganisms within phagolysosomes of phagocytes. HBDs also play an 
important role in adaptive immunity. 
 
A recent study indicates that human β defensin 1 (HBD-1) is chemotactic for immature 
dendritic cells and HBD-2 is chemotactic for memory CD 4+ T-cells(Garcia et al., 2001a).  
HBD-3 is also chemotactic for freshly isolated peripheral blood monocytes which initiate in turn 
the adaptive immunity(Yang et al., 2001).  Thus, HBDs may promote adaptive immune 
response by attracting and recruiting dendritic cells and memory T-cells to the site of microbial 
invasion through the interaction between HBDs and chemokine receptor 6 (CCR6) on the 
surface of the cells of adaptive immunity (Yang et al., 1999). 
Tissue expression of human β defensins 
Human β defensin 1 (HBD-1) and human β defensin 2 (HBD-2) are constitutively expressed by 
epithelial and mucosal cells in many organs such as kidney, pancreas, gingival, airway tracts, 
and female reproductive tracts(Valore et al., 1998, Seo et al., 2001, Krisanaprakornkit et al., 
1998, Dale et al., 2001, Bals, 2000, Alp et al., 2005). HBD-2 expression is up-regulated by 
exposure to bacterial cell wall components such as lipopolysaccharides (LPS) and 
proinflammatory cytokines such as tumour necrosis factor (TNFα). HBD-3, which was first 
isolated from psoriatic scales, is expressed in both epithelial and non epithelial cells and is 
considered to have diverse functions(Harder et al., 2001, Dhople et al., 2006).  Recently, HBD-
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4 was identified and its expression was observed in human testis(Garcia et al., 2001b) and 
genetically modified keratinocytes(Smiley et al., 2007). 
Recently, the expression of HBD-1 and HBD-2 has been detected in monocytes and 
macrophages and their expression increased after exposing cells to bacterial cell membrane 
components such as LPS or proinflammatory cytokines such as IFNγ in an ex vivo 
environment(Duits et al., 2002). 
To date, it is not known how the expression of HBDs in peripheral blood leukocytes is altered 
in vivo in response to systemic inflammatory disease or by invading bacteria (bacteraemia and 
septicaemia) and whether different types of HBDs are induced in response to different types of 
septicaemia. 
Peripheral blood leukocytes are among the first cells to be recruited to sites of infection and 
inflammation following platelet aggregation. It is not known if these act by producing HBDs as 
well as being directly phagocytic. Fang et al. demonstrated that HBDs were produced by 
leukocytes on ex-vivo challenge by bacteria(Fang et al., 2003) and recently a study showed 
that leucocytes with patients with septicaemia have decreased inducibility to BD2(Book et al., 
2007). Each of the three HBD’s seems to have a more specialised function and also more 
specific activity against particular subgroups of microbes. As sepsis and infections result from 
a variety of bacteria we investigated the in vivo expression of HBD 1, 2 and 3 in patients with 
microbiologically positive and microbiologically negative sepsis (systemic inflammatory 
response syndrome) and compared the expression with that of healthy volunteers. There have 
been no studies to date ascertaining the expression of these peptides in vivo in relation to the 
circulating bacteria.  
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Thus the aim of this study was to analyse peripheral blood leukocytes from patients with 
septicaemia and compare the expression profiles of HBD 1, 2 and 3 with those of normal 
healthy subjects in order to determine whether the expression levels were increased in 
peripheral blood leukocytes in response to systemic infections. 
The future aim of this study is to differentiate individuals who are more susceptible to develop 
septicaemia from those who have lesser predisposition to septicaemia dependent on the 
natural expression pattern of HBDs in their peripheral blood leukocytes. Moreover, HBD as 
natural antibiotics could be used as therapeutic agents to combat the bacterial infections in 
patients with septicaemia when bacterial strains have not yet developed resistance against 
these natural antibiotics. 
 
4.2 Materials and Methods 
The blood samples of patients and control groups were collected at West Wales General 
Hospital, Carmarthenshire NHS Trust, Carmarthen, Wales. The study was undertaken after 
obtaining a favourable ethical committee approval. 
Samples were collected from clinically septic patients and peripheral blood counts and blood 
cultures were performed at the same session. Leukocytes were isolated from fresh peripheral 
blood from patients and control groups, to be analysed at RNA and protein level, using density 
gradient centrifugation with HistopaqueTM. For RNA extraction the leukocytes were frozen at    
–80°C in SV total RNA lysis buffer (Promega, UK), and for immunohistochemical purposes 
they were fixed in 4% paraformaldehyde in PBS.  The details of the methods were as 
described in the Chapter 2 – General Methodology. After processing 20 samples, only 3 were 
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found to have a positive blood culture even after 48 -72 hours; leading to doubts as to whether 
organisms had been present in the samples or if the plates had been contaminated. To utilise 
the resources more efficiently the method was modified and the samples which were 
microbiologically positive within 24 hours were taken as positive. One ml of the blood was 
aliquoted and the leukocytes were isolated after lysing the RBC’s with SV RNA lysis solution 
(Promega, UK). The microbiologically positive samples were then processed at the end of 24 
hours. The drawback with this method was that the blood sample had to be stored at 4°C for 
24 hours and it is well documented that this does result in decrease of RNA yield. However 
considering the paucity of resources and given that PCR is a very sensitive technique it was 
decided to proceed with the modification. The leucocytes were pelleted and re-suspended in 
175μl of SV total RNA lysis buffer (Promega, UK), and stored at –80°C until further processing. 
The remaining blood sample was snap frozen and stored at –80°C. 
Thus the final inclusion criteria for the study were: 
 
For the microbiologically positive group 
• Clinical suspicion of sepsis 
• Microbiologically positive blood cultures with 24 hours of incubation 
• Adults  
• Able to give an informed consent 
• Not on immunosuppressive medication and no history of haematological and 
immunosuppressive diseases. 
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For the microbiologically negative group 
• Clinical suspicion of sepsis 
• Microbiologically negative blood cultures after 5 days of incubation 
• Adults  
• Able to give an informed consent 
• Not on immunosuppressive medication and no history of haematological and 
immunosuppressive diseases 
 
For healthy controls 
• Healthy without any acute or chronic symptoms 
• Adults 
• Not on any medications 
• Not suffering from immunosuppressive conditions 
 
HBD gene expression: 
HBD gene expression was analysed at RNA and protein levels by reverse transcriptase PCR 
and immuno-cytochemistry respectively. 
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HBD gene expression analysis at RNA level 
 
In this study, the expression of three different β defensins (HBD-1, HBD-2 and HBD-3) was 
analysed at mRNA level by extracting total RNA from isolated leukocytes and converting it into 
cDNA. The concentration of RNA in each of the samples and the OD at 260/280 (a reflection of 
the quality of the RNA) is shown in table 4.1. This was then analysed using RT-PCR and 
quantitative RT-PCR. The methods were as described in Chapter 2 – general methodology. 
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Table  4.1  The OD 260/280 ratio and the concentration of the extracted RNA in ng/μl 
from each patient sample. 
Patient 
number 
260/280 ratio 
 
RNA concentration (ng) per 1 
μl 
BE1 1.85 17.43 
BE3 1.82 9.83 
BE4 1.97 31.66 
BE5 1.96 26.65 
BE6 1.95 27.87 
BE7 1.8 24.1 
BE8 1.66 21.5 
BE9 1.67 13.3 
BE10 1.72 38.4 
BE11 1.72 44.0 
BE12 1.85 29.3 
BE13 1.94 36.7 
BE14 1.89 29.1 
BE15 1.81 31.7 
BE16 1.86 35.3 
BE17 1.94 43.1 
BE18 1.93 46.4 
BE19 1.90 66.7 
BE20 1.90 34.6 
BE21 1.95 95.9 
 130
Patient 
number 
260/280 ratio 
 
RNA concentration (ng) per 1 
μl 
BC1 1.98 57.6 
BC2 1.79 18.2 
BC2A 1.89 51.7 
BC3 1.57 110.8 
BC3A 1.79 22.1 
BC4 1.89 49.9 
BC4A 1.89 46.7 
BC5 1.75 45.3 
BC5A 1.83 36.0 
BC6 1.84 15.8 
BC7 1.79 28.5 
BC7A 1.73 16.7 
BC8 2.0 31.9 
BC8A 1.77 28.6 
BC9 1.80 30.7  
BC9A 1.71 39 
BC10 1.72 33.9 
BC11 1.96 49.4 
HC1 1.73 36.93 
HC2 1.68 40.23 
HC3 1.72 67.45 
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RNA was diluted in 10µl of nuclease free water. Two µl of the sample was used to check OD 
and to calculate the concentration. The volume added per reverse transcriptase reaction was 
adjusted so that the concentration of mRNA was 200-500ng per reaction.  
 
 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR): 
 
RT-PCR is a sensitive technique to detect mRNA expression of specific gene using specific 
primers and cDNA as a template. After cDNA synthesis had been performed, PCR was carried 
out for three different defensin genes using three different primer pairs for β defensins 1, 2 and 
3. Expression of the β-actin gene was used as internal control to ensure that the cDNA, which 
was served as a template, was synthesised correctly and PCR was carried out properly. 
 
Classical RT-PCR was initially performed and the samples were run on 2% agarose gel 
stained with ethidium bromide (EtBr). Β actin gene expression was detected but there was no 
detecable expression of the defensin genes. The minimum amount of DNA required for 
detection using EtBr and photography is 2ng in a 0.5cm wide band(Joseph Sambrook and 
David W. Russell., 2001). Since the expected copy number of these genes was likely to be 
low, it was decided to use the more sensitive quantitative RT-PCR to detect any possible 
expression compared to the controls. To keep the intra-experimental errors to minimum it was 
decided to perform a duplex real time PCR combining primers for the housekeeping gene β 
actin, and the HBD gene in each of the tubes and also the PCR was performed for 45 cycles. 
Some of the products were re-amplified and run on gels to confirm the products. Tables 4.2 
and 4.3 show the sample set up and the cycling conditions for quantitative duplex RT-PCR 
reaction respectively. 
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Table 4.2 : Sample mixtures for quantitative duplex PCR.  
 
  
 
 
 
 
 
 
 
 
 
 
*volumes were adjusted to ensure optimal template cDNA concentration 
 
 
 
Tube contents 
Tube 1 β 
defensin 1+β 
actin 
Tube 2 β 
defensin 2 
+β actin 
Tube 3 β 
defensin 3+β 
actin 
PCR Master Mix 12.5 μl 12.5 μl 12.5 μl 
Nuclease-free* water 5.5 μl 5.5 μl 5.5 μl 
cDNA* 2 μl 2 μl 2 μl 
Defensin 
Primer+Probe mix 
(TET) 
2.5 μl  2.5 μl 2.5 μl 
Actin Primer+Probe 
mix(FAM)  
2.5 μl 2.5 μl 2.5 μl 
Total 25μl 25μl 25μl 
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Table 4.3. Optimised cycling conditions for the duplex PCR 
 
 
 
 
 
 
 
 
 
 
 
Immunocytochemistry 
The leucocytes were fixed in 4% paraformaldehyde and a Cytospin® 3 Cytocentrifuge 
(Shandon, UK) was used to deposit a monolayer of leukocytes on slides while maintaining 
cellular integrity for further staining by immunocytochemistry.  
 
Cytospin procedure 
After sample chambers had been assembled in the following order –  labelled slides with the 
samples number, filters and sample chambers – 40 μl of suspended fixed leukocytes were 
added to the sample chamber and spun at 1000 rpm for 5 minutes at low acceleration. Six 
slides were made for each patient and control sample to be stained with three different β 
defensins specific antibodies by immunocytochemistry. 
Description Number of 
Cycles 
Temperature° C Time 
Hotstart activation  1 95 15 minutes 
 
 
Amplification 
cycles 
 
 
44 
94 (Denaturation) 45 seconds 
56 
(Annealing) 
45 seconds 
72 
(Extension) 
45 seconds 
Final  extension 1 72 5 minutes 
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Optimising leukocytes slides: 
Leukocytes slides that had been obtained by cytospin preparation were checked under the 
microscope before the immunocytochemistry labelling in order to assure the proper distribution 
of the cells on the slides. One slide out of six from each sample was stained with Hematoxylin 
or Giemsa(Lillie, 1977). The distribution and morphology of the leukocytes on the slides were 
examined by conventional light microscope at 10X (Figure 4.1) and 40 X (Figure 4.2) 
magnifications. 
 
Figure 4.1 Distribution of leukocytes in the leukocyte smear 
  Leukocytes nuclei appear purple under Giemsa staining. Objective 10X. 
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Figure 4.2. A healthy control smear stained with Giemsa 
 This shows different types of leukocytes in the smear of healthy control sample under Giemsa 
staining. A: Lymphocyte which can be characterised by dark stained nucleus occupied most of 
the cells with thin rim of pale cytoplasm around it. B: polymorphonuclear leukocyte 
(granulocyte) in this case a neutrophil which can be identified by multi-lobed dark stained 
nucleus. Objective 40X. 
 
Immunocytochemistry labelling and microscopic analysis: 
After confirming the morphology of the cells by staining with H&E and Geimsa stains; 
immunocytochemistry was performed using the commercially available antibodies as 
described earlier (Chapter 2).  
A 
B 
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3.3 Results  
Twenty patients (male to female ratio 1:1) whose blood cultures were judged positive within 24 
hours of incubation were included in the study (Table 4.4). In the blood culture negative group 
there were 18 patients recruited of which 11 were males and 7 females. The mean age in the 
microbiologically positive group was 60.65 years and that of the negative group was 60.5 
years. The blood samples from 3 healthy volunteers were also included in the study. All three 
were male and the mean age was 35.3 years. The healthy volunteers were chosen from the 
younger age group in order to control for the fact that there is scope for a blunted innate 
immune response in the elderly population. In this experiment, even if the response to infection 
or inflammation was minimal it would be detected as all results were expressed relative to the 
healthy controls. The mean body  temperatures in the microbial positive and negative groups 
was 38.46°C and 38.42°C respectively while in the healthy volunteer group it was 36.8°C.The 
mean duration of symptoms in the two groups were similar; 2.8 days in the positive group and 
2.7 days in the negative group respectively. 
 
Table 4.4.shows the Demographics of the Patients and organisms identified 
Patient 
code Sex Age(years) Temperature(°C) 
Duration 
of 
symptoms
(days) 
Organisms 
identified  
BE1 M 51 38.2 3 Streptococcus 
BE3  F 57 37.9 4 Staphylococci 
BE4 F 82 38.5 2 Staphylococci 
BE5  M 61 36.4 5 yeast 
BE6 F 65 38.4 2 Staphylococci 
BE7 F 88 37.9 2 Streptococci 
BE8  M 19 39.2 3 
Staphylococci+ 
Diphtheroids 
BE9  M 39 38.2 4 
Staphylococci+ 
Diphtheroids 
 137
Patient 
code Sex Age(years) Temperature(°C) 
Duration 
of 
symptoms
(days) 
Organisms 
identified  
BE10 M 88 39.4 2 Staphylococci 
BE11 F 78 37.8 1 Staphylococci 
BE12 M 64 38.8 3 Streptococcus 
BE13 F 69 39.1 4 Staphylococci 
BE14 M 75 38.5 2 Staphylococci 
BE15 M 72 39.1 2 Streptococci 
BE16 M 56 37.8 3 
Gram negative 
bacilli 
BE17  F 76 37.9 3 Streptococci 
BE18 F 32 39.1 4 
Gram negative 
bacilli 
BE19  F 40 39 2 Streptococci 
BE20 M 80 37.8 2 Streptoccoi 
BE21 F 21 40.1 2 Meningococci 
Mean  60.65 38.46 2.8  
BC1 M 65 38.1 2 None 
BC2 M 62 39.2 3 None 
BC3 F 47 38.2 3 None 
BC4 M 65 38.4 2 None 
BC5 F 68 37.9 4 None 
BC6 M 69 38.1 2 None 
BC7 M 40 37.8 4 None 
BC8 F 30 38.4 2 None 
BC9 M 35 37.9 2 None 
BC10 M 70 38.6 5 None 
BC11 M 61 39.1 2 None 
BC12 F 66 37.9 2 None 
BC13 F 50 38 4 None 
BC14 F 56 39.2 2 None 
BC15 M 75 37.8 3 None 
BC16 M 87 39.1 3 None 
BC17 F 61 39.7 2 None 
BC18 M 82 38.1 2 None 
Mean  60.5 38.42 2.7  
HC1 M 29 36.4  None 
HC2 M 35 37.1  None 
HC3 M 42 36.9  None 
Mean  35.33 36.8   
BE represented samples from culture positive group whereas BC were the culture negative group. HC1,2 and 3 
were the healthy controls. 
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The quality of the extracted RNA was tested by spectroscopic analysis (Table 4.1). RNA was 
converted to cDNA using an Improm-IITM reverse transcriptase kit (Promega, UK) and 
quatitative PCR analysis was performed on an Opticon II QPCR machine as described 
previously. The samples were analysed using the software supplied by the manufacturer and 
the 2-∆∆Ct method was for expression analysis(Livak and Schmittgen, 2001). It was decided to 
use relative quantification rather than absolute quantification as the quality of RNA was an 
important factor in the experiment. As we were working with extremely small volumes of blood 
determining the expression of the defensin genes relative to an internal control measured in 
the same tube (duplex) with similar primer efficiencies was considered ideal. 
Some representative samples were run on 4% agarose gel to confirm the presence of the 
correct size products. Prior to performing the duplex assay the primers and probes were tested 
and optimised both individually and in combinations, and the correct size products confirmed. 
Some of the results of the duplex quantitative RT –PCR, run on gel electrophoresis are shown 
in Figure 4.3; the top panel shows the assay with HBD1 and actin primers. The HBD 
expression was lower than the actin expression as can be seen from the faint HBD1bands. 
The second panel shows the HBD2 and actin expression while panel 3 shows the HBD3 and 
actin expression. The HBD3 expression was clearly higher than actin expression.   
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HBD1 and Actin
HBD2 and Actin
HBD3 and Actin Blank
Blanks
 
Figure 4.3 The analysis of the amplicons produced in duplex assays of defensins and 
actin 
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Table  4.5 The mean HBD expression along with the details of the bacteria isolated  in 
patients  in the microbiologically positive group.  
Patient 
code Microbiology 
HBD1RNA 
Expression
(2- ∆∆Ct) 
HBD2RNA 
Expression
(2- ∆∆Ct) 
HBD3RNA 
Expression
(2- ∆∆Ct) 
BE1 Streptococcus 0.3 20.8 504.5 
BE3  Staphylococci 1.9 19.2 1254.3 
BE4 Staphylococci 1.9 22.1 2351.9 
BE5  Yeast 0.8 19.5 1293.6 
BE6 Staphylococci 0.7 13.5 2885.6 
BE7 Streptococci 11.3 11.8 7889.2 
BE8  
Staphylococci+ 
Diphtheroids 32.6 18.8 2687.7 
BE9  
Staphylococci+ 
Diphtheroids 0.6 17.7 1382.1 
BE10 Staphylococci 4.0 15.5 1750.0 
BE11 Staphylococci 2.6 20.1 1754.2 
BE12 Streptococcus 8.4 14.6 1747.0 
BE13 Staphylococci 6.0 13.1 551.10 
BE14 Staphylococci 2.6 16.8 921.71 
BE15 Streptococci 6.8 17.7 1949.8 
BE16 
Gram negative 
bacilli 9.1 20.7 2487.8 
BE17  Streptococci 6.2 16.2 843.7 
BE18 
Gram negative 
bacilli 4.8 13.5 465.3 
BE19  Streptococci 4.4 15.4 2625.1 
BE20 Streptoccoi 4.5 15.4 1097.2 
BE21 Meningococci 5.2 13.6 190.5 
Mean  5.7 16.8 1831.6 
SD  7.0 3.0 1638.9 
The patient code is indicated as BE. The end of the table shows the summary statistics in the 
form of overall mean and the estimate of variability in the form of Standard deviation (SD).  
Table 4.5 above shows the summary of the microbiological and PCR findings. As seen all the 
three HBDs were expressed in all the samples irrespective of the type of micro-organisms 
isolated. The expression of HBD3 was markedly elevated (mean 1831 times compared to 
healthy controls normalised to the house keeping gene.)  
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Table  4.6 The mean HBD expression along with the details of the bacteria isolated  in 
patients  in the microbiologically negative group.  
 
 
 
 
 
 
 
 
 
 
 
The patient code is indicated as BC. The end of the table shows the summary statistics in the 
form of overall mean and the estimate of variability in the form of Standard deviation (SD).  
Table 4.6 above shows the summary of PCR findings in microbiologically negative patients. 
The expression of all the three HBDs was seen in all the samples. The expression of HBD3 
was markedly elevated (mean expression was 1450 times expression in healthy normal 
controls normalised to the housekeeping gene β actin). 
 
Patient 
code 
HBD1RNA 
Expression 
(2- ∆∆Ct)  
HBD2RNA 
Expression 
(2- ∆∆Ct) 
RNA Expression 
(2- ∆∆Ct) 
BC1 4.2 12.6 1404.3
BC2 1.7 15.9 461.8
BC3 9.0 20.4 2453.6
BC4 10.8 16.4 5629.0
BC5 1.0 17.1 392.9
BC6 15.2 14.1 1452.8
BC7 30.1 15.0 920.7
BC8 1.9 20.5 378.3
BC9 0.1 14.8 987.5
BC10 0.6 23.4 1126.9
BC11 0.6 17.1 6033.0
BC12 0.1 21.6 860.3
BC13 1.2 17.6 1260.4
BC14 1.2 19.2 608.3
BC15 4.2 16.1 806.0
BC16 0.2 18.0 389.0
BC17 0.3 16.6 468.3
BC18 2.1 14.2 470.9
Mean 4.7 17.3 1450.2
SD 7.6 2.8 1678.1
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Immunocytochemistry 
 Immunocytochemistry was performed using three different specific commercially available 
primary antibodies against three different β defensins HBD1, HBD2 and HBD3. The binding 
was visualised using DAB (Diamino-Benzidine) (DAKO, UK). The methods were as described 
in Chapter 2. Negative controls were designed where no primary antibodies were added, 
instead horse or rabbit serum was used. Positive controls were in the form of skin and buccal 
epithelial samples which were previously shown to express the HBD. 
The aim of the immunohistochemical staining was to localise the source of HBD production in 
vivo HBD’s are known to be secretory proteins and on stimulations more than 70% of the 
protein is released into circulation from the cells. Depending on the degree of stimulation, 
variable amounts of the synthesised peptide are released into the circulation and hence 
individual cells were expected to be variably stained depending on the degree of synthesis and 
the peptide released into circulation. In our patients however no protein could be distinctly 
visualised in the polymorphonuclear cells. There was a halo of DAB around individual cells and 
this was considered as background stain (Figure 4.4). However this was variable and more 
marked around some cells compared to others. This variability was persistent in spite of using 
different concentrations of the antibody and variation in times of development with DAB. Since 
HBD’s are cytoplasmic proteins and are secretory in nature, it can be expected that the protein 
would be localised in the perinuclear region. Due to variability in the intensity of this halo in the 
perinuclear region it can be considered that some of the cells expressed HBD1, 2 & 3 proteins. 
However this staining was of very low intensity suggesting that even if the HBD’s were 
produced by the peripheral blood cells, most of it was secreted out. Thus, the HBD1, 2 and 3 
expression was not localised to polymorphonuclear cells, lymphocytes or monocytes. 
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Figure 4.4 The results of immunostaining with HBD antibodies and developed using 
DAB. Magnification 20x ;  Panel A shows the; no primary –ve , Panels B,C, D shows the slides 
stained with HBD1,2 & 3 antibodies respectively. Arrow in panel C shows a polymorphocytic 
leucocyte, while the arrow in panel D shows a lymphocyte. 
 
A 
C 
B
D
negative HBD1 
HBD2 HBD3 
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Discussion 
Sepsis has been defined as systemic illness resulting from the microbial invasion of normally 
sterile parts of the body(Lever and Mackenzie, 2007). The condition has an estimated mortality 
of 30-50 per 100,000 population per year(Eisen et al., 2006), and is ranked among the top 10 
causes of death. The incidence of sepsis is put at 3 per 1000 population per year in 
USA(Angus et al., 2001). A similar clinical picture does occur in a number of non-microbial 
conditions. The similarity between the microbial and non–microbial states is the nature of the 
cytokines and immune regulatory peptides present; although the term sepsis should not be 
used for these conditions. Sometimes there can be a mixed picture wherein there may be a 
suspicion of microbial stimulus in the background of systemic inflammatory activity.  
Sepsis results from the entry of the pathogen into the blood stream which in turn results from 
the breach of immunological or physical barrier. Sepsis can proceed to severe sepsis which is 
defined as presence of hypoperfusion or dysfunction of one of the organ systems; or to septic 
shock characterised by refractory hypotension despite adequate fluid resuscitation and 
requiring the need for vasopressor agents. Why some people develop full blown septic shock 
associated with high mortality while others respond and improve from the initial stage of sepsis 
is unclear and a number of pathogen and patient factors are implicated. It is possible that the 
innate responses within the blood stream including the variable HBD expression may play an 
important role in containing the progress of the sepsis. Leucocytes and mainly the neutrophils 
being the major immune cells in the blood stream do play an important role in controlling 
sepsis. This is probably related to the fact that neutrophilia is one of the primary responses to 
inflammation or sepsis. The effects of leucocytes are either directly mediated by their own 
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phagocytic action or by the release of mediators such as alpha or possibly β defensins from 
their granules. 
The present project was an endeavour to ascertain the in vivo status of the leucocytes in 
relation to the production of the HBD1, 2 and 3. Β defensins are cationic antimicrobial peptides 
originally isolated from haemofiltrate in the case of HBD1(Bensch et al., 1995) and from 
psoriatic scales in the case of HBD2 and 3(Harder et al., 2001). Their expression was 
considered to be mainly localised to keratinocytes but recently they have been isolated from 
variety of different tissues. The other interesting feature of HBD has been the inducibility in 
response a number of microbial and non-microbial stimuli. Since blood and its components 
form an important part of the immune system, we envisaged that leucocytes which are the 
primary defence cells may also act by inducing the expression of β defensins. 
Our study demonstrates that the leucocytes have an enhanced expression of HBD2 mRNA in 
patients with sepsis but there was no significant difference between the patients who were 
microbiologically positive and negative (unpaired t-test 2 tailed significance between the 
groups 0.638). Our findings are similar to those of Book  and colleagues(Book et al., 2007) as 
regards enhanced expression in a septic population. The expression of HBD3 in leucocytes 
has never been investigated before; we demonstrate for the first time that the leucocytes in 
patients with sepsis show very high levels of HBD3 mRNA expression much higher as 
compared to normal healthy individuals. The HBD1 expression was variable in individual 
patient samples. 
Blood is composed of plasma and the cellular elements. The cellular elements are mainly 
composed of red blood cells or erythrocytes and the white blood cells or leucocytes. Since 
mature RBCs lack a functional nucleus they are not capable of transcription and thereby 
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cannot produce any inducible factors in response to stimulation. Thus the leucocytes are the 
only cells in the blood capable of responding to stimulation and producing various inducible 
factors. Functionally leucocytes are considered to be an inherent part of the immune system. 
Among the leucocytes the neutrophils or the polymorphonuclear cells comprise the majority 
(70%) of the population, while lymphocytes and monocytes comprise the remaining 30%. HNP 
or alpha defensins are a class of antimicrobial peptides which have been shown to be 
constitutively produced by neutrophils. It has been shown previously that neutrophils do not 
have a basal expression of HBD however they do produce HBD1, and 2 in response to ex-vivo 
stimulation. We demonstrate that the expression of HBD also occurs in vivo in response to the 
appropriate stimulation. 
Proteins similar to HBD have been isolated from bovine neutrophils (BNP)(Selsted et al., 
1993). HBD1 was originally isolated from the haemofiltrates, but since those patients were 
suffering from end stage renal failure it was considered that these were produced as a 
urogenital epithelial barrier and secreted into the blood stream. The studies in the past have 
shown no demonstrable basal expression of HBD1, 2, or 3 in leucocytes by reverse 
transcriptase PCR in blood of normal people(Fang et al., 2003). It has however been shown by 
Duits et al (2002) that freshly extracted monocytes show expression of both HBD1 and HBD2, 
which was further enhanced by stimulation suggesting that some of the leucocytes have a 
basal level of HBD expression. In consensus with Duits et al we demonstrate a low basal 
expression of HBD in individuals (Mean±2SD HBD1-1.13±0.57; HBD2 1.50±1.37; HBD3 
3.51±5.58). The difference in the sensitivity of the detection procedures that is traditional PCR 
versus quantitative PCR probably accounts for the difference between our findings and those 
of  our predecessors.  
 147
The promoter region of HBD1 contains consensus sites for NF-IL-6 and Interferon (IFN)-γ 
suggesting the potential of inducibility of these peptides(Liu et al., 1997). HBD2 has a number 
of consensus sites in its promoter region, these include NF-қβ (Nuclear factor қβ), Activator 
protein -1 (Ap-1) and NF-IL-6 (Nuclear factor IL-6).  HBD3 is induced in keratinocytes by TGF-
α(Sorensen et al., 2003), TNF- α(Harder et al., 2001), but not by IL-1 or IL-6 and neither does 
the promoter have consensus sites for NF-қβ, suggesting  differential ways of regulation of 
these two inducible HBDs(Garcia et al., 2001a). 
  
Figure  4.5  The patho-physiological mediators of sepsis. (Adapted from Lever, A. et al.(Lever 
and Mackenzie, 2007) 
Sepsis is characterised by the presence of microbes and their toxins. These in turn trigger the 
immune pathways with the aid of a number of pathogen recognition receptors(Bochud and 
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Calandra, 2003), that in turn result in the release of number of cytokines, lymphokines and also 
activation of a number of transcriptional pathways as seen in the figure 4.5. 
The most important cytokines that are implicated in the triggering of the sepsis syndrome are 
the “proximal”or the early cytokines namely TNF-α and IL-1β. These in turn with their myriad 
effects and along with the microbial products mediate the release of the “distal” or late 
cytokines which include IL-6 and IL-8(Blackwell and Christman, 1996). It is considered that 
cytokines are not stored in a “ready format” but are synthesised in response to the challenge. 
Studies have shown that the primary cytokines like TNF- α peaked in about 60 minutes 
following stimulation(Michie et al., 1988). 
It is interesting to note that IL-1β and IL-6 are potent inducers of HBD2 while TNF- α induces 
HBD3 expression. Thus it likely that these cytokines play an important role in the induction of 
these peptides from leucocytes. The degree of induction is dependent on the degree of 
triggering factors and also on the leucocyte count and a number of patient factors which 
influence the translational machinery of the patient. As regards the individual cells which are 
responsible for production, our study is flawed by the fact that individual leucocyte cell 
populations were not separately analysed for their expression. Given the fact that all the 
patients in the study had raised neutrophils counts and that immunocytochemical studies 
suggest the possible localisation of HBD’s to leucocytes, it can be hypothesised that the main 
source of production were neutrophils and lymphocytes; the two main cell populations among 
leucocytes. Since polymorphonuclear cells are the predominant cell population of leucocytes 
and also the main effector cells in case of bacterial sepsis, it can further be derived that the 
polymorphonuclear cells are the major cell population producing HBD in the inflammatory and 
bacteria induced sepsis conditions.  
 149
In our study the mean expression of HBD between the microbiologically positive and negative 
group was similar, suggesting that the regulation of these factors is governed by other 
inflammatory mediators apart from microbial stimuli. Thus the possible mechanism of induction 
of these peptides in leucocytes is mediated by cytokines and also involves the translational 
machinery as these peptides not stored in the leucocytes. This also draws attention to the 
possibility that these peptides may be more than simply antimicrobial and may actually play a 
part in immune regulation. The relative preponderance of HBD3 as compared to HBD2 is 
unclear but it can be hypothesised that relatively lower HBD2 may itself be a factor in the 
pathogenesis of sepsis, as it has been shown that in patients with sepsis the inducibility of 
HBD2 is reduced(Book et al., 2007). However this warrants further investigation and larger 
studies both in vitro and in vivo.  
It is being increasingly perceived that increased levels of cytokines by themselves are 
detrimental to the overall outcome and this has brought forth the concept of anti-cytokine 
therapies for the treatment of sepsis syndrome(Suffredini, 1994). It has also been perceived 
that because of the complexity of the interactions involved and with individual cytokines, it is 
better to focus on the immunomodulatory or even anti-inflammatory cytokines like IL-10. It has 
been shown by Boniotto et al that HBD2 is a potent inducer of a number of cytokines including 
the pro-inflammatory and anti-inflammatory groups. Although and HBD1 and HBD3 have been 
shown to induce IL-8, they seem to lack the capacity to cause a more generalised 
response(Boniotto et al., 2006). These findings together with our findings suggest other 
important functions of immunomodulation of HBD2. We propose that HBD3, with its universal 
salt insensitive antimicrobial property and broad spectrum of antimicrobial activity, is the prime 
antimicrobial peptide induced in states of sepsis and its action is partly supported by HBD1 
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and 2. However HBD2 further mediates more important actions of orchestrating the cytokine 
response by way of its cellular receptors; those currently identified include CCR6 and TLR4.  
Future studies need to be undertaken to understand the inter-relationships among these 
antimicrobial peptides, and to decipher yet unknown functions of these important group of 
peptides. Studies also need to be undertaken to separate out the various leucocytes cell 
fractions and individually analyse the protein and RNA concentrations of HBD’s. Also plasma 
defensin levels should be estimated to get better overall picture. This information would used 
in formulating novel therapeutic strategies utilising the potential of these peptides as 
antimicrobial and immunoregulatory molecules. 
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Chapter 5 
Buccal HBD 1, 2 and 3 expression profiles in peri-
operative states – correlation to cortisol levels. 
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5.1  Introduction  
Stress has been defined as “a constellation of events, which begins with a stimulus (stressor) 
that precipitates a reaction in the brain (stress perception), which subsequently activates 
physiologic systems in the body (stress response)”(Dhabhar, 2000). Stress can result from 
negative life events which have been broadly classified into either objective discrete events like 
bereavements, trauma , surgery and infections, or self reported list of events like daily hassles 
and life events(Herbert and Cohen, 1993). Stress in a hospital setting can result from major 
polytrauma, burns, infections or surgical procedures: the accompanying physiological 
responses can impact both positively and adversely on an individual. Stress responses on one 
hand help the individual to prepare and survive the stressful event effectively while on other 
had the mediators of stress response have been implicated to have damaging effects. A 
number of studies have shown that stress can be immunosuppressive and thus can be 
damaging to health(Khansari et al., 1990, Marucha et al., 1998, Herbert and Cohen, 1993). 
There have been other studies which have suggested that stress responses are important to 
help patients survive the stressful stimulus. Studies by Dhabhar et al.  have shown that acute 
stress actually stimulates the skin immune function while chronic stress suppresses it(Dhabhar 
and McEwen, 1999). 
 
Human β defensins (HBD) are a family of cationic innate defense peptides which are primarily 
considered antimicrobial. Three subtypes of these HBD1, 2 and 3 have been identified in the 
buccal mucosa(Saitoh et al., 2004). HBD1 is constitutive while HBD2 and HBD3 are inducible 
in response to a number of microbial and inflammatory stimuli. The inflammatory stimuli are a 
part of the cytokine cascade which is also activated during stress. However it is not known how 
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the stress hormones which are also activated during stress influence the expression of these 
peptides in-vivo. 
 
Steroids are also considered an important aspect of treatment of critically ill patients and it has 
been a matter of perennial debate as to the risks, benefits and timing for supplementing 
steroids in the treatment of these patients. One of the reasons of the controversy has been the 
down-regulation of the immune system by the steroids. It has been shown by Duits et al. that 
HBD3 expression is down regulated in cultured bronchial epithelial cells and mononuclear 
phagocytes. There have been no studies looking at the influence of steroids on the in vivo 
expression of these peptides. The current experiment was planned to determine the variation 
of HBD expression compared with expression of the innate stress hormone cortisol. 
 
Patients in high stress clinical conditions such as burns, polytrauma and major surgical 
procedures are prone to infections. HBDs are antimicrobial peptides that are considered an 
important component of innate host defence system. We studied the expression of HBD in the 
buccal mucosa in relation to cortisol levels in patients undergoing major surgical resection for 
malignancies.  
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5.2  Materials and Methods 
The study was carried out at the West Wales General Hospital, Carmarthenshire NHS trust in 
Wales, UK after getting a favourable ethical committee approval. Patients undergoing major 
surgical procedures which would require them to be admitted to the critical care areas i.e. HDU 
or ITU during the post-operative period as part of the hospital policy were recruited for the 
study. The patients were recruited, after obtaining an informed consent, over a period of 1 
year. 
 
Inclusion criteria 
• Patients undergoing major surgery 
• Admission to the hospital night prior to surgery 
• Post –operatively planned to be admitted to critical care area 
• Not on steroids or immunosuppressive therapy 
• Not suffering from immunosuppressive conditions 
• Expected mean hospital stay of about 1 week as per the hospital policy/departmental 
policy.  
 
Exclusion criteria 
• Children 
• Patients on steroids or immunosuppressive therapy 
• Patients with lesions or conditions involving oral cavity 
• Patients unable to consent 
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The common procedures among the recruited patients were open radical prostatectomies 
(complete removal of the prostate gland to treat extensive prostate cancer), cystectomies 
(removal of the urinary bladder for treatment of bladder cancer) with or without neo-bladder 
reconstruction and operations for extensive bowel malignancies. 
Prior to undertaking the actual study of correlating cortisol and buccal HBD levels and a 
preliminary study (Study 1) was performed. 
 
The objectives of the preliminary study were to determine: 
• If there was any specific pattern of cortisol expression in critically ill patients 
• If it was possible to successfully and consistently detect cortisol levels using saliva 
• the factors influencing the cortisol levels  
Over a 6 month period 12 patients were recruited; the recruitment criteria were the same as 
above. Patients had 4 hourly salivary and blood cortisol samples. A record of a number of 
parameters and significant activity during these 24 hours was maintained. 
 
Study 1- Assessment of salivary cortisol 
Salivary cortisol assessment was done using commercially available ELISA based assay 
(Salimetrics, Cat log No-1-0102/1-0112, USA) according to the manufacturers protocol. The 
tests were done in triplicate to ensure reliability. 
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5.3  Results 
12 patients were recruited in the study, of which four were females and 8 males. The mean 
age of the recruited patients was 55.5 years with a range of 19-78 years.  
 
Correlation between sedation, serum cortisol and plasma cortisol levels 
There was no significant correlation found between the salivary and serum cortisol results. 
However there was significant correlation between serum cortisol and degree of sedation as 
assessed by Ramsay sedation score (refer to table 5.1 below), irrespective of whether only 
paired samples of salivary cortisol were used or not. The increase in sedation score suggestive 
of the patient being more sedated was associated with lower serum cortisol levels and vice 
versa as seen in figure 5.1.  Table 5.1 shows the correlation between all the cortisol samples 
and the sedation score while the table 5.2 shows the correlation between the paired samples; 
sedation scores with samples contaning enough saliva to analyse were only considered and 
sedation scores at time points where there was not enough cortisol to be sampled were 
eliminated. 
 Table 5.1The Pearson correlation co-efficient between sedation score and the cortisol 
levels (both salivary and serum) 
 
 Serum cortisol nmol/L Salivary cortisol nmol/L Sedation score 
Serum 
cortisol 
(nmol/L) 
Pearson Correlation 
1 -0.1 -.496(**)
Sig. (2-tailed)  0.4 0.0
N 70 33.0 70.0
Salivary 
cortisol 
(nmol/L) 
Pearson Correlation 
-0.1 1.0 -0.1
Sig. (2-tailed) 0.4  0.5
N 33.0 34.0 34.0
Sedation 
score 
Pearson Correlation -.496(**) -0.1 1.0
Sig. (2-tailed) 
0 0.5  
N 70 34.0 71.0
**  Correlation is significant at the 0.01 level (2-tailed). 
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Not enough saliva was obtainable for assay in all samples and only 33 of the 70 samples had 
enough saliva (47%) for analysis. 
 
Table 5.2  The Pearson correlation co-efficient between sedation score and the cortisol 
levels (both salivary and serum).  
  
 
 
Salivary cortisol 
nmol/L 
Serum cortisol 
nmol/L 
Sedation score 
 
Salivary 
cortisol 
nmol/L 
Pearson Correlation 
1 -0.1 -0.1 
Sig. (2-tailed) 
 0.4 0.5 
N 34 33.0 34.0 
Serum 
cortisol 
nmol/L 
Pearson Correlation -0.1 1.0 -.450(**) 
Sig. (2-tailed) 0.416  0.0 
N 33 33.0 33.0 
sedationscore Pearson Correlation 
-0.1 -.450(**) 1.0 
Sig. (2-tailed) 
0.45 0.0   
N 34 33.0 34.0 
**  Correlation is significant at the 0.01 level (2-tailed). 
 
The missing values have been eliminated and only paired samples have been considered.  
There was no significant correlation between the salivary and serum cortisol even after 
replacing the missing values using the linear trend method in SPSS 14 (Refer to table 5.3). 
Similarly there was no correlation between salivary cortisol and sedation (Table 5.3). 
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Table 5.3 shows the correlation between the sedation score and the cortisol levels (both 
salivary and serum) after replacing the missing cortisol values using the linear trend 
method in SPSS 14. 
 
 Sedation score 
TREND(salivary 
cortisol) 
TREND(serum 
cortisol) 
Sedation score Pearson Correlation 
1 -0.1 -.487(**)
  Sig. (2-tailed) 
  0.5 0.0
  N 72 72.0 72.0
TREND(salivary 
cortisol) 
Pearson Correlation 
-0.1 1.0 -0.1
  Sig. (2-tailed) 
0.5 0.5
  N 72 72.0 72.0
TREND(serum 
cortisol) 
Pearson Correlation 
-.487(**) -0.1 1.0
  Sig. (2-tailed) 
0 0.5
  N 72 72.0 72.0
 **  Correlation is significant at the 0.01 level (2-tailed). 
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Figure 5.1 Box and whiskers plot demonstrating the association between the Plasma 
cortisol levels and the Ramsay sedation score.  
It can be seen from figure 5.1 that an increasing sedation score is associated with a fall in the 
median plasma cortisol levels. 
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Figure 5.2.  Box and whiskers plot demonstrating the lack of association between the 
salivary cortisol levels and the Ramsay sedation score. 
It can be seen that there is no specific identifiable association. 
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Circadian rhythm 
Circadian rhythm is a cyclical variation of biological activity based on a 24 hour internal 
biological clock for example the sleep-awakeness cycle. In healthy individuals the serum 
cortisol levels show a circadian rhythm associated with an early morning surge in the levels of 
cortisol. There was no definite pattern of circadian rhythm seen in salivary cortisol samples 
(Figures 5.2, 5.3), while the mean serum cortisol showed a peak around 8 am. This however 
correlated with the decreased level of sedation at this time in these patients (Figures 5.2, 5.3). 
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Figure 5.3 Box plot showing the cortisol levels (both salivary and Serum) on Y axis and 
its variation with time on x axis.  
The dark lines in the middle of the boxes represent the median value. It can be seen that 
median serum cortisol levels peeks at 8am while mean salivary cortisol shows little variation. 
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Affect of activity on cortisol levels 
There was no demonstrable effect of variation in cortisol levels with activities such as starting 
feeds or altering physical positions (data not shown). 
 
Study 2: Effect of cortisol on the secretion of HBD in the oral mucosa 
Methods 
Since there was no real rhythm in the salivary cortisol secretion, the sample was taken early in 
the morning. The first sample was taken on the day of surgery just after dawn. The second 
sample was taken on the first day post-surgery. If it was not possible due to practical 
considerations then the second sample was taken on the second day post-surgery. The third 
sample was taken on the day of patients discharge between days 7-10 days from the day of 
surgery; depending on when the patient was being discharged. 
Each sample included a salivary sample collected using a salivette™ (Starstedt, USA), cheek 
scrapings were obtained using a cell scraper (BD Flacon™, UK). The cheek scrapings were 
taken from the buccal surface of both cheeks. A part of the cheek scrapings was to be used for 
immunocytochemistry, this was fixed in 4% paraformaldehyde; the other part for real time PCR 
analysis was dispersed in sterile PBS. This was then pelleted and re-suspended in SV RNA 
lysis (Promega; UK) buffer and subsequently stored at -80°C until further processing. 
 
RNA extraction, cDNA conversion & real time PCR analysis 
RNA extraction was done using SV total RNA extraction system (Promega; UK) as described 
earlier. The cDNA conversion was done using ImProm-II™ (Promega; UK) reverse 
transcriptase kit. The RNA concentration was estimated using spectroscopic analysis and 
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between 200 to 500ng of RNA was converted per reaction. Duplex quantitative PCR analysis 
was performed using Opticon II real time machine (Bio-rad, UK) with β actin as internal control 
(house keeping) gene. 
 
Results 
Table 5.4. Demographics of the patients recruited for study 2. 
 Patient id. Sex Age(years)
1 1 male 52
2 2 male 63
3 3 male 70
4 4 male 72
5 6 male 54
6 7 male 70
7 8 female 77
8 9 male 71
9 10 male 78
10 11 female 72
11 12 male 55
12 14 male 73
13 15 female 75
14 16 male 78
15 17 female 70
16 18 male 75
17 19 female 75
18 20 male 69
Total N 18                  
  Mean     69.39
 
There were 18 patients recruited over a period of 6 months. The male: female ratio was 15: 3 
and the mean age as seen in the table was 69.39 years (Table 5.4) 
. 
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Table 5.5. Mean cortisol values and their standard deviations in the three phases of the 
study. 
 
cortisol 
Mean 
Standard 
Deviation Total N Missing 
Timing pre-operative 17.107 8.207 18 3
post-
operative 16.129 9.342 18 8
pre-discharge 12.554 4.654 18 8
 
From each patient, 3 sets of samples were to be collected. However some samples were 
insufficient, while some samples could not be collected as the patient had been discharged 
(Table 5.5). Three sets of samples, pre-operative, post-operative and pre–discharge were 
collected from 18 patients. There was no perceived need for additional controls as the pre-
operative samples would serve as baseline while immediate post-operative would serve as 
post-stressor, acute response phase, while the pre-discharge samples would serve as post–
stressor phase.  
 
Among the salivary cortisol samples, 35% (19) samples were missing or insufficient. 16 of the 
insufficient samples were from the post–operative and the pre-discharge group. Most of these 
patients provided blood cortisol samples as well, but these were not considered due to lack of 
correlation in these circumstances as free cortisol index (FCI) was not available. Free cortisol 
index is the ratio of serum total cortisol level to cortisol binding globulin level. It is considered 
predictor of the true cortisol levels in blood especially in patients who may be hypo-
proteinaemic. 
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Figure 5.4 Bar charts with error bars depicting the mean salivary cortisol at the pre-
operative phase, immediate post –operative phase and discharge phase. 
 
The mean cortisol was highest in the pre-operative group in our set of patients; however there 
was a considerable variation between the individual patients as evidenced by the error bars in 
the figure 5.4. The mean cortisol levels progressively decreased in the immediate post –
operative phase to its lowest in the pre-discharge group. As seen the variation was also much 
less in the pre-discharge group and most of the samples showed a trend towards decreasing 
cortisol response compared to the pre-operative situation. The difference between the groups 
was not statistically significant when compared by paired t–test (Refer to table 5.6). 
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Table 5.6  The results of the paired sample t-test between the pre-operative samples and 
post-operative or pre-discharge salivary cortisol samples. 
Paired Samples Test 
 Paired Differences t df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence Interval 
of the Difference       
        Lower Upper       
Pair 1 Preoperative cortisol 
– Discharge cortisol 
4.9 9.7 3.1 -2.1 11.9 1.6 9.0 0.1
Pair 2 Preoperative cortisol 
– Postoperative 
cortisol -0.2 10.3 3.2 -7.6 7.1 -0.1 9.0 0.9
 The table shows the results with actual number of samples available. 
 
The missing samples values were replaced using linear trend method in SPSS 14 and paired t-
test did not show any significant difference between the time points.(Refer to table 5.7) 
 
Table  5.7  Results of the paired sample t-test between the pre-operative samples and 
post-operative or pre-discharge salivary cortisol samples. 
 Paired Samples Test 
 Paired Differences t df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference       
        Lower Upper       
Pair 1 LINT(Preoperative 
cortisol) - 
LINT(Postoperative 
cortisol) -0.8 10.4 2.8 -6.8 5.3 -0.3 13.0 0.8
Pair 2 LINT(Preoperative 
cortisol) - 
LINT(Dischargecortisol) 
3.0 8.6 2.1 -1.4 7.5 1.5 16.0 0.2
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Table 5.8 shows the mean HBD1,2 and 3 expression at different time points. As seen in Table 
5.8 and Figure 5.5 the mean HBD1 and 3 expression were higher in the pre-operative patients 
and progressively decreased in the post-operative and pre-discharge stages. The HBD2 
expression however peaked at the post–operative time. There was considerable individual 
variation in the HBD1 levels in samples taken in the pre and post–operative periods as seen by 
the standard deviation. The variation in the individual patients in pre-discharge period was 
least for all HBD’s as seen. 
 
Table 5.8. Mean HBD1, 2 and 3 expression and the standard deviation (SD) at different 
time points. 
  
HBD1 HBD2 HBD3 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Timing pre-operative 2.3 3.7 1.4 1.2 1.5 1.4 
post-operative 
1.9 4.2 1.6 1.5 0.8 0.6 
pre-discharge 0.7 0.7 1.2 0.7 0.8 0.3 
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Figure 5.5 Graphical representation of the variation of Cortisol and HBD1,2 & 3 RNA 
expression at the different time points in the study, namely pre-operative, post –
operative and pre-discharge stages. 
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Table 5.9. The mean difference between the HBD 1,2  and  3 mRNA expression between 
different time points  
 Paired Differences t df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference       
        Lower Upper       
Pair 1 PreopHBD1 - 
PostopHBD1 
0.5 6.1 1.6 -2.9 3.9 0.3 
14.
0 0.8
Pair 2 PreopHBD1 - 
DischargeHBD1 2.2 4.3 1.3 -0.6 5.1 1.7 
10.
0 0.1
Pair 3 PreopHBD2 - 
PostopHBD2 -0.1 1.6 0.4 -1.0 0.8 -0.3 
14.
0 0.8
Pair 4 PreopHBD2 - 
DischargeHBD2 0.4 1.6 0.5 -0.7 1.5 0.8 
10.
0 0.4
Pair 5 PreopHBD3 - 
PostopHBD3 0.7 1.6 0.4 -0.1 1.6 1.8 
14.
0 0.1
Pair 6 PreopHBD3 - 
DischargeHBD3 1.0 1.4 0.4 0.1 1.9 2.4 
10.
0 0.0
 
The results were not statistically significant.  
 
The difference in the expression of the HBD1, 2 & 3 RNA at different time points was assessed 
using paired t-test (Table 5.9). The paired t-test was used to see if there was statistically 
significant difference between the pre-operative expression of these peptides as compared to 
the post –operative and the pre-discharge samples. As seen in Table 5.8, the difference in the 
HBD expression was not significant for any of the HBDs as compared to the basal, pre-
operative, expression. 
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Figure 5.6  The variation in the cortisol levels and the HBD1,2 &3 mRNA levels at 
different time points. The Y axis shows the mean with 95% confidence intervals (CI) and the 
X axis represents the different time points. As seen in Fig 5.6 there was considerable variation 
of cortisol levels and HBD1, 2 &3 between the patients. The variation was most marked in 
immediate post-operative cortisol levels and HBD1mRNA levels followed then by the levels in 
the pre-operative states.  The variation in both the cortisol levels and the levels of HBD1, 2&3 
was least in the pre-discharge state. 
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Variation of Cortisol and HBD levels- Table 5.10 
  CORTISOL HBD1 HBD2 HBD3 
 P1 P2 D P1 P2 D P1 P2 D P1 P2 D 
P1 
cortisol 
PC 
1 0.3 0.1 -0.4 0.1 -0.6 -0.2 -0.3 -0.4 0.1 -0.1 0.3 
  Sig.    0.3 0.7 0.2 0.8 0.1 0.4 0.3 0.2 0.9 0.7 0.4 
  N 
15 
10.
0 
10.
0 13.0 12.0 
10.
0 13.0 12.0 
10.
0 13.0 12.0 10.0 
P2 
cortisol 
PC 
0.3 1.0 0.3 -0.7 0.3 -0.5 0.5 -0.6 0.0 -0.1 -0.6 0.3 
  Sig.  0.3   0.6 0.1 0.6 0.3 0.3 0.2 1.0 0.9 0.1 0.6 
  N 
10.0 
10.
0 6.0 8.0 7.0 6.0 8.0 7.0 6.0 8.0 7.0 6.0 
DC PC 0.1 0.3 1.0 0.1 0.3 0.2 -0.3 -0.4 -0.1 -0.4 0.3 -0.6 
  Sig.  0.7 0.6   0.9 0.5 0.7 0.4 0.3 0.7 0.3 0.4 0.1 
  N 
10.0 6.0 
10.
0 10.0 9.0 
10.
0 10.0 9.0 
10.
0 10.0 9.0 10.0 
P1 HBD1 PC -0.4 -0.7 0.1 1.0 -0.2 0.1 0.4 0.2 0.0 .498(*) 0.2 0.2 
  Sig.  0.2 0.1 0.9   0.6 0.8 0.1 0.4 0.9 0.1 0.4 0.5 
  N 
13.0 8.0 10. 16. 15.0 
11.
0 16.0 15.0 
11.
0 16.0 15.0 11.0 
P2 HBD1 PC 0.1 0.3 0.3 -0.2 1.0 0.4 -0.2 -0.2 -0.4 -0.2 .795(**) -0.1 
  Sig.  0.8 0.6 0.5 0.6   0.2 0.6 0.6 0.2 0.5 0.0 0.9 
  N 
12.0 7.0 9.0 15. 15.0 
10.
0 15. 15.0 
10.
0 15.0 15.0 10.0 
DHBD1rg
eHBD1 
PC 
-0.6 -0.5 0.2 0.1 0.4 1.0 -0.2 -0.1 0.0 0.2 0.0 -0.5 
  Sig.  0.07 0.3 0.6 0.7 0.2   0.41 0.74 0.9 0.4 0.9 0.1 
  N 10 6 10 11 10 11 11 10 11 11 10 11 
P1 HBD2 PC -0.2 0.4 -0.2 0.4 -0.1 -0.2 1 0.3 -0.0 0.2 -0.079 0.25 
  Sig.  
0.433 0.2 0.4 0.1 0.5 
0.4
71   0.2 
0.9
83 0.3 0.7 0.4 
  N 13 8 10 16 15 11 16 15 11 16 15 11 
P2 HBD2 PC 
-0.3 -0.5 -0.3 0.2 -0.1 -0.1 0.3 1 
-
0.1
66 -0.036 0.014 -0.025 
  Sig.  
0.3 0.1 0.3 0.4 0.5 0.7 0.2   
0.6
47 0.9 0.96 0.945 
  N 12 7 9 15 15 10 15 15 10 15 15 10 
DHBD2 PC -0.4 -0.0 -0.1 0.0 -0.4 0.0 -0.0 -0.1 1 -0.1 0.03 0.112 
  Sig.  0.2 0.9 0.7 0.8 0.2 0.9 0.9 0.6   0.713 0.935 0.742 
  N 10 6 10 11 10 11 11 10 11 11 10 11 
P1 HBD3 PC 0.0 -0.0 -0.3 .498(*) -0.2 -0.2 0.26 -0.036 - 1 0.084 .862(**) 
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*  Correlation is significant at the 0.05 level (2-tailed). 
**  Correlation is significant at the 0.01 level (2-tailed). 
 
Key P1- Pre operative, P2- post operative, D –discharge, PC-Pearson’s correlation coefficient,Sig- Significance 2 tailed  
 
Table 5.10 Results of Pearson’s correlation between the HBD1,2 & 3 RNA expression 
and the cortisol expression at the different phases respectively. 
There was significant positive correlation between the pre and post-operative mean HBD1 and 
HBD3 mRNA levels. No significant correlation was seen between the cortisol levels and HBD 
levels (Table 5.10). 
0.1
26 
  Sig.  
0.8 0.8 0.2 0.05 0.461 
0.4
89 0.331 0.9 
0.7
13   0.765 0.001 
  N 13 8 10 16 15 11 16 15 11 16 15 11 
P2HBD3 PC 
-0.1 -0.6 0.3 0.2 .795(**) 
0.0
39 -0.079 0.014 
0.0
3 0.084 1 0.229 
  Sig.  0.743 0.1 0.4 0.4 0 0.9 0.78 0.96 0.9 0.765   0.524 
  N 12 7 9 15 15 10 15 15 10 15 15 10 
D HBD3   0.276 0.2 -0.5 0.2 -0.062 -0.4 0.25 -0.025 0.1 .862(**) 0.229 1 
  Sig.  
0.44 0.6 0.0 0.5 0.866 0.1 0.458 0.945 0.7 0.001 0.524   
  N 10 6 10 11 10 11 11 10 11 11 10 11 
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Immunocytochemistry 
 
 
Figure 5.10- Immuno-localisation of HBD1, 2 & 3 proteins.  
Slides were stained with specific primary antibodies and developed with DAB. Panel A shows no primary antibody 
negative control , arrows shows buccal epithelial cells ; as seen no DAB stain is seen. Panels B,C,D show the 
slides stained with specific HBD1, 2 & 3 antibodies respectively, arrows point to cells which show localisation of 
the protein. 
HBD- HBD1 Post-operative 
HBD2 Post-operative HBD3 Post-operative 
A B
C D
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The HBD1, 2 and 3 protein localised in the buccal epithelial cells was detected by 
immunocytochemistry. Immunocytochemistry was only used to localise the HBD proteins to 
ascertain their source in the oral cavity to be buccal epithelial cells (5.10). HBD are secretory 
proteins and depending on the maturity of the individual epithelial cell and the degree of 
stimulation, they can have variable amount of defensin peptide.  Hence it is expected that 
there would be variation in the peptide level among the individual cells. The number of cells 
obtained per patient sample for immunocytochemistry was about 50. These cells were to be 
re-distributed between 3-4 slides, thus the number of cells available on each slide per patient 
per HBD was about 15. The low cell number per slide made any kind of objective, statistically 
significant expression analysis impossible, hence immunocytochemistry was used only as a 
tool to localise the proteins. Saliva was considered as a better source of quantifying the HBD 
peptide expression in the oral cavity using high pressure liquid chromatography (HPLC) 
techniques. Although saliva was collected, it was considered outside the remit of the current 
PhD to perform peptide quantification using HPLC. 
 
5.4 Discussion 
Salivary cortisol gives the direct measurement of serum free cortisol. Cortisol in a healthy 
person exists in three different types: type a) 10% physiologically active free unbound form, 
type b) 20% bound to albumin and type c) 70% bound to cortisol binding globulin. Types b and 
c are physiologically inactive. Serum cortisol represents total cortisol which includes the free 
and bound cortisol forms. However a number of factors influence protein binding and levels 
and hence serum free cortisol measurement is considered a better predictor of adrenal 
function in critically ill patients(Umeda et al., 1981, Hamrahian et al., 2004). Salivary cortisol 
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measurement is a direct reflection of serum free cortisol and is considered useful for 
measurement of free cortisol levels(Umeda et al., 1981). In patients with extensive 
inflammation and hyper-metabolic states such as sepsis, poly-trauma and  post –operatively 
there are changes in the globulin, albumin and the protein content, hence measuring total 
serum cortisol does not give a true measure of stress response evoked in these situations. 
These patients are known to have acute phase responses which can result in variations in 
cortisol-binding globulin levels and combined with nutritional status and other factors such as 
hydration status can also result in the alteration of albumin and total protein levels(Pugeat et 
al., 1989). A number of physio-pathological changes occur during acute phase response that 
result in alteration of globulin and albumin levels; these include increased permeability of the 
blood vessels, decreased hepatic synthesis(Ruot et al., 2000) and increased degradation of 
globulin by elastase secreted from activated neutrophils(Bladon et al., 1996). Since these 
effects could be transient depending on a number of factors including variation in cytokine 
levels and hormones it is difficult to interpret the total free cortisol levels as both the globulin 
and albumin levels are extremely variable. In these circumstances salivary cortisol or serum 
free cortisol is taken as a better predictor of true cortisol levels and to reflect the cortisol 
response(le Roux et al., 2003). This may explain our findings of lack of correlation between the 
salivary and serum cortisol in critically ill patients. 
 
In states of sedation our results demonstrate lower levels of serum total cortisol while the 
salivary cortisol does not show significant changes. Propofol was the predominant agent used 
for maintaining sedation in our cohort of patients. It is well documented that this drug causes 
increased vascular permeability mediated by nitric oxide signalling pathways(Chen et al., 
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2007). The increased vascular permeability is associated with loss of intravascular proteins 
which in turn causes a decrease in the apparent total cortisol levels, i.e serum total cortisol 
levels. This explains our observation of a significant negative correlation between sedation 
score and serum cortisol levels. However as shown by the lack of correlation between the 
salivary cortisol and sedation levels, this does not reflect true variation in cortisol response but 
is a reflection of transient variation in albumin and cortisol binding globulin levels. 
 
Thus our study reinforces the message that measurement that salivary cortisol, which reflects 
the active form, that is serum free cortisol, is a better measure of true cortisol levels especially 
in critically ill patients as it is not influenced by alterations of the protein levels or by physical 
activity or sedation. The collection of saliva is also non-invasive and hence can be used even 
in children and people who have needle phobia. 
 
The drawbacks of salivary cortisol 
It should however be borne in mind that measurement of salivary cortisol is not routinely 
available in the clinical setting. Currently it is predominantly used as a research tool, however it 
is utilised for diagnostic purposes in some hospitals. The most important drawback associated 
with salivary cortisol measurement is insufficiency of the salivary sample. As salivation is 
controlled by the autonomic nervous system, most of the patients in critically ill state or those 
with activated stress responses do not salivate.  The problem is exacerbated as some of these 
patients are dehydrated or hypo-volaemic. This problem can be circumvented to some extent 
by increasing the duration for which the cotton plug used for salivary collection is kept in the 
oral cavity and also by using special cotton plugs which contain stimulants in the form of citric 
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acid. The plugs in our study were kept for the cavity for 2 minutes. Longer durations were not 
used as patients did not tolerate the plugs which resulted in feelings of nausea. Care must also 
be taken to avoid the risk of aspiration of the plug especially if these are used in children or in 
comatose patients. 
 
Salivary cortisol and surgery 
This is the first study comparing the pre and post operative the salivary cortisol levels in 
patients undergoing major surgery for malignancies. Our study demonstrated a progressive fall 
in the mean salivary cortisol levels in our group patients from day 0 pre-operative (day of 
surgery) to day of discharge. It has been recognised that the surgery itself is a stress factor 
and does cause stress response. The studies previously demonstrated an increase in the 
serum cortisol levels immediately after surgery as compared to the pre-surgical values(Bellon 
et al., 1998, Glaser et al., 1995). The degree of response was proportional to the degree of 
tissue trauma during surgery. However these studies were done in truly elective conditions 
wherein there was no ongoing pathological process; for example the study by Glaser et al 
compared elective laproscopic and open cholecystectomies, and by default elective 
cholecytectomy is contraindicated in the presence of any signs of inflammation of the gall 
bladder. One of the inclusion criteria in our study was that patients needed to have major 
surgery which required them to be admitted to the critical care area as per the hospital policy.  
In our study the patients recruited had extensive malignancies with local spread, requiring 
radical procedures to eradicate the malignancy. Some tumours can themselves evoke a stress 
response while in some types of cancers such as lung cancers(Lichter and Sirett, 1968) 
elevated cortisol levels may be a paraneoplastic feature. In our study the types of malignancies 
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were either urological or gastrointestinal; there have been studies suggestive of elevated 
cortisol as a result of direct effect of these malignancies. The workup to surgery and the 
psychological impact of the whole process is likely to have an influence on the cortisol levels, 
however it is possible that these malignancies may directly cause elevated cortisol levels by 
yet undescribed pathways. Thus it is not surprising that most of individual patients and the 
mean cortisol in the pre-operative state were highest. The inflammation and the stress 
responses associated with surgery and also the malignancy are likely to show a down trend 
with time. This is reflected in our group of patients as a progressive fall of mean salivary 
cortisol form pre-operative to post –operative and pre discharge states. The patients who had 
a lower cortisol levels pre-operative stage had a peak at the post-operative period followed by 
a fall at the pre-discharge stage. This trend however was not seen in 2 patients (patient ID 7, 
17). These patients had similar cortisol levels during the pre- and post- operative periods and 
their cortisol levels progressively increased to the time of discharge. It is possible that these 
patients had residual pathology in situ which did not surface to the time that they were 
discharged. The difference in the cortisol levels between the groups that is in the post-
operative and the pre-discharge state as compared to the pre-operative state were not 
statistically significant as assessed by paired t-tests. This could be accounted for by the 
marked individual variations and insufficient number of successful samples (having enough 
saliva for evaluation).  
 
Human Β –Defensins (HBD) and Cortisol 
Although our study did not demonstrate a statistically significant correlation between the 
salivary cortisol levels and the HBD1, 2, and 3 expression, it is the first study of its kind and 
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helps understand the physiological response of the innate immune system in preparation and 
during a major stress event. Our study showed an increase in the HBD1 and 3 mRNA 
expression in the pre-operative state and progressive tapering down of the expression similar 
to that of the cortisol pattern. There was statistically significant correlation between the HBD1 
and HBD3 mRNA levels in the pre-operative and the post–operative groups. The HBD2 mRNA 
expression unlike HBD1 & 3 mRNA levels peaked in the immediate post-operative period 
before falling to less than pre-operative levels by the pre-discharge state. 
HBD1, 2 & 3 are expressed in the oral cavity and serve as the first line of defense against 
microbial invasion(Dale and Krisanaprakornkit, 2001, Dunsche et al., 2002). In oral 
pathological conditions and inflammatory states the HBD’s are variably expressed with HBD2 
and or 3 being more elevated compared to HBD1(Dommisch et al., 2005). These antimicrobial 
peptides in the oral cavity  are considered to be stimulated in the presence of inflammation by 
the inflammatory cytokines specially TNF-α(Saitoh et al., 2004). 
 
We have demonstrate for the first time a significant correlation between the HBD1 and HBD3 
mRNA levels when the levels of HBD1 and 3 were high; this suggests to a possibility of 
crosstalk between these peptides which until now have been considered primarily 
antimicrobial. Increased levels of HBD1 and 3 in the pre-operative and the early post operative 
phase also demonstrate the heightened level of innate immune defences at the mucosal front 
in preparation for the stress event. This further co-relates with the fact that the majority of the 
oral cavity pathogens belong to the Staphylococcal group against which HBD3 is specifically 
active. Increased levels of HBD2 in the immediate post –operative period supports the 
increasing lobby of evidence suggesting to the more diverse role of HBD2 apart from being 
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antimicrobial. Following the trauma of surgery the pro-inflammatory cascade is activated which 
includes IL-1 and IL-6 which are known to stimulate the HBD2 expression. Some of the 
inflammatory mediators like TNF-α induce the expression of HBD3. These cytokine responses 
prevail for variable amounts of time following surgery, being dependent on a number of patient 
dependent factors. IL-6 is the most important mediator in the early post–operative phase which 
mediates activities like acute phase response(Sheeran and Hall, 1997), IL-6 is also a very 
potent inducer for HBD2. This response is however soon suppressed by the 
immunosuppressive influence of the cortisol(Desborough, 2000). This probably explains the 
peak HBD2 levels in the post –operative phase. The other cytokines gradually decrease in 
time and this combined with microbial stimuli in the oral cavity determine the progressive fall in 
the HBD2 and HBD3 expression. 
There was considerable variation in the individual levels of cortisol and the inherently 
expressed HBD1 in the pre and the post operative state, being more marked in the immediate 
post operative state. The levels of cortisol depend on the level of stress and its mediators while 
the factors influencing the levels of HBD1, 2 & 3 can be variable. In the pre-operative state the 
level of stress is expected to be variable depending on the psychological response to the 
malignancy and surgery. Also as suggested earlier the direct effect of malignancy may also 
influence the cortisol levels. Again in the immediate post-operative phase depending on the 
extent of the tissue trauma and the scale of surgery the cortisol levels can be extremely 
variable. This was demonstrable in our study as variation in the levels of cortisol demonstrated 
by 2SD of 9.34 in the immediate post-operative phase, while this was 8.2 in the pre-operative 
phase. As expected the variability decreased in the pre-discharge phase as levels of cortisol 
returned to normalcy with decreasing stress and stress mediators. HBD1 is normally inherently 
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expressed at a number of different sites of the body while HBD2 and 3 are normally inducible 
peptides. In the oral cavity presumably as it is perennially inhabited by some inherent flora all 
the three peptides are inherently expressed to variable levels depending on the flora. In our 
study the variability of HBD1, 2 & 3 was highest in the immediate post-operative phase as 
compared to the pre-operative phase.  
The primary function of the innate immune system is the first line of defence against the 
invading micro-organisms, as secondary function components of the innate immune system 
also trigger the adaptive immune system to serve as a secondary line of defence again. In the 
oral cavity HBD serve as the first line of defence to prevent infections possibly by maintaining a 
homeostatic environment by keeping the flora in the oral cavity under check. The current study 
was an endeavour to understand how the body responds during an imminent major stress 
event in relation to expression of innate defence peptides HBD1, 2 & 3. The increased HBD1 & 
3 mRNA expression in the pre-operative phase suggests to the activation of the innate immune 
responses to prepare for the stress event, especially given the fact that the oral cavity flora are 
sensitive to the HBD 1 & 3. As the stressors intensify by the actual onset of the tissue trauma 
the expression of these peptides is further induced at the mRNA level as evidenced by the 
increased mRNA expression. HBD2 and HBD3 have been shown to serve as a link between 
the adaptive and the innate immune system. The marked increase in the HBD2 along with an 
increase in HBD3 in the immediate post-operative phase suggest to the activation of the 
signalling pathways which can trigger the adaptive immune system to serve as a secondary 
defence mechanisms if the primary defence capacity is exceeded. The localisation of peptides 
by immunocytochemistry to the buccal epithelial cells suggests to the successful translation 
mechanisms. 
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Conclusion  
Our study demonstrates increased expression of antimicrobial peptides HBD1, 2, and 3 at the 
mRNA level in the early peri-operative period. This probably reflects the body’s natural 
response at the mucosal front for a major stress event. The outcome of the stress event is 
however is based on the complex interplay between the degree of microbial challenge, 
duration of the stressor, the level of tissue and protein breakdown, the nutritional and the 
reserve capacity of the patient. The study also demonstrates for the first time the possibility of 
cross talk between the different HBDs. This requires further scrutiny but will be an important 
milestone in determining the scope of using these peptides for modulating the immune 
response to prevent infections in patients undergoing major stress events. 
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Chapter 6 
Expression analysis of Human Β Defensins 
1, 2 & 3 in keloid scars 
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6.1 Introduction 
 Keloids are abnormal scars wherein the scar tissue takes a disfiguring appearance and 
extends over and around the original wound. The Smith Papyrus first described a disfiguring 
scar around 300BC however it was Jean Louis Alibert who coined the term ‘cheloide (Greek 
words; chele-crabs claw, oid-like) in 1806(Yang et al., 2003) to describe the crab claw like 
extension of the lesion into normal skin. The first systemic review of keloids appeared in 
literature in 1961 by Cosman and co-workers describing presentation, characteristics and 
possible treatment of keloids; subsequently Peacock and colleagues described the difference 
between  keloids and hypertrophic scars(Peacock et al., 1970). 
 
Keloids are considered to result from an exuberant healing response and  abnormal dermal 
fibroblast proliferation(Calderon et al., 1996), secondary to cutaneous injury(Xia et al., 2006) 
with persistent growth of the wound tissue even after re-epithelisation and extension beyond 
the original boundary of injuring stimulus; being pathognomonic features. 
 
Incidence and distribution 
Keloids are benign or partially benign dermal mesenchymal tumours occurring on almost any 
part of the body; being less common in cornea(Bourcier et al., 2004) . They were initially 
thought not to occur on the weight bearing areas of the body namely palms and soles(Chipev 
et al., 2000) however there have been cases reported from these areas as well(LeFlore and 
Antoine, 1991). The incidence of keloids is higher among africans and asians(Tuan and 
Nichter, 1998) with equal sex distribution(Oluwasanmi, 1974). These lesions have been 
described in children with Lowe’s syndrome and  Rubinstein-Taybi syndrome(Bourcier et al., 
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2004). The tendency to form scars increases with the increasing gestational age and cellular 
maturity after 60-90 days gestation(Cass et al., 1997), and the incidence of keloids is higher 
around puberty and during pregnancy. 
 
Symptoms and clinical presentation 
Itch (alloknesis) and pain (allodynia) are common symptoms of keloid patients. Itching is 
common around the edge whereas pain is common around the centre of keloid. These two 
sensations are carried by small nerve fibres and may  result from small nerve neuropathy(Lee 
et al., 2004) or due to the increased expression of neuropeptides like β CGRP and Substance 
P. The other common symptom is the disfiguring appearance of the scar. Apart from the 
physical symptoms there are immense psychological issues owing to the disfigurement 
associated with these lesions. 
 
Aetiology  
The aetiology of keloids can be variable however the common pathway is via the cutaneous 
insult. This can be in the form of a piercing for cosmetic reason for example ear lobule keloids, 
or surgical incision or trauma and burns. Other conditions like chicken pox and acne which can 
cause vesicles or breach of skin and infection or inflammation can cause keloids. The 
incidence of keloids following burns can be variable ranging from 4-16%. 
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Pathogenesis 
Keloid was initially considered to be a dermal pathology but this view has changed with the 
unfolding knowledge. The patho-physiological mechanisms involved are complex and unclear 
and involve dermo-epidermal interactions. Keloids are associated with a significant morbidity 
from both a physical and psychological perspective and an effective treatment continues to 
evade this condition(McGrouther, 1994). The current treatments are ineffective and 
unsatisfactory and are associated with a high recurrence rates. More efforts and resources are 
needed to evaluate Keloid pathogenesis to have effective control of this disease 
entity(McGrouther, 1994). Current research reveals that in keloids, the epidermis shows 
abnormalities of keratinocyte proliferation and differentiation(He et al., 2004). There is 
dysfunctional regulation of the extracellular matrix (ECM) which contains hyaluronic acid, 
fibronectin(Diegelmann et al., 1979, Babu et al., 1989) and bi-glycans but no elastin(Bhangoo 
et al., 1976) or cellular components of normal scar milieu resulting in disproportionate extra-
cellular matrix accumulation and tissue fibrosis. Keloids thus are characterised by histological 
features of prolonged inflammatory fibrotic activity marked by the presence of inflammatory 
cells like Mast cells and an environment rich in cytokines(Zhang et al., 2006). Keloids are 
histologically characterized by the presence of abundant collagen types 1 and 3(Abergel et al., 
1985, Naitoh et al., 2001) and high metabolic rate(Ueda et al., 1999) mainly due to anabolic 
glycolysis(Ueda et al., 2004). The mechanism of keloid formation probably includes alteration 
in growth factors, collagen turnover, tension alignment and genetic and immunologic 
contributions(Al-Attar et al., 2006). 
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Keloid and Cellular Components  
Keloid fibroblast show no significant differences either in morphology or growth kinetics to 
normal skin fibroblasts in vitro, although in a keloid they are arranged in a an irregular 
crisscross and overlapping pattern suggesting loss of polarity(Huang et al., 1998). Like other 
skin-derived cells they maintain a monolayer and display contact inhibition in cultures(Koch et 
al., 1997). Basal and superficial keloid fibroblasts show increased doubling time compared to 
the central keloid fibroblasts (Luo et al., 2001). Keloids are a local pathological process with no 
systemic influence as suggested by an in vitro study wherein the growth kinetics of keloid 
derived fibroblasts and normal dermal fibroblasts remained similar irrespective of culturing in 
the presence of keloid or normal patient sera(McCoy and Cohen, 1981). Keloid fibroblasts 
have localised hyper-androgen metabolism and are composed of polyclonal fibroblasts 
disproving the concept of over- proliferation of a single clone of cells(Chevray and Manson, 
2004, Moulton-Levy et al., 1984). 
 
Role of apoptosis 
Keloid fibroblasts have increased proliferation rate due to lower inherent threshold for S phase 
entry(Calderon et al., 1996) and have higher rate of programmed cell death, 
(apoptosis)(Akasaka et al., 2001) and reduced survival(Akasaka et al., 2005) which is reflected 
in vitro by expression of caspase 2,3,9 and terminal deoxynucleotide transferase-mediated 
dUTP nick-end labelling (TUNEL). This apoptotic activity becomes more aggressive if the 
Keloid fibroblasts (KF) are deprived of serum and can be inhibited significantly by the caspase-
3 inhibitor, Ac-Asp-Glu-Val-Asp-fluoromethyl ketone (DEVD-FMK)(Akasaka et al., 2000). Fas 
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protein is expressed excessively in Keloid and peri-keloid normal skin(Lu et al., 2003), and is 
mainly expressed in the central hypocellular region of Keloid with localisation along the cell 
surfaces. In contrast P53 and bcl-2 expression is localised to hypercellular, peripheral areas of 
Keloid in a peri-nuclear pattern. This focal up-regulation of p53and bcl-2 may produce a 
combination of increased fibroblast proliferation and decreased cell death in the younger, 
hypercellular areas of Keloid and this phenotype is reversed in older areas of Keloid. Such a 
distribution difference may be responsible for preventing malignant changes in 
Keloids(Palladino et al., 2003, Ladin et al., 1998). Subsequent studies showed that Keloid 
fibroblast are resistant to Fas mediated apoptosis; this resistance is reversed by neutralisation 
of autogenous TGF-β-1 thus suggesting a role of TGF-β-1 in resistance of Keloid fibroblasts to 
apoptosis(Chodon et al., 2000). Similarly Keloid fibroblast have enhanced expression of IGF-1 
receptors which helps them to resist etoposide induced apoptosis(Sell et al., 1995) and also 
enhances their invasive activity(Ishihara et al., 2000). Keloid fibroblast proliferation can be 
inhibited by all isoforms of retinoid especially Tretinoin(Daly and Weston, 1986). 
  
Fibrosis  
Fibrosis is the key pathological event in Keloid pathogenesis. Keloid fibroblasts have an 
inherent capacity to synthesize more collagen(Diegelmann et al., 1979). Also increased 
fibrosis in keloids may be due to influence of multiple factors which are still unclear. It is 
generally perceived that the reparative fibrotic process progresses to pathological fibrosis due 
to chronic influence of pro-inflammatory cytokines which are known to exist in keloids. 
Increased expression of the propiomelanocortin gene and lack of regulation of cytokines like 
TGF-β is suggested in pathogenesis(Teofoli et al., 1997). An imbalance in the inflammatory 
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cell subpopulation of macrophages and lymphocytes particularly CD4 and CD8 lymphocytes 
and fibroblast may also play a role(Boyce et al., 2001). Similarly Keloid fibroblasts show 
resistance to macrophage/lymphocyte cytokine- oncostatin M which is a stimulator of normal 
fibrotic repair via activation of collagen and glycosaminoglycan synthesis in normal dermal 
fibroblast; thus leading to abnormal fibrosis(Duncan et al., 1995). Epidermal keratinocytes are 
also suggested to play a role through paracrine and double paracrine effects(Funayama et al., 
2003) and epidermal-mesenchymal(Lim et al., 2001) signalling to promote dermal fibroblast 
proliferation and decrease apoptosis. The co-culture of Keloid keratinocytes and Keloid 
fibroblasts expressed more TGF-β-1,3 and TFG-β-1 receptors on both cell lines thus 
suggesting to cross talk between the cell types and complex interactions(Xia et al., 2004). The 
cellular difference between Keloids and hypertrophic scar was thought to be due to the 
presence of myofibroblast in hypertrophic scar but study of Keloid ultra structure has disproved 
this by showing the presence of myofibroblast in Keloid(Lehmann et al., 2002). 
 
Keloid and Extracellular Matrix 
Keloido-genesis is considered to be a fibrotic pathology due to the excessive extra-cellular 
matrix (ECT) production. Keloid collagen is distributed in the form of nodules which form the 
structural unit of Keloid(Kischer and Bailey, 1972). These nodules in turn are composed of 
compactly packed uni-directionally arranged collagen fibrils(Kischer and Brody, 1981) which 
can be visualised by transmission electron microscopy after toluidine blue O stain(Kischer, 
1984). Collagen deposition increases with time from the base to surface and is concentrated 
along the lateral branches of new vessels Keloids are thus considered products of granulation 
tissue(Kischer et al., 1990). The Keloid matrix contains increased amount of collagen I and III 
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packed into nodules(Prathiba and Suryanarayanan, 1999) occluded vessels, 
fibronectin(Kischer and Hendrix, 1983), immunoglobulin, chondroitin-4-sulphate, integrin alpha 
1,2(Szulgit et al., 2002) and higher partial pressure of carbon dioxide with low partial pressures 
of oxygen. Procollagen type-1 carboxyterminal propeptide (P1CP) represents type I collagen 
metabolism in fibroblasts and Keloid fibroblasts (KF) expressed more P1CP on application of 
histamine,TGF-Β-1 and EGF than control normal fibroblast (NF). This increased metabolism of 
collagen type-1 was suppressed by gamma interferon(Kikuchi et al., 1995). This enhanced 
ECT production is considered to be due to suppressed activity of cyclooxygenase-2 in KF as 
compared to NF. The activity of cyclooxygenase was enhanced by macrophage migration 
inhibitory factor (MIF), a pluripotent cytokine in NF as compared to KF. MIF also induced 
increased production of prostaglandin E2 an anti- fibrogenic molecule in NF as compared to 
KF thus suggesting  a role of prostaglandins in the pathogenesis of Keloids(Hayashi et al., 
2006). Keloid fibroblast show increased production of ECT proteins such as  fibronectin, 
tenascin C(Han et al., 2005, He and Han, 2004) and undulin(Dalkowski et al., 1999) both at 
RNA and protein levels as compared to NF. This activity is further enhanced by the TGF 
isofrom TGF-β-1(Babu et al., 1992, Bettinger et al., 1996). Similarly free radicals such as 
nitrous oxide can simulate Keloid fibroblasts to produce excessive collagen(Cobbold, 2001). 
The production of extracellular proteins and glycoproteins such as fibronectin, 
glycosaminoglycans (GAG) and collagen by Keloid fibroblasts can be inhibited in vitro by 
pentoxifylline, an analogue of methylxanthine theobromine, in a dose dependent 
manner(Berman and Duncan, 1989, Habib et al., 2003). Low energy neodymiun:YAG laser 
decreased collagen production in vitro; suggesting  their use in modifying ECT in 
keloids(Castro et al., 1983).  
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Hyaluronic acid (HA) an important glycosaminoglycan and a component of the ECT has been 
found to form a pericellular coat around the cells. This tends to localise cytokines which 
induces collagen production. Alaish and co-workers demonstrated that Keloid fibroblasts 
synthesised higher amounts of hyaluronic acid compared to normal fibroblasts and thus in turn 
synthesised more collagen(Alaish et al., 1995). This increased synthesis of HA is reversed by 
triamcinolone acetonide which also softens and reduces Keloid size possibly due to enhanced 
degradation of collagen(Cohen et al., 1977). The Keloid matrix has similar types (type I and III) 
of collagen as  normal skin(Clore et al., 1979) but  high levels of tenascin C, an ECT 
glycoprotein that has been proposed as a marker for keloids(Dalkowski et al., 1999). 
 
Keloid Vasculature 
Keloids not only have an abnormal local microenvironment but also have altered vasculature It 
was previously thought that the Keloids had decreased vascular density and that the resulting 
hypoxia played an important role in pathogenesis(Beer et al., 1998). Recent studies 
demonstrated increased vascular density(Amadeu et al., 2003) and that the new 
microvasculature grows from below to the free surface in an environment rich in inflammatory 
cells and fibroblasts(Kischer et al., 1990). This increased angiogenesis is due to the increased 
expression of TGF-1 and vascular endothelial growth factors (VEGF).in Keloid 
fibroblasts(Fujiwara et al., 2005b). The major source of VEGF is epidermis rather than 
dermis(Gira et al., 2004). VEGF secretion could be blocked in vitro by verapamil, a calcium 
channel antagonist which also decreases the rate of proliferation of fibroblasts(Giugliano et al., 
2003). The local invasive nature of Keloids is probably due to angiogenesis factors like 
vascular endothelial growth factor, basic fibroblast growth factor and platelet derived growth 
 193
factor and their respective receptors(Jiang et al., 2004). Keloids contain significant 
microvascular occlusion which begins during the granulation phase of wound healing. Thus 
occlusion produces a hypoxic environment that results in Keloids secondary to excessive 
collagen production(Kischer, 1992). This collagen forms nodules which contain only a few 
micro-vessels, most of which are occluded(Kischer and Bailey, 1972) due to increase in the 
number of endothelial cells. The micro-vessels are mainly peripheral at the edges of the 
nodules(Kischer and Brody, 1981). Keloids reveal an increase in subepidermal venous vessels 
which correlates very closely to the hyperaemic nature of Keloid(Lametschwandtner and 
Staindl, 1990). The neovascularisation in Keloids is promoted by increased expression of 
macrophage inflammatory protien-1(MIP-1), monocyte chemoattractant protien-1(MCP-
1),interleuken-8(IL-8) and heme oxygenase(Zhu et al., 2005). 
 
 
Keloid and Growth Factors. 
 
The molecular basis of Keloid formation is governed by interplay of cellular signal pathways, 
specific target gene activation and the natural microenvironment resulting in prolonged 
inflammation and an altered balance in extra-cellular matrix metabolism(Le et al., 2004). 
Keloids have increased expression of TGF-β1 and TGF-β-2 without any increase in TGF-β-
3(Lee et al., 1999, Borel and Maquart, 1998) and this auto-production of TGF-β-I is minimised 
by truncated TGF β receptor II(Liu et al., 2002b). Similarly Keloids have an increased 
expression of TGF receptors I,II (TGG-R1/TGF-R11) and basic fibroblast growth 
factor(Hanasono et al., 2003).The increased expression of TGF β –I was inhibited in vitro by 
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tamoxifen(Mikulec et al., 2001) TGF-β stimulates the release of connective tissue growth factor 
CTGF) which is considered as a downstream mediator of TGF-β scarring and fibrotic activity. 
Both keloid and hypertrophic scars have increased intrinsic expression and exaggerated 
expression of CTGF in response to TGF –β stimulation(Colwell et al., 2005). Insulin like growth 
fFactor (ILGF) has synergetic effects with TGF-β-1 thus enhancing the production of ECT 
proteins 25 fold(Daian et al., 2003). The increased production of TGF-β 2 is mediated via p38 
mitogen activated protein (MAP) kinase(Xia et al., 2006). KF cultured on collagen gel contracts 
the gel to a greater extent than the gel populated with NF, and this difference can be 
eliminated by TGF-β application to NF cultured in a gel(Kamamoto et al., 2003). Such 
contraction can be minimised by the application of TGF-β-1 inhibitor called SB-
431542(Hasegawa et al., 2005). 
 
SMAD-3 signalling 
 
The SMAD-3 signalling pathway also plays an important role in Keloid pathogenesis through 
epithelial mesenchymal interaction(Tsujita-Kyutoku et al., 2005, Phan et al., 2005). The effect 
of TGF-β is terminated by negative feedback mechanism through SMAD6,7(Yu et al., 2005). 
These proteins are under-expressed in Keloid fibroblast. 
Keloids also show increased expression of heat shock protein 47(Chen and Cen, 2005), free 
radicals(Selsted et al., 1996) and thrombospondin-1. The  upregulation of 
plasminogen/plasmin system possibly mediates Keloid formation by thrombospondin-
1(Centeno et al., 2002). Keloids exhibit increased phosphorylation through tyrosine kinase 
which is linked to many cytokine receptors like epidermal growth factor (EGF), discoidin 
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domain (DD), shc and adaptor protein. EGF stimulates the growth of  Keloid fibroblasts 
(Harper, 1989) and Keloid fibroblasts have increased collagen synthesis(Diegelmann et al., 
1979), this probably is related to increased expression of collagenase inhibitors alpha-1 
antitrypsin and alpha-2-macroglubulin(Diegelmann et al., 1977). TNF-α is a potent pro-
inflammatory agent involved in activation of signal events and transcriptional programs such as 
NF kappa β. TNF-α up-regulates NF kappa β in KF 15 times more than NF and Keloid tissue 
also expresses higher levels of TNF-receptor associated factors-TRAF1,TRAF2-TNF-alpha, 
inhibitor of apoptosis (c-1AP-1), and NF kappa β than normal skin(Messadi et al., 2004). 
The Keloid fibroblasts produce type-1 collagen, matrix metalloproteinase-1(MMP-1) (interstitial 
collagenase), matrix metalloproteinase-2 (MMP-2) (gelatinase-A), matrix metalloproteinase-
9(Neely et al., 1999) and tissue inhibitor of matrix metalloproteinase (TIMP-1). Increased 
production of MMPs has role in the high migratory activity of cultured Keloid 
fibroblasts(Fujiwara et al., 2005a). Keloid derived fibroblasts show enhanced proliferation in 
the presence of platelet derived growth factor (PDGF) due to increased expression of PDGF 
receptors(Haisa et al., 1994) on the fibroblast surface. PDGF exerts its role through ERK(Liu et 
al., 2003). Similarly the invasive property of Keloid fibroblasts can be explained by increased 
expression of insulin like growth factor-1 (ILGF-1) and its receptors on Keloid fibroblasts, and 
such invasive properties of KF can inhibited by neutralizing antibody to ILGF-1(Ohtsuru et al., 
2000, Yoshimoto et al., 1999).   
Interferon-gamma 2b (IFN-γ-2b) normalises the excessive synthesis of collagen, 
glycosaminoglycans and collagenase by KF and reduces Keloid reoccurrence by enhancing 
expression of p53 and apoptosis(Ladin et al., 1998, Jacob et al., 2003). Imiquimod is a rapid 
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and potent inducer of IFN-γ-2b and imiquimod treated Keloids showed significant down 
regulation of caspase-3 and up regulation of DFFA(Jacob et al., 2003). 
 
Keloids are considered to have some immunological aspects due to the expression of 
antinuclear antibodies mainly directed against fibroblasts and the presence of raised levels of 
immunoglobulins A,G and M (Kischer et al., 1983).  
 
The urokinase –mediated plasminogen (uPA) activation and inhibitory system is known to play 
a role in wound remodelling, angiogenesis and cell migration. Studies have shown a strong 
expression of uPA in the extracellular matrix of Keloids suggesting a role in the expansion of 
the Keloid beyond the wound margins(Leake et al., 2003). However other studies have shown 
that Keloid fibroblasts expressed low levels of urokinase plasminogen activator (uPA) and high 
levels of plasminogen activator inhibitor(PA-I) thus favouring the collagen accumulation(Tuan 
et al., 2003, Tuan et al., 1996). This increased expression of PA-I is stimulated by increased 
expression of VEGF(Wu et al., 2004). 
 
Epidermal growth factor receptors (EGF-R) can induce the fibroblast motility in normal wound 
healing but this response is somewhat diminished in Keloid fibroblasts due to the rapid loss of 
EGF-R upon exposure to EGF(Satish et al., 2004). 
Hypoxia produced at the healing wound either by surgical techniques or poor vasculature can 
induce Keloid formation possibly due to the over- expression of vascular endothelial growth 
fFactor (VEGF)(Steinbrech et al., 1999) and hypoxia induced factor-1(HIF-1)(Zhang et al., 
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2003). This expression of VEFG and HIF-1 is augmented when Keloid fibroblasts are co-
cultured with mast cells (Zhang et al., 2006). 
 
The acidic and basic fibroblast growth factor (FGF) can decrease the biosynthesis of collagen-
1 by down-regulating gene expression. The effect of acidic FGF is enhanced in the presence 
of heparin but basic FGF does not need heparin to inhibit the collagen biosynthesis(Tan et al., 
1993). 
Prevention of Keloid  
Keloids remain one of the best examples to the dictum that “prevention is better than cure”. 
There is no effective treatment and hence all possible steps should be taken to prevent the 
formation a Keloid. It is evident that inflammation plays an important role in Keloid 
pathogenesis and monofilament suture initiates less inflammation than multifilamentous suture 
like vicryl rapide leading to  less scaring and Keloid formation(Niessen et al., 1997).  
 
Formation of Keloids can be minimised by accurately apposing the wound edges, placing the 
suture under minimal tension, everting the skin edges, placing the wound in Langer’s lines, 
adequately supporting the wound and ensuring the wound is free of infection and 
haematoma(Wallace et al., 2006). The inflammatory phase of wound can be modified 
pharmacologically by anti-inflammatory agents, fibroblast proliferation can be slowed by 
radiotherapy and collagen bundle orientation by pressure application(Ketchum, 1977).  
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Keloids and current treatments 
Occlusive therapies include silicone and such other occlusive dressings. There is no clear 
evidence in relation to these therapies that are thought to act by promoting local hydration. 
However they can cause adverse effects in the form of local maceration and irritation. 
 
Compression therapy involves using local pressure with or without Silicone. There is no clear 
evidence as to mechanism of action of this therapy, but concepts such as fibroblast 
degeneration from local hypoxia or temperature differences have been proposed. 
 
Pharmacological therapies 
Triamcinolone acetonide(Carroll et al., 2002) and heparin(Carroll and Koch, 2003) have been 
shown to decrease the cellular proliferation and collagen production by dermal fibroblasts. 
Triamcinolone acts by mediating the release of bFGF and lowering the release of TGF-b1 
while heparin increases both of bFGF and TGF-b. The response to triamcinolone acetonide 
inhibition on keloid fibroblast is far less than on normal skin fibroblasts(Russell et al., 1982). 
Administration of hydrocortisone decreases hyaluron levels by approximately 70%(Meyer et 
al., 2000). Flashlamp Pulse-Dye Laser (PDL) which is another modality used to treat Keloids 
suppresses the Keloid proliferation, induces Keloids fibroblast apoptosis and up-regulates 
extracellular signal regulated kinase (ERK), p38 mitogen-activated proteins kinase (p38MAP 
kinase)(Kuo et al., 2005a) and down- regulates TGF-β1(Kuo et al., 2005b). Interferon has 
shown impressive reduction is size and collagen production of Keloids(Low and Moy, 1992). 
Phan and co-workers (2003) showed that Quercet, a dietary compound which has strong 
antioxidant and anticancer properties,  can block the TGF-β/SMAD-signalling pathway(Phan et 
 199
al., 2004) and ILGF-1 signalling transduction(Phan et al., 2003), resulting in decreased Keloid 
fibrosis. Similarly endothelial cell growth factor (ECGF) and heparin minimise Keloid fibrosis by 
inhibiting  collagen production by Keloid fibroblasts(Bontems et al., 1991). 5-Fluorouracil , a 
pyrimidine analogue and  a common cancer chemotherapeutic drug, has been used in Keloid 
treatment. The mode of action is probably by antagonising the effect of TGF-β and it also 
inhibits both SMAD3and SMAD4 transduction and formation of SMAD/DNA complex induced 
by TGF-β(Wendling et al., 2003). Other pharmacological treatments include bleomycin, 
doxurubicin, tamoxifen, tacrolimus, imiquinoid, retinoic acid, and verapamil. 
 
Human β-Defensins and Keloids 
Keloids appear to have a multi-factorial pathogenesis where a number of factors interplay to 
form these lesions in individuals with suitable genetic predisposition. The multi-factorial 
pathogenesis can be summarised as either an increased exposure to, and/or expression of the 
inflammatory mediators. These inflammatory mediators influence the fibroblasts either directly 
or indirectly to produce excessive collagen or decrease collagen breakdown resulting in the 
formation of the Keloids. Human β defensins (HBD) are a group of peptides which were 
originally considered to be primarily anti-microbial in function. Up to 28 HBDs have been 
described although the more extensively studied are HBD 1, 2, and 3. As the research and 
understanding of these peptides has progressed, a number of other functions have been 
attributed to them. HBD1 has been shown to play a role in cell differentiation(Frye et al., 2001) 
while HBD2 has been shown to be a link between the innate and the adaptive immune 
system(Yang et al., 1999). HBD2 has a number of indirect effects and mediates release of a 
number of inflammatory mediators(Niyonsaba et al., 2001). To date there is no information on 
 200
the expression pattern of HBDs in Keloid lesions. Since Keloids result from increased 
exposure to inflammatory mediators, the expression of HBD 1, 2 and 3 in Keloid lesions at 
both RNA and protein levels was investigated. 
 
 
6.2 Materials and Methods 
The clinical part of the study was undertaken at The Royal London Hospital of the Barts and 
the London NHS trust. Keloid samples from various body sites of 10 Afro-carribean patients 
were collected (Ethical Committee approval Ref.05/Q06603/22). Normal skin samples were 
obtained from people undergoing elective plastic surgical procedures after obtaining an 
informed consent. 
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Table 6.1-Demographics of the keloid patients 
Sample Ethnicity Gender Age Anatomical Site 
Keloid-1 Afro-
carribean 
M 27 Ear lobule  
Keloid-2 Afro-
carribean 
M 30 Chest  
Keloid-3 Afro-
carribean 
F 20 Ear lobule  
Keloid-4 Afro-
carribean 
F 22 Ear lobule 
Keloid-5 Afro-
carribean 
F 19 Abdomen 
Keloid-6 Afro-
carribean 
M 22 shoulder 
Keloid-7 Afro-
carribean 
F 19 Ear lobule  
Keloid-8 Afro-
carribean 
F 20 Ear lobule 
Keloid-9 Afro-
carribean 
F 21 Abdomen 
Keloid-10 Afro-
carribean 
M 20 Ear lobule 
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The patients were given all the required information under Tissue Act April.2006 and a valid 
informed consent were taken from each patient. Tissue was transport from Theatre to 
Laboratory in saline soaked gauze. The tissue sample was registered in Tissue Register kept 
in laboratory for future record. On arrival the skin and keloid samples were cut into blocks of 
approximately 2cm x 2cm x1 cm using a scalpel with a size 22 blade (Swan-Morton, Sheffield 
U.K.). Then the cut skin or Keloid samples were snap frozen in liquid nitrogen and stored at -
800C until needed. 
 
Snap frozen pieces of skin and Keloid were mounted in Cryo-M-Bed (Bright, Huntington, UK) 
and 7 μm thick sections cut on a cryostat (Slee, Mainz, Germany) at -250C .Sections were 
thaw mounted on Superfrost® plus microscope slides (Knittel Glaser, Germany) and air-dried 
for 30 minutes, before storage at -800C until required.  
 
HBD 1,2 and 3 Protein expression Immuno-histochemistry  
Immuno-histochemical analysis was performed to study the expression analysis at the protein 
level. The methods were similar to those described earlier in chapter 2 (general methodology). 
The anti-bodies optimised previously were used in the same dilutions as described earlier. 
 
The frozen sections were thawed and once dried, fixed in acetone alcohol for 10 minutes. The 
slides were then washed with water and processed as described in chapter 2. The slides were 
developed with DAB and subsequently analysed after counter staining with haematoxylin and 
eosin. 
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RNA expression and real time PCR analysis. 
RNA was extracted from snap frozen tissue specimens using SV total RNA isolation kit 
(Promega, UK) as described (in chapter 2 – General methodology) according to the 
manufacturer’s protocol. The RNA obtained was reconstituted after concentration to obtain the 
desired concentration for cDNA conversion and DNA amplification. Less than 1µg of total RNA 
was used per reaction for cDNA conversion and 2µl of template cDNA was used per reaction 
of PCR. Real time PCR was performed using Opticon II PCR machine. The amplification was 
carried out using gene specific intron spanning primers and labelled minor groove binding 
probes as described in the chapter on general methodology. 
 
6.3 Results 
All the 10 patients recruited in the study were of Afro-Carribean origin and the male to female 
ratio was 4:6. The mean age of the patients was 22 years with a range between 19-30 years. 
As seen in table 6.1, the commonest site of the Keloids was ear lobules in our group; while the 
other sites analysed included abdomen, shoulder and chest. The most common aetiology for 
the Keloids in our group of patients was piercing for cosmetic purposes. 
 
Protein expression 
Immunohistochemical analysis showed that HBD1 and 3 were expressed at varying levels in 
all Keloid samples whereas none of the samples showed any detectable HBD2 expression. 
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HBD1 expression 
HBD1 was seen almost evenly throughout all layers of epidermis and in some samples the 
protein was more localised in the stratum corneum. The mean expression of HBD 1 in the 
Keloid samples was 1.9 while mean in normal skin was 1.5. 
 
HBD2 expression 
There was no expression of HBD 2 seen in any of the samples. However the normal skin 
samples showed variable expression while the negative controls without the primary antibody 
did not show any staining. The expression of HBD2 in normal samples was mainly localised in 
the stratum corneum. 
 
HBD3 expression 
The Keloid samples showed higher expression of HBD3 than normal controls. The expression 
was predominantly seen in the stratum corneum and other superficial layers of epidermis. The 
mean HBD3 expression in keloids was 2.4 while the mean in normal skin was 1.5. 
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Figure 6.1, shows the representative sections stained with HBD1 antibody and 
developed using DAB (magnification 20x). Panel A- shows the section from patient 2 
(pre-sternal keloid); the arrow shows the localisation of HBD1 in stratum corneum using 
specific antibody and DAB, Panel B –shows the normal skin section stained with HBD1 
and the arrow shows the localisation of the protein in stratum corneum. Panel C-shows 
the keloid skin sample stained with no primary antibody. The arrow points to stratum 
corneum and it can be seen that there is no HBD1 localisation. Melanocytes containing 
melanin can be seen in the basement membrane. 
 
 
A B
C 
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Figure 6.2 –Shows Β Defensin-2 expression in Keloid and site matched normal skin 
sample (magnification 20x). Panel A shows the ear lobule keloid stained with HBD2 
antibody. No HBD2 was localised in the keloid sample. Panel B shows a normal skin 
around ear (face lift) stained with HBD2 antibody. As seen HBD2 protein was localised 
to epidermis, mainly stratum corneum (arrow). Panel C shows the same ear lobule 
keloid not stained with the primary antibody (negative control). 
 
 
A B 
C
HBD2
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Figure 6.3 Β Defensin-3 expression in Keloid from shoulder region (Patient K6)and site 
specific Human Skin (chest). Panel A shows the localisation of HBD3 to stratum 
corneum and cells of basement membrane (arrows). In the basement membrane the 
melanocytic pigmentation can also be seen as the darker pigment. Panel B shows the 
normal skin section stained with HBD3. The brown stain represents the HBD3. Panel C 
shows the keloid sample stained without the Primary HBD3 antibody (-ve control. As 
seen there is no protein localisation in the stratum corneum (top arrow) or in the 
basement membrane. The brown/black pigment seen in the basement membrane is the 
melanocytic pigmentation. 
 
 A B
C
HBD3 
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The expression of HBD1 and 3 was variable in keloids from different sites as seen in figures 
6.1.6.3 and 6.4 and table 6.3. There was no HBD2 peptide expression in any of the keloid 
samples (Figure 6.2 and Table) 6.3. 
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Figure 6.4 shows the distribution of the HBD1, 2 and 3 proteins in the keloid tissue 
samples. The mean expression in the normal and the keloid samples is shown to wards 
the end of the graph. As seen none of the keloid samples actually showed HBD2 protein 
expression 
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Table 6.2 summarises the stoichiometric analysis of sections stained with HBD1,2 and 3 
antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Site Sample HBD1 HBD2 HBD3 
Ear lobule K 1 2 0 3 
Chest K 2 3 0 0 
Ear lobule K 3 1 0 3 
Ear lobule K4 2 0 3 
Abdomen K5 3 0 2 
Shoulder K6 1 0 2 
Ear lobule K7 2 0 3 
Ear lobule K8 2 0 2 
Abdomen K9 2 0 1 
Ear lobule K10 1 0 2 
Mean All Keloids 1.9 0 2.4 
Normal skin      
Face  Face 1 2 2 
Breast   Breast 2 1 1 
Mean Normal skin 1.5 1.5 1.5 
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The results of qualitative Immunoreactivity of HBD1,2 and 3 antibodies on keloid 
samples has been summarised in Table 6.3. 
Type of Defensin-β Immunoreactivity Distribution of expression  
of Defensin -β 
 
HBD1 
 
 
 
Positive, 
variable  
Expression  at  
Different sites 
 
Dense at Stratum Corneum and faint 
through out the Epidermis other layers of 
epidermis 
 
HBD2 
 
 
Negative 
 
No Expression in any layer of epidermis 
 
HBD3 
 
 
Positive 
 
Dense expression at Stratum Corneum 
and  
Some expression in the basal layer 
 
Real time PCR analysis 
Gene expression was calculated by ∆∆Ct method. Briefly the method can be explained as 
follows: The Ct of the gene of interest and the housekeeping gene was determined  
The difference between the Ct of the housekeeping gene and the gene of interest (∆Ct) is 
calculated. This gives the expression of the gene of interest in each sample relative to the 
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housekeeping gene (β actin). In order to normalise the expression, the ∆Ct of the individual 
sample is subtracted from the mean ∆Ct of the normal skin to obtain the ∆∆Ct for each of the 
genes. Subsequently -∆∆Ct is determined and the individual expression is expressed as 2-∆∆Ct. 
This gives the expression of the gene of interest relative to the β actin gene normalised to the 
expression in normal skin. Table 6.4 shows the ∆Ct values for each of the samples and the 
statistical significance (standard deviation (SD)). 
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Table 6.4 summarises the mean ∆Ct values for each of the HBD’s. B1 stans as BD1, B2 
for BD2 while B3 stands for BD3. IF the Ct was beyond 40 cycles, the expression was 
disregarded and the expression was taken as zero. In these situations eg as in BD2 in 
keloid samples ∆Ct was taken as zero. 
Site Sample 
Mean B1 
∆Ct(Ct actin 
–Ct B1) SD 
Mean B2 
∆Ct(Ct actin –
Ct B2) SD 
Mean B3 
∆Ct(Ct actin –
Ct B3) SD 
Ear lobule K 1   2.3 0.6 0.00 0.00   9.7 0.1
Chest K 2  -3.1 1.3 0.00 0.00   5.9 0.3
Ear lobule K 3  0.8 0.2 0.00 0.00 10.5 0.7
Ear lobule K4 2.6 0.3 0.00 0.00  9.9 0.1
Abdomen K5 1.5 0.2 0.00 0.00 10.1 0.3
Shoulder K6  2.3 0.4 0.00 0.00 10.2 0.4
Ear lobule K7 1.7 0.2 0.00 0.00 10.3 0.1
Ear lobule K8 1.7 0.3 0.00 0.00  6.2 0.2
Abdomen K9 1.4 0.3 0.00 0.00  8.9 0.1
Ear lobule K10 1.8 0.1 0.00 0.00  9.3 0.8
Mean All keloids 1.3 0.4 0.00 0.00  9.1 0.2
Normal skin         
Mean Face   1.1 0.3 5.0 1.5  7.4 0.2
Mean Breast     -0.6 1.5 2.2 0.4  6.9 0.8
Mean Normal skin  0.2 0.9 3.6 0.9  7.2 0.5
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Table 6.5- shows the mRNA expression in the keloid and normal skin samples The 
mRNA expression is presented normalised to house keeping gene Βeta actin relative to 
the mean expression in normal skin. | 
 Sample 
B1RNA  
Log 2-∆∆CT 
B2RNA  
Log 2-∆∆CT  
B3RNA  
Log 2-∆∆CT  
Ear lobule K 1  22 0 22
Chest K 2  2-3 0 2-1
Ear lobule K 3  21 0 23
Ear lobule K4 22 0 23
Abdomen K5 21 0 23
Shoulder K6 22 0 23
Ear lobule K7 22 0 23
Ear lobule K8 21 0 2-1
Abdomen K9 21 0 22
Ear lobule K10 22 0 22
Normal skin   
Mean Face  Face  21 21 20
Mean Breast  Breast   2-1 2-1 20
t-test    0.230 0.002
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Figure 6.5 shows the graphical representation of the mRNA expression in the keloid and 
normal skin samples. The mRNA expression is shown on the Y-axis in log scale and is 
normalised to the housekeeping gene Βeta actin and relative to the mean expression in 
normal skin. 
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Figure 6.6 shows the sites of the different keloid samples and their mRNA expressions 
 
The mRNA expression of HBD1 and 3 was variable in different keloid samples and also was 
varied depending on the site. There was no detectable HBD2 mRNA expression in any of the 
keloid samples while the all the three HBD’s were expressed to variable extent in the normal 
skin specimens. The keloid from chest region had less HBD1 and 3 expression compared to 
mean HBD1 &3 expression in normal skin as seen in figures 6.6 and 6.7. 
 
HBD 1 RNA expression  
The expression of HBD1 was variable in the individual Keloid samples as seen in the table a. 
number. Except for the Keloid from the chest (K2), the expression of HBD1 in Keloid samples 
was higher (mean 3 times the expression in normal) than the mean HBD1 expression in 
normal samples. The difference in the expression of HBD1 between the normal samples and 
the Keloid samples was not significant (Unpaired T –Test 2 tailed significance =0.230). 
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HBD2 RNA expression 
There was no detectable product for HBD2 in any of the Keloid samples; product that was 
detected after 40 cycles was taken as insignificant. There was variable expression of HBD2 in 
normal breast and face skin samples. The HBD2 expression in the normal breast sample was 
25% lower than the mean HBD2 expression in normal skin samples.  
 
HBD3 RNA expression 
The HBD3 expression was variable in Keloid samples from different sites. The HBD3 was 
predominantly higher (mean Keloid HBD3 was 5.3 times normal) as compared to the mean 
HBD3 expression in normal skin samples. This difference in the expression was statistically 
significant (unpaired t-test 2 tailed statistical significance 0.002). 
 
 
6.4 Discussion:- 
Wound healing is one of the most primitive but important innate immune response exhibited 
by the human body. The reparative process results in the fibrotic scar formation. The process 
of cutaneous wound healing can be divided into three phases: inflammation, proliferation 
which comprises re-epithelialisation, granulation tissue formation and neovascularisation, 
and maturation. Such a complex process is governed by well organized secretion of 
cytokines, growth factors and chemokines(Werner and Grose, 2003). The Keloids represent 
an abnormal healing process and are associated with a complex interplay of cytokines and 
growth factors which influence the cellular components and extracellular components to form 
these benign disfiguring lesions. Though fibroblasts are the main cellular components 
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involved causing the fibrotic process, it is proposed that dermo-epidermal interactions play 
an important role in the pathogenesis(Lim et al., 2002). The morphology of a Keloid is 
associated with a hyper-proliferative dermal and epidermal component. Keratinocytes being 
the principal component of epidermis and also the main source of HBD; their expression was 
investigated for the first time in this study.  
 
Throughout the three phases, different cellular and humoral components interplay to bridge 
the epithelial gap and to lay down the collagen tissue to provide adequate strength. During 
the maturation phase there is remodelling of collagen wherein there is change of type III 
collagen to type I and also a process of degradation and synthesis to achieve optimal 
scarring. Thus the final outcome is a result of the balance between the syntheis and 
breakdown of collagen which in turn results from a balance between the profibrotic and anti-
fibrotic cytokines. There are a number of growth factors and cytokines secreted during the 
wound healing process but the most important profibrotic mediators are TGF-β, SMAD-3, 
CTGF, ED-A fibronectin and the anti-fibrotic mediators are TNF-α, IFN-γ(Leask and 
Abraham, 2004). Thus, the final outcome of scarring process is a result of balance between 
these two sets of cytokines and their downstream mediators. 
 
HBD are cationic mucosal and skin proteins of innate immune system(Donnarumma et al., 
2004) expressed by the keratinocytes and found in the interstices between the cells. They 
are primarily considered antimicrobial as they are localised at sites of environmental 
interfaces and are induced by infective and inflammatory agents. The role of antimicrobial 
peptides is being clearly recognised in the innate defence of mammals at the epithelial 
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front(Huttner and Bevins, 1999). As new functions of these peptides are uncovered it is 
becoming obvious that HBD may have additional important roles. 
 
HBD1 is a 3.9 kDa peptide of 36 amino acids residues and is mainly produced by various 
epithelial tissues including urogenital(Bals et al., 1998), respiratory system(Alp et al., 2005) 
and human skin. This isomer of β defensin, although constitutively expressed,can be induced 
by microbial derived molecules such as lipopolysaccharide (LPS)(Bohling et al., 2006, 
Becker et al., 2000) and peptidoglycan(Bals, 2000). The expression of BD1 is also stimulated 
by pro-inflammatory cytokines such as IFN-γ(Duits et al., 2002) and TNF- α however the 
relative stimulation is much less compared to other HBDs(Lehmann et al., 2002). Other 
studies have shown that BD1 expression is not enhanced by TGF- α, TGF- β, IL-1, IL-2, 4, 6, 
8, 17 and TNF- α(Sorensen et al., 2005). HBD1 is expressed consistently in skin and besides 
its antimicrobial property it is a strong chemo-attractant in the inflammatory milieu and is salt 
sensitive. It has been shown to promote differentiation of keratinocytes(Frye et al., 2001) and 
the type of HBD expression by keratinocytes depends on the stage of their 
differentiation(Chadebech et al., 2003) and extracellular and intracellular concentration of 
calcium ions. 
The expression of HBD1 in Keloids has never been investigated and this study demonstrates 
that the HBD1 is expressed in all Keloid samples tested. The expression was variable in 
Keloids from different sites and this is similar to normal skin wherein there is a site specific 
variation(Ali et al., 2001). There was no significant statistical difference in the expression 
between the Keloid samples and the normal skin samples although the expression in Keloid 
samples is relatively high (mRNA expression 3 times normal). Keloids are associated with 
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increased levels of TGF- β(Lee et al., 1999) and also increased levels of IL-6, TNF- α, IFN- 
β(McCauley et al., 1992) and increased sensitivity of Keloid tissue to inflammatory 
mediators. These inflammatory mediators either do not increase the expression of HBD1 or 
cause a relatively small increase in the HBD1 expression. The promoter region of HBD1 
contains consensus sites for NF-IL-6 and interferon IFN-γ(Liu et al., 1997). Although 
constitutive, the presence of these consensus sites suggests to possibility of enhanced 
expression and transcriptional regulation by these cytokines. However since the cytokines 
which are increased in Keloids are not the ones that trigger any of these mediators the lack 
of increased HBD1 can be explained.  
 
HBD2 consists of 41 amino acids and has 4.3 kDa peptide, is mainly expressed in psoriatic 
skin and is intensely induced by interleukin (IL-1), tumour necrosis factor alpha (TNF-α), 
interferon gamma (IFN-γ) and bacteria(Abiko et al., 2002). In normal skin, where  it is variably 
expressed, HBD2(Ali et al., 2001) is localized to uppermost layer of epidermis called the 
Stratum corneum and is inherently expressed in chronic wounds(Butmarc et al., 2004). HBD2 
is synthesized and stored in laminar bodies of the stimulated keratinocytes of the spinous and 
granular layer. The laminar bodies may then release their content during differentiation of 
keratinocytes and dendretic cell  maturation(Biragyn et al., 2002), and after barrier disruption 
into the intercellular spaces of the epidermis layers where high amounts HBD2 are detected. 
The BD2 acts through toll-like receptors 4 (TLR-4)(Biragyn et al., 2002) and TLR-2(Birchler et 
al., 2001, Hertz et al., 2003) and is salt sensitive which can be overcome by its increase 
concentration.  
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Apart from antimicrobial activity HBD2 activates mast cells(Niyonsaba et al., 2001) to 
degenerate and generate prostaglandin D2, has a chemoattractive role for mast cell and 
stimulate keratinocytes to produce interleukin 8, 18 and 20. Furthermore the production of 
hBD2 by IL-1 and IL-18 is under the control of MAP kinase p38 MAPK and ERK. The promoter 
region of HBD2 contains consensus sites for NF-kβ activator protein 1 (AP-1) and NF-IL-6(Liu 
et al., 1998). It has been shown previously that HBD2 is stimulated only in the presence of NF-
kβ and IL-1 mediated stimulation; isolated NF-kβ activation does not result in trigger 
stimulation(Takahashi et al., 2001). 
 
We have shown in this study that there is no demonstrable protein or RNA expression of 
HBD2 in Keloids. The normal skin showed variable levels of HBD2 expression depending on 
the site of body and local factors such as hygiene and bacterial colonisation. The Keloid 
samples in our cohort were obtained from different body sites and none of them expressed 
HBD2. As seen above, the known mechanisms of induction of HBD2 include NF-kβ, AP-1 or 
NF-IL-6 pathways. The anti-fibrotic cytokines namely TNF-α and IFN-γ activate the pathways 
and induce production of HBD2, but these are not the predominant cytokines in Keloids in 
which the pro-fibrotic cytokines, which do not activate the HBD2, dominate. HBD2 was 
originally isolated form psoriatic scales and psoriasis is a hyper-inflammatory non–infective 
diseased state characterised by high levels of pro-inflammatory cytokines such as TNF-α 
(TRAF-2) , IFN-γ , IL-1 (TRAF-6) andIL-6(Nickoloff et al., 2007). These cytokines have a 
capacity to stimulate production of BD2 owing to presence of consensus sites on the promoter 
region. This probably explains increased levels of HBD2 although there is no bacterial 
stimulus. It can also perceived that the role of these peptides is more protective and 
 221
prophylactic as they are produced in the absence of bacterial mediators also they may have 
yet un-described functions. As regards to the lack of HBD2 expression in Keloids is probably 
due to absence of mediators; microbial and non–microbial (cytokines) and thus there are no 
factors to induce HBD2 expression. 
 
HBD3 is a 5.1 kDa protein and has 45 amino acids residues. HBD3 is an inducible protein 
expressed significantly in keratinocytes and tonsillar tissue and to a variable extent in small 
amount is expressed in epithelium of respiratory, gastrointestinal tract (GIT) and genito-urinary 
tract (GUT). HBD3 has strong antimicrobial activity against gram negative and gram positive 
bacteria including fungi. Its expression is induced by bacterial contact and TNF-α(Harder et al., 
2001) and IFN-γ  It has been shown recently that IGF-1 and TGF-α selectively increase the 
expression of BD3 in human keratinocytes(Sorensen et al., 2005). BD1 and 3 have been 
shown to be selectively induced in differentiated keratinocytes in an in vitro environment.(Abiko 
et al., 2003) In our study we demonstrated an increased expression of HBD3 in keloids at both 
RNA (5.3 times normal skin expression) and protein levels compared to normal skin samples. 
As seen above there are a number of infective and non-infective factors which can induce 
HBD3 expression and HBD2 and 3 are induced by different pathways. The increased 
expression in Keloids is probably mediated by the IGF-1 as Keloids have been shown to have 
increased expression of IGF receptors(Daian et al., 2003) or is a consequence of multilayers 
of differentiated keratinocytes producing HBD3 which are seen in the Keloid scar. 
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Keloids- epidermal pathology influencing the dermis. 
Keloids result from a cutaneous insult either in the form of a severe or trivial injury. Although it 
is suggested that Keloids can occur spontaneously, it is considered that these are a result of 
insignificant trauma that is ignored(Pitche, 2006). The cutaneous injury results in platelet 
aggregation and activation of coagulation cascade and release of inflammatory mediators. 
These mediators attract other cell populations namely macrophages, PMN and T lymphocytes. 
These cell populations produce cytokines and growth factors which result in epithelialisation, 
synthesis of ECM, and neo-vascularisation. As the wound healing proceeds to the maturation 
phase the final outcome is dependent on the balance between the factors influencing the 
degradation and synthesis of ECM.  
 
The platelets attracted to the site of injury produce the cytokines which trigger the inducible 
component of HBD. HBD 2, and 3 in turn re-inforce the chemotactic influence mediated by the 
cytokines produced by platelets and attract the inflammatory cells. It has been shown that 
HBD1 and 3 expression is stimulated in differentiated keratinocytes(Abiko et al., 2003). HBD2 
is enhanced in differentiated keratinocytes by the pro-inflammatory cytokines such as IL-1α(Liu 
et al., 2002a). However there is no expression of HBD2 in Keloids probably due to the 
absence of cytokines which can induce HBD2 expression. We propose that HBD2 has a role in 
regulation of anti-fibrotic cytokines as it has been shown to be important in regulating other 
immune factors(Dommisch et al., 2007) and thus its absence results in a pro-fibrotic state. The 
current known cellular receptors for HBD2 include TLR4 and CCR-6 while the cellular 
receptors for HBD1 and HBD3 are yet to be identified(Boniotto et al., 2006). Differential 
expression of HBD1 and 3 is related to variation in differentiation of epidermal cells at different 
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sites as HBD expression shows sitewise variation and the expression influences differentiation 
of keratino(Bourcier et al., 2004)cytes(Abiko et al., 2003).  
 
Previous studies have shown the differential expression of HBD1 and 2 on facial and foreskin 
at Stratum corneum  and the Malpighian layer  of the epidermis(Ali et al., 2001). The unique 
expression of these proteins helps the cellular differentiation of keratinocytes(Abiko et al., 
2003). 
 
Once HBD proteins are expressed, these can induce the formation of cytokines such as 
Interleukin-8 and monocyte chemoattractant protiens-1(MCP-1)(Boniotto et al., 2006) by 
monocytes in the inflammatory milieu. BD are known  to induce tumour vasculogenesis  by 
increase expression of vascular endothelial growth factor (VEGF) on dendritic cell (DC) 
precursors(Conejo-Garcia et al., 2004) and act as chemoattractant for monocytes, 
macrophages, DC and T lymphocytes. As all these factors are key players in keloid formation; 
it is likely that the absence of immuomodulatory HBD2 and increased expression of HBD3 
which influences keratinocyte differentiation plays a role in Keloid pathogenesis.  
Thus this study brings forth a novel aspect to Keloid pathogenesis, and also suggests that 
HBD2 and 3 are more than antimicrobial peptides. We believe that these peptides are 
important mediators of the cytokine cascade and understanding their regulation may 
hold(McCoy and Cohen, 1981) the key to a number of pathological conditions associated with 
altered cytokine and growth factor profiles. 
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Chapter 7 
 
General Discussion  
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7.1 β Defensins- A unique class of antimicrobials 
 
Antimicrobial peptides are polypeptides with less than 100 amino acids characterised by 
inherent antimicrobial activity at physiological conditions in the tissue of their origin(Ganz, 
2003).They have been an area of active interest and about 750 different eukaryotic 
antimicrobial peptides have been reported(http://www.bbcm.univ.trieste.it/%7Etossi/pag5.htm, 
accessed 07/ 2008, Brogden et al., 2003). These peptides have been grouped basing on 
similarities in their 3D structure, charge, functional similarity and sequence homology. Broadly 
they can be classifies as shown in fig 7.1. 
 
Figure 7.1- Showing the broad classification of antimicrobial peptides in animals. 
 226
The two important classes of antimicrobial peptides in humans are defensins and cathelicidins. 
As seen from figure 7.1 HBD (Human β Defensins) are cysteine stabilised cationic peptides 
with a β-sheet and are characterised by their unique tertiary structure. They also have some 
other characteristics which make these peptides of special interest. 
 
Origin 
HBD are evolutionarily conserved throughout the plant and the animal kingdom(Brogden et al., 
2003, Ganz, 2003). Similar proteins as are found in humans have been identified among plants 
and a number of other organisms in the animal kingdom. The primitive nature of these 
peptides gives evidence to the fact that these peptides have continued to remain useful 
throughout evolutionary process and hence there was minimal need for change. These 
continue to remain effective as antimicrobials in plants, lower animals and humans. 
 
Synthesis and structure 
HBD along with α-Defensins are among the smallest of the cationic antimicrobial peptides 
ranging from 38-42 amino acid residues and having a weight of 4-6 KD. The HBD precursor 
lacks or has a small pro-piece unlike the other defensins(Selsted and Ouellette, 2005). The 
possible reason for this is unclear but might explain the rapid induction and synthesis of these 
peptides when stimulated.as post translational processing requires single peptidase 
only(Ganz, 2003). Owing to their unique tertiary structure and their charge, HBD are known to 
act as antimicrobials by forming pores in the cell membranes of microbes explained by the 
carpet worm hole model(Ganz, 2003). This antimicrobial activity is pronounced at non-ionic or 
low ionic conditions, and can be seen at extremely low HBD concentrations of 1-10µg/ml.The 
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microbial activity is competitively inhibited by increasing salt and plasma protein 
concentrations. Thus HBD have more marked anti-bacterial activity at physiological conditions 
thereby serving a preventive function in the first instance. Subsequently at times of challenge, 
they are induced both in type and quantity thereby serving a secondary therapeutic function. 
 
Pattern of expression 
HBD’s as seen earlier are of different types and each of them has more marked activity against 
specific micro-organisms. The pattern of expression of each type of HBD seems to be variable 
between different sites on the body .In most of the sites there is a basal level of expression of 
HBD1sometimes along with other HBD’s and upon stimulation there is enhanced expression of 
HBD 1 and other HBD depending on the nature of stimulation. Thus it appears that apart from 
the difference in the activity with the change of environment, the innate defence provided by 
HBD is 2 staged as evidenced by the pattern of expression. The primary defence is in the form 
of the basal expression of particular type of HBD or HBD’s which upon need is enhanced 
either on its own or in combination with other HBD. 
It is possible that different HBD act synergistically potentiating the action of each other either 
directly or indirectly. 
 
Human β Defensins –more than just antimicrobials 
 
Since the discovery of HBD in 1995 when HBD1 was isolated from human blood filtrate of 
patients undergoing dialysis(Bensch et al., 1995), scientific knowledge has expanded 
significantly in the last thirteen years in relation to these peptides. In the early years following 
discovery of these peptides they were considered to be primarily antimicrobial being the first 
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line of defence against microbial invasion and forming a part of the innate immune system. 
However with increasing understanding of the structure and functions of these peptides, they 
are now recognised as being more than antimicrobial.  
The antibacterial activity of HBD was the first to be established in a number of in-vitro and in-
vivo studies. Subsequent studies demonstrated their activity against viruses(Sun et al., 2005) 
and fungi. All these studies provided evidence to these peptides forming a part of the innate 
defence barrier. The other non-antimicrobial functions are progressively being unravelled as 
additional studies demonstrate more diverse functions.  
HBD1 has been shown to promote cell differentiation in keratinocytes(Frye et al., 2001). HBD 2 
has been shown to act as signalling molecule to trigger the adaptive immune system by 
recruiting immature dendritic cells and memory T cells using the CCR6 receptor(Yang et al., 
1999). HBD3 has also been shown to have chemo attractant properties to T-lymphocytes and 
immature dendritic cells(Dhople et al., 2006). The chemotactic properties have been linked to 
the disulphide bridges in the structure(Wu et al., 2003). It has also been shown BD2, and 3 
induce secretion of pro-inflammatory cytokine IL-18 in keratinocytes(Niyonsaba et al., 2005), 
and also mediate induction of tissue remodelling proteins such as matrix metalloproteinases 
(MMP)(Varoga et al., 2005) and reduction of MMP inhibitors. 
  
Burn wounds – more than just loss of skin cover 
 
Burns are one of the most complex injuries encountered in medical practice. These injuries are 
associated with multiple co-morbidities and a multidisciplinary care addressing the multiple 
problems faced by these patients is required to achieve a favourable outcome(Hettiaratchy and 
Dziewulski, 2004a). The injuries in a burn patient can be broadly sub-classified into: 
 229
1. Physical  
2. Psychological 
3. Biological  
 
The physical injury relates to the actual burn. This could be of variable depth from superficial to 
full thickness and results in partial to complete loss of skin cover respectively. Basing on the % 
total burn surface area (TBSA) and the depth of the burn; management is planned as 
described previously. However this physical aspect of injury related to loss of skin is 
associated with psychological and biological injury, which is more pronounced with the 
increase in the percentage and depth of burn wound. The psychological injury relates to the 
trauma associated with the actual incident resulting in the burn, and also the social stigma 
associated with the injury, scarring etc and its related co-morbidities. The biological injury 
relates to the alteration in the myriad biological functions of the body to maintain an internal 
homeostatic environment following the insult. These result from the release of inflammatory 
mediators and cytokines following the burn injury, and also from the loss of biological function 
of the skin. These effects are usually seen when the TBSA exceeds 30%(Hettiaratchy and 
Dziewulski, 2004b). Thus the burn injury results in more than of loss of skin physical barrier. 
 
Human β Defensins and burn wounds 
 
A great interest has developed in the recent years in HBD inview of their unique properties 
especially in relation the burn wounds. HBD mRNA expression has been shown to be 
upregulated in burn wounds in some of the previous studies(Poindexter et al., 2006, Kaus et 
al., 2008). 
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In the current PhD the role of HBD was further investigated in relation to a number of factors 
seen in burn injury. The first few experiments (chapter 3) were aimed at understanding the 
expression profile at protein and RNA levels in burn wounds, and the influence of local factors 
like duration since burn, type and quantity of bacteria present in wounds.  
 
Expression profile of HBD in burn wounds: 
• Expression in relation to duration of burn wound. 
• Expression in relation to site of burn wound. 
• Expression in relation to the type of bacteria present in burn wound. 
• Expression in relation to the number of bacteria present in burn wounds. 
The result of the study showed an increased expression of HBD1, 2, 3 mRNA in burn wounds 
relative to psoriatic skin. Similar levels were not demonstrable at protein stage (Chapter 3). 
Having understood the expression profile an attempt was made to establish the source of 
HBD. It was known from our own study and previous studies that keratinocytes were the main 
source of HBD expression. Since granulation tissue with predominance of leucocytes, 
macrophages forms a major part of the healing burn wounds especially in the early stages 
following injury. It was decided to investigate if these blood cells contributed to the HBD 
expression in vivo. It was shown by Fang et al that human peripheral blood has no expression 
of HBD mRNA in-vivo. However on ex-vivio stimulation of leucocytes by LPS or dead bacteria 
HBD1 and 2 mRNA was detectable but not HBD3. In order to find out whether this was the 
scenario in-vivo i.e. if the peripheral blood cells contributed to HBD expression in the presence 
of inflammatory mediators or bacteria or bacterial products, which is the environment seen in 
burn wounds. 
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Since it was not practically and ethically possible to recruit patients with major burns and 
extract leucocytes from the granulating wound beds an alternative model was looked into 
where similar conditions existed in peripheral blood. A study was planned looking into the 
expression of HBD in patients with microbiologically positive and negative blood cultures and 
comparing the expression between the two groups to healthy volunteers. Chapter 4 gives the 
full details of the study. 
The results of our study demonstrated that the expression of HBD1, 2 and 3 was enhanced to 
similar levels in both the microbiologically positive and negative groups at both the RNA and 
the protein stage. Thus suggesting that the enhance expression was mediated by the 
inflammatory mediators like cytokines than the by the microbes itself. It can be further derived 
from the study that the blood cells contribute to the HBD1, 2 and 3 mRNA and protein 
expression.  
It is a well recognised fact that major burns described as those involving more than 25-30% of 
TBSA are associated with catabolic hypermetabolic state, negative nitrogen balance and loss 
of lean body mass(Meyer et al., 1994, James et al., 2002). These are considered to be 
secondary to alterations in the hypothalo-pituatary adrenal axis following release of 
cytokines(Woloski et al., 1985). This in-turn causes release of stress hormones mainly cortisol, 
which has been shown to be 10 times higher than in normal individuals(Garrel et al., 1995). It 
has also been reported that there is loss of circadian rhythm in burn patients similar to that 
seen in critically ill patients(Molteni et al., 1979). In our previous study (chapter 5) we have 
demonstrated that critically ill patients in ITU/HDU do not have a circadian rhythm of cortisol 
expression. This increase in stress hormones is useful to help tide over the stressful situation 
however is also associated with a number of changes in metabolism and immune system 
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some of which can be deleterious. It is considered that during such major stress events there 
is down regulation of the innate immune system resulting in oppurtunitistic infections in these 
groups of patients. 
HBD are considered a part of the innate immune defence and serve not only as the first line of 
defence, but also a link connecting the adaptive and the innate defence mechanisms. Due to 
their pivotal role in the defence mechanisms, it was decided to investigate if the expression of 
HBD is influenced by the high cortisol levels which in turn are a reflection of the stress in 
patients. As it was practically difficult to obtain enough patients to have a meaningful study with 
majors burns (>30%) and it was not possible to have controls, especially the baseline if the 
burns patients were recruited. Hence a model was chosen in the form of patients undergoing 
major surgical procedures who, as per their clinical protocol, were expected to be nursed in the 
critical care environment in the immediate post-operative period. The study was planned such 
that a sample of cortisol and HBD could be studied at three stages; a baseline (pre-operative), 
day 1 post–operative and Day 9/10 post-operative or pre-discharge sample. It has been shown 
in previous studies that patients undergoing major surgical procedures have a stress response 
manifested by lack of circadian rhythm which is usually restored in about 8-10 days time 
following surgery. This model appeared to be closely mimicking the conditions seen in burns in 
a controlled way and over a shorter time span and hence was decided upon. 
The results of the study (chapter 5) showed that the HBD1 and 3 were high in the pre-
operative period compared to normal controls, and this was further elevated in the immediate 
post-operative period. There was statistically significant positive correlation between the HBD1 
and 3 levels. HBD2 was found elevated during the immediate post-operative period and 
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progressively with time all the three HBD showed a down-trend. There was no significant 
negative correlation between the cortisol levels and the HBD levels. 
Thus drawing up from this study it can be suggested that in major stress conditions like burns 
the natural response of the body is to augment the immunity at the mucosal and skin surfaces. 
There is initially enhanced expression of inherently expression HBD1 and this is associated 
with increased HBD3 as there appears to be a cross talk between these two defensins. It is 
important to note that HBD1 and HBD3 have specific activity against staphylococcal species 
(which are the organisms initially responsible for wound infections). While HBD1 is inherently 
expressed and is active at physiological pH and salt concentrations, HBD3 is active at high salt 
concentrations and is predominantly induced. Thus the defence at muco-cutaneous levels is 
mediated as a 3 tier system. The primary tier comprises the inherently expressed antimicrobial 
peptide HBD1, a predominantly inherent antimicrobial peptide at physiological pH which is also 
inducible. The next tier comprises HBD3, an inducible but mainly locally acting antimicrobial 
peptide, both under physiological and pathological conditions. The third tier consists of HBD2, 
an inducible peptide with inherent antimicrobial activity, but also serving as triggering molecule 
to the adaptive immune system. In our group of patients, cortisol did not seem to adversely 
effect the HBD expression. 
 
Scars are an inherent component of burns, leaving a permanent mark on these patients after 
the acute sequelae of burn settles down. Quite often in major burn patients the scars can be in 
the form of keloids or hypertrophic scars. These type of scars, particularly keloid, are difficult to 
treat as the mechanisms underlying the formation of keloids are not clear. The aetiology of 
keloids is considered to be multi-factorial subsequent to a cutaneous insult. A number of 
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inflammatory and immune mediators have been implicated in the pathogenesis and it is 
considered that an imbalance between the pro and anti-fibrotic cytokines leads to the keloid 
formation. It is however not known what triggers the imbalance between the pro and anti-
fibrotic mediators shifting the balance to the pro-fibrotic state. Since HBD spear to have more 
diverse functions and to complete the investigation into the role of HBD in burn pathogenesis, 
it was decided to investigate the expression profile of HBD in keloids (chapter 6).  
The results of study (chapter 6) show that there was no HBD2 expression at both mRNA and 
protein levels in keloids. The HBD1 and 3 mRNA was 3 and 5 times higher, respectively, in 
keloids compared to the mean expression in normal skin samples.  
In summary the study suggests to a possible role of HBD’s mainly lack of HBD2; an anti-
fibrotic cytokine inducer in keloid pathogenesis. 
 
Summary  
The studies undertaken during the PhD demonstrate for the first time that HBD1, 2 and 3 are 
induced to very high levels at mRNA levels in burn patients, but parallel levels were not seen 
at protein levels. 
The bacteria isolated from the burn wounds showed a trend changing from colonising 
organisms to more resistant forms in time. 
The peripheral blood leucocytes demonstrated an increased expression of HBD 1, 2 and 3 
mRNA in clinically septic patients (both micro-biologically negative and positive patients), 
compared to normal controls. The study suggests that peripheral blood cells produce HBD in 
response to inflammatory mediator’s invivo, thus alluding to a possible contribution of HBD 1, 2 
and 3 in granulation tissue in burn wounds. 
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There was no down regulation of HBD1, 2 and 3 in the presence of increased cortisol levels, a 
reflection of heightened stress as seen in burns. HBD1 and 3 mRNA expressions showed an 
early up-regulation followed by elevation in HBD2 mRNA levels. All the three HBD proteins 
were localised to buccal epithelial cells. 
There was no HBD2 mRNA and protein expression in keloid tissue specimens from different 
parts of the body. The absence of HBD2- a unique intrinsic peptide with an ability to trigger the 
anti-fibrotic cytokines suggests to the possibility that HBD’s are implicated in the pathogenesis 
of keloids. 
 
7.2 Conclusion & Scope for clinical application 
The current work was an endeavour to investigate and review the role of HBD 1, 2 and 3 in 
burn wounds. The results of the studies undertaken show that the natural response of the body 
in the epithelial remnants in burn wounds, the periburn tissue and the peripheral blood cells is 
to enhance the mRNA expression of HBD. Protein was not localised to similar high levels, 
suggestive of extensive consumption of this secretory protein or potential deficiencies in the 
translational mechanisms in the immature cells. The high stress and the accompanying 
immuno-suppression do not seem to directly down-regulate the HBD expression. The keloid 
scars do not have any expression of HBD2 either at protein and mRNA level. 
The treatment of burn patients has tremendously improved with improvement in the critical 
care support and better understanding of the pathogenesis in burns. However infection still 
continues to be an important problem in major burns, and the development of ever new 
generation of the existing antibiotics seems to be hampered by the increasing bacterial 
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resistance. In this era of increasing bacterial resistance designing novel therapies using 
primitive, conserved antimicrobial peptides like HBD seems like a promising alternative. 
HBD’s as has been discussed show a wide spectrum of antimicrobial activity against varieties 
of bacteria, fungi and viruses and each of the subtypes have more marked activity against 
specific microbes. They have unique mechanism of action and inspite being in the plant and 
animal kingdom from times immemorial, they successfully continue to be lethal to microbes. 
The current study provides more information which is useful to plan and streamline such 
therapeutic strategies. Drawing from the results of the studies on burn wound samples it can 
be suggested that the HBD’s should be supplemented as proteins which could be incorporated 
into wound dressings or collagen scaffolds. If the idea was to use cultured skin substitutes, 
then the the HBD, s can be made to overexpress invitro before transferring the skin onto the 
patient. Novel therapeutic strategies for the treatment of keloids can also be planned by 
considering enhancing the invivo expression of HBD2 mRNA or supplementation of HBD2 
proteins. The results of these studies can also be applied to the non-burn scenarios like 
chronic non-healing wounds where similar microbes as in delayed burn wounds have been 
found. Such wounds can also be supplemented with HBD to promote healing and prevent 
infection. The individual HBD used has to be tailored to the duration and the nature of the 
wound, for instance acute wounds would benefit from supplementation of HBD1 and 3, while 
HBD2 should be used for chronic wounds. However such experiments should be carefully 
trialled given the possibility that these HBD peptides may have many more yet undescribed 
and undiscovered properties. 
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7.3 Future work 
Having established the in-vivo expression profile of HBD in burn wounds and the conditions 
seen surrounding these complex wounds, the next step would be to apply the results for 
potential therapeutic use. The project can be taken forward in different directions as follows: 
 
• In-vitro studies relating to enhanced expression of HBD 1, 2 and 3 both individually and 
separately in organotypic skin models and analysing their influence on epithelisation, 
differentiation and prevention of infection. 
• Large scale synthesis of these peptides using recombinant techniques; and subsequent 
direct topical use of these peptides in an aqueous base. 
• Use of stimulants of HBD mRNA expression for topical application in oil base or direct 
injection into the lesion. Dermal scaffolds with incorporated HBD2 can also be used 
following excision and grafting of keloid lesion to prevent recurrence. 
• Application of HBD supplemented Dermal or CSS (cultured skin substitutes) to non-burn 
chronic wounds including diabetic or venous ulcers. 
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